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CHAPTER 1 
INTRODUCTION 
 
Introductory comments 
The two goals of this work have been to characterize the glucose-dependent paracrine 
regulation of glucagon inhibition from the pancreatic islet α-cells, and to develop a useful 
methodology for studying the dynamic molecular processes in these cells.  Along the way, these 
goals have been facilitated by collaborative experiments with a variety of laboratories using 
different cellular systems, which are described.  This document begins with an introduction to 
the physiology of the pancreatic islet of Langerhans and is followed by two chapters that 
describe specific materials and methods and the results of work conducted toward the first goal 
of identifying the paracrine mechanisms of glucagon inhibition.  Next, an instrumentation 
overview follows, discussing the tools used for spectral imaging to monitor multiple molecular 
events in living cells, some of which were developed during this work.  Additionally, the 
experimental findings and validation of the spectral imaging methodology is presented.  This 
dissertation is then concluded with a discussion about the results, their relevance with respect to 
current literature as laid out in the introduction, ongoing studies, and future directions.  
 
Glucose homeostasis and metabolic diseases 
Metabolic diseases are a class of disorders that can be described as dysfunctions in the 
conversion of food into energy, or usage of stored energy.  These include type 1 and type 2 
diabetes mellitus, which are characterized by chronic hyperglycemia, and can lead to severe 
complications such as coronary artery disease, diabetic retinopathy, kidney disease, and stroke.  
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The prevalence of metabolic diseases in the world is rising at an alarming rate along with the 
rapidly increasing rates of obesity, a common comorbidity (Prevention 2011).  The purification of 
insulin and first injections into diabetic patients in the 1920s heralded the end of type 1 diabetes 
as a conventionally lethal disease, but we now know that insulin is by no means a cure (Bliss 
1997).   
Diabetes is characterized by chronic hyperglycemia, which leads to other clinical signs 
including polyuria, polydipsia, and polyphagia.  The chronic hyperglycemia is typically attributed 
to a reduction in glucose-stimulated insulin secretion or a reduction in the responsiveness of 
target tissues to secreted insulin that results in a loss of glycemic control.  In addition to high 
blood glucose, diabetic patients present with low plasma insulin levels and high plasma 
glucagon and free fatty acid levels (Berg 2002).  Insulin therapy and pharmaceuticals that 
stimulate insulin secretion drive glucose uptake by relevant tissues to oppose hyperglycemia, 
but alone, this is not sufficient to counter the effect of elevated plasma glucagon that 
accompanies diabetes (Cryer 2002).   
Patients with type 2 diabetes often have insulin-resistant tissues, and thus require a 
different strategy for achieving euglycemia.  This includes diet changes, exercise, and a 
rigorous blood glucose-monitoring regime; along with drugs that stimulate insulin secretion from 
the pancreas (Cryer 2002), or increase the insulin sensitivity of relevant tissues and block 
hepatic glucose production (Edgerton, Johnson et al. 2009).  However, solely manipulating 
insulin levels or function to treat disease symptoms can have negative consequences as well. In 
fact, the largest risk factor for diabetic patients undergoing insulin-based treatment strategies is 
acute hypoglycemia, a condition responsible for 2-4% of deaths in type 1 diabetic patients.  This 
insufficiency of current treatments for diabetes management has encouraged research efforts 
toward a more detailed understanding of the pathophysiology and associated risk factors, with 
the goal of preventing the onset of diabetes and developing more effective therapeutics.  One of 
the avenues of this research is the regulation of glucagon secretion from the pancreatic α-cells 
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that contributes to the chronic hyperglycemia associated with diabetes. Much of this dissertation 
work has focused on the normal mechanisms of glucose in suppressing glucagon secretion. 
 
Significance of glucagon in regulating blood glucose levels 
In addition to a loss of insulin secretion or function, patients of both type 1 and type 2 
diabetes have elevated plasma glucagon levels that contribute to the hyperglycemic state.  It 
has even been suggested that glucagon hypersecretion is the primary driver of chronic 
hyperglycemia (Unger and Cherrington 2012).  Often called a “counter-regulatory” hormone, 
glucagon stimulates the release of glucose into the blood stream when blood glucose levels are 
low, thus opposing the action of insulin.  Though glucagon was identified just a few years before 
the purification of insulin (Kimball and Murlin 1923), it was not purified until later and 
comparatively little has been revealed about its regulation (Gromada, Franklin et al. 2007).  
However, it has become clear that glucagon-secreting islet α-cells play a critical role in glucose 
homeostasis.  The persistence of α-cell function, especially in type 1 and advanced type 2 
diabetes, makes the α-cell an important target for therapeutic intervention.   
In addition to the chronic hyperglycemia that dysregulated glucagon secretion 
contributes to, severe hypoglycemia is just as dangerous.  Glucose is the primary source of 
energy for the brain, which is unable to synthesize glucose and stores only small amounts as 
glycogen.  Thus, low plasma levels of glucose can lead to brain damage, and if unaddressed, 
coma and death.  Hypoglycemic episodes are also the primary limiting factor for glycemic 
control of both type 1 and late-stage type 2 diabetes, which limits the ability to consistently 
maintain normal blood glucose levels (Cryer 2002). 
This has prompted a surge in research targeting glucagon regulation as a treatment for 
type 2 diabetes that has resulted in the development of glucagon receptor antagonists in varying 
stages of regulatory approval for treatment (Drucker and Nauck 2006; Christensen, Vedtofte et 
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al. 2011).  Clinical studies with these drugs have demonstrated that accurate suppression of 
glucagon secretion restores normal glucose homeostasis in diabetic patients (Degn, Juhl et al. 
2004; Madsbad 2009; Kielgast, Krarup et al. 2011).  However, the off-target molecular effects 
remain uncharacterized and a number of negative side effects are being noted in some patients 
(Alves, Batel-Marques et al. 2012).  This highlights the importance of understanding the 
molecular regulation of glucagon secretion, and the infusion of research will hopefully lead to 
safe and effective therapeutic options that target the α-cell.  Additionally, recognizing that 
multiple tissue types have reciprocal relationships with the endocrine pancreas adds complexity 
to the healthy and pathological states but may also provide novel targets to pursue for 
treatment.   
 
The islet of Langerhans 
The human pancreas is largely made up of acinar tissue responsible for producing 
digestive enzymes, which include trypsin, chymotrypsin, RNase A, phospholipase A2, and α-
amylase that are secreted into the pancreatic duct for functions in the small intestine.  
Approximately 1-2% of this tissue is composed of multicellular islands of cells called the islets of 
Langerhans that provide the endocrine function of the pancreas, which is responsible for 
maintaining glucose homeostasis.  Approximately one million islets are scattered throughout the 
exocrine tissue separated by a thin collagen layer.  They are roughly spherical in shape and 
exhibit diameters from 40 – 200 μM (with 1000 – 10,000 cells) (Motta, Macchiarelli et al. 1997; 
Kilimnik, Kim et al. 2009).  There are several specialized cell types that make up the islet, 
including insulin-secreting β-cells, glucagon-secreting α-cells, somatostatin-secreting δ-cells, 
pancreatic polypeptide-producing cells, and ghrelin-containing ε-cells (Cabrera, Berman et al. 
2006).  These cell types cooperate in a number of ways including cell adhesions, junctional 
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protein interactions, via secreted factors, and membrane receptors (Marks, Tan et al. 1990; 
Ravier, Guldenagel et al. 2005; Konstantinova, Nikolova et al. 2007; Head, Orseth et al. 2012). 
Islets are highly vascularized and highly innervated, two properties that are critical to 
their function.  The fenestrated vasculature throughout the islet permits the rapid exchange of 
gases and facilitates the transport of hormones to other tissues via the blood stream.  
Additionally, though the endocrine pancreas accounts for 1-2% of the tissue, it receives 10-15% 
of the blood supply (Jansson and Hellerstrom 1983).  It has also been proposed that blood flow 
through the islet vasculature, via both volume and direction, plays an important role in directing 
islet function (Bonner-Weir and Orci 1982; Nyman, Wells et al. 2008; Nyman, Ford et al. 2010).  
For example, studies have shown that blood moves directionally from β-cells toward α-cells, 
suggesting that proximal α-cells may see a higher concentration of insulin than more distal 
targets (Maruyama, Hisatomi et al. 1984).  Similarly, somatostatin secreted from islet δ-cells, 
which are juxtaposed to both α- and β-cells, regulates the hormone secretion from both 
neighboring cell types (Schuit, Derde et al. 1989).  In addition to the significant vascularization in 
the islet, the proximity of nerve terminals allows for parasympathetic and sympathetic nervous 
system control over the excitable islet cells, which provides another level of regulation for 
hormone secretion (Ahren 2000).  
While many functions of the islets in maintaining blood glucose homeostasis are well 
conserved in mammals, the cytoarchitecture is quite different between human and mouse islets, 
which are the most common animal models for research (Cabrera, Berman et al. 2006; Kim, 
Miller et al. 2009).  The differences in cellular composition can be seen in Figure 1-1 and are 
described in more detail below.  
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Figure 1-1. Murine and human islet α, β, and δ cell distribution.  Immunofluorescence of a single 
optical section of a murine (left) and human (right) islet fixed and stained with primary antibodies 
to glucagon (red), insulin (green), and somatostatin (blue). 
 
Human islet composition 
While the same primary cell types have been identified in both human and murine islets, 
there is a greater variability in the composition and relative arrangement of these cell types in 
human islets.  Generally, a human islet may be composed of ~60% β-cells, ~30% α-cells, and 
~10% δ-cells, pp-cells, and ε-cells (Brissova, Fowler et al. 2005).  The arrangement of the cells 
within the islet is also heterogeneous and allows a very high percentage of cells access to 
adjacent blood vessels.  It has also been shown that the islet architecture is size-dependent, 
with larger islets having a larger fraction of α- and δ-cells, and smaller islets exhibiting similar 
cellular composition to murine islets.  Historically, the apparent lack of organization in cellular 
distribution in human islets was proposed to play a role in the differences in islet function 
between species.  However, recent studies using 3-D reconstruction techniques have provided 
more quantitative information about the islet cell distribution and populations.  By fitting the data 
to either a model where particular cell-cell contacts have distinct probabilities or a model based 
on random mixture, this study reported a significantly better fit to the former.  Additionally, the 
distance calculated between cells demonstrated that there was a preferential association 
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between α- and β-cells and allows for the intermingling of δ-cells (Kilimnik, Jo et al. 2012).  The 
proximity of different cell types to each of the others as reported by both early and recent 
studies, likely contributes to paracrine regulation from secreted factors among the cells 
(Cabrera, Berman et al. 2006; Kilimnik, Jo et al. 2012).  
There are also differences in gene expression between human and murine islets.  For 
example it has been demonstrated that the glucose transporter expressed in human β-cells is 
GLUT1 and GLUT3, not GLUT2, which has been well-characterized in the mouse islets 
(McCulloch, van de Bunt et al. 2011).  There are many other such differences between human 
and mouse islets including developmental transcription factors v-maf musculoaponeurotic 
fibrosarcoma oncogene homologue (MAF) B, PDX1, and glucose-regulated expression of 
PDX1, insulin, MAFA, and glucokinase, which suggest potentially significant differences in islet 
function between species (Dai, Brissova et al. 2012; Guo, Dai et al. 2013).  There are also, 
however, a number of highly conserved regulatory processes that span many species’ islets, 
including the regulation and molecular singling of insulin and glucagon in their target tissues 
(Noyes, Katz et al. 1995; Leevers 2001).  Additionally, the function of pancreatic islets with 
respect to normalizing blood glucose levels is robust and nearly identical across species.  
 
Murine islet composition 
Rodent islets have a larger percentage of β-cells than human islets (> 70%) and fewer α-
cells (< 20%), with the remainder (5-10%) made up of δ-cells, pp-cells, and ε-cells.  In terms of 
arrangement about the islet, α-cells are typically found in the periphery, around a core of β-cells.  
The δ-cells, pp-cells, and ε-cells are distributed sparsely throughout the islet.  While the 
significance of this arrangement is not well understood, extensive studies have been performed 
on the connectivity of islet β-cells by gap junctional complexes, which contribute greatly to the 
syncytial function and pulsatility observed in insulin secretion from coupled β-cells (Ravier, 
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Guldenagel et al. 2005; Head, Orseth et al. 2012).  While human and murine islets are both 
highly vascularized, the cytoarchitecture of mouse islets lends them to directional regulation via 
blood flow.  It is generally accepted that blood moves through islet capillaries toward peripheral 
-cells from the core -cells, which may underlie the paracrine regulation of glucagon secretion 
by secreted factors from the -cells (Jansson and Hellerstrom 1983; Nyman, Ford et al. 2010).   
 
Islet endocrine physiology 
 The peptide hormones insulin and glucagon secreted from islet cells make up the 
majority of the endocrine function of the pancreas.  The integrated network of islet capillaries 
facilitates the delivery of these hormones to target tissues, which include the liver, muscle, and 
adipose tissue, depicted in Figure 1-2.  Insulin and glucagon have opposing functions in the 
body; insulin is an anabolic hormone, triggering the uptake and storage of glucose, fatty acids, 
and amino acids.  Glucagon is a catabolic hormone, mobilizing glucose, fatty acids, and amino 
acids from stores into the blood.  Dysregulation of these hormones as the origin of diabetes is 
termed the “bi-hormonal” hypothesis, posited in the 1970s, which has driven an increase in the 
attention paid to glucagon in research as well as the clinic (Unger and Orci 1975).  
 
Figure 1-2. Target tissues for secreted islet hormones. 
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 The liver is a critical site of hormone action because the blood flow proceeds directly 
there from the pancreas and it is one of the major storage locations for glucose.  Upon 
increases in blood glucose levels and insulin-stimulated uptake into the liver, glucose is 
polymerized into the storage form, called glycogen.  This is a branched polymer chain of 
glucose molecules connected by a α (1→4) linkage that is readily reduced for delivery to the 
blood stream by glucagon action on the liver when blood glucose levels are low (Berg 2002).  
Insulin has several functions in the liver including the stimulation of glycogen synthesis and 
glycolysis and the inhibition of glycogen breakdown and gluconeogenesis.  Glucagon also 
significantly impacts liver function by stimulating amino acid uptake, gluconeogenesis, and 
glucose release while inhibiting glycolysis and fatty acid synthesis.  
The opposing functions of insulin and glucagon on the liver are critical in the 
maintenance of blood glucose homeostasis, and their respective molecular mechanisms of 
action will be covered in a later section.  Dysregulation of insulin and glucagon during diabetes 
leads to abnormalities in glycogen function and is the source of inappropriate ketone production 
characteristic of severe diabetes.  The importance of the relationship between the islet 
hormones and the liver is highlighted by the strong association between many liver diseases 
and diabetes.  There are three categories of associations that have been described: liver 
disease as a consequence of diabetes, diabetes and dysregulated glucose homeostasis 
resulting from liver disease, and coincidently occurring diabetes and liver disease (Wraith 1989; 
Iozzo, Pratipanawatr et al. 2001; Tolman, Fonseca et al. 2007).  
 Fatty acid metabolism is also regulated by glucagon and insulin in the adipose tissue.  
Triglycerides are the storage form of fatty acids, which are an important energy source and are 
readily reduced to provide free fatty acids to the blood (Spector 1975).  Decreasing insulin levels 
during hypoglycemia relieve the inhibition of lipases in adipocytes, allowing the oxidation of 
triglycerides to free fatty acids (Goldberg, Eckel et al. 2009).  Glucagon, as well as epinephrine, 
stimulates lipase activity to increase available energy during periods of high demand.  Diabetic 
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patients exhibit increased levels of free fatty acids due to impairments in regulated triglyceride 
turnover, which correlates with hyperglucagonemia and the onset of peripheral and liver insulin 
resistance (Boden and Shulman 2002).  Understanding the relationship between glucagon, 
insulin, and adipocytes is important for obesity and metabolic disease (Mauriege, Klein 
Kranenbarg et al. 1996). 
 Finally, the muscle is a critical target tissue for insulin, as ~80% of glucose uptake is 
accounted for by this tissue and stimulated by insulin receptor signaling (Thiebaud, Jacot et al. 
1982).  During diabetes, reduced glycogen synthase activity and impaired glycogen synthesis in 
the skeletal muscle are the primary defects responsible for insulin resistance in this tissue 
(DeFronzo and Tripathy 2009).  Another interesting observation from studies of skeletal muscle 
diseases such as inclusion-body myositis, polymiositis, and inflammatory myositis is an 
association with insulin resistance and diabetes (Broccolini, Ricci et al. 2004; Cuthbertson, 
Smith et al. 2005; Limaye, Lester et al. 2010; Lopez-Menduina, Martin et al. 2010).  The 
relationship between metabolic target tissues and islet hormone secretion has profound 
implications for irregularities in whole-body glucose homeostasis, though many questions 
remain unanswered at the level of cellular and molecular interplay among them. 
 The roles of insulin and glucagon in regulating metabolic tissue have been a major focus 
of diabetes research.  Another important body of work has been done characterizing the source 
of these hormones, their molecular function and regulation, and respective roles in metabolic 
disease.  The multi-cellularity and differential cellular function in the islet highlight the complexity 
of this critical endocrine organ.  The primary cell types responsible for glucose homeostasis are 
the α-, β-, and δ-cells, although there is an increasing appreciation for the contribution of the 
other cell types to islet disease (Koska, DelParigi et al. 2004; Poykko, Ukkola et al. 2005).  The 
remainder of this section details the primary islet cells, their respective hormones, and 
molecular regulation.   
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α-cells and glucagon signaling 
Glucagon is a peptide hormone composed of 29 amino acids that is translated as a pre-
prohormone and packaged into vesicles after several proteolytic cleavages in the rough 
endoplasmic reticulum (ER) and Golgi apparatus to form the mature hormone.  There are other 
cleavage products from the same gene that have important biological function including 
glucagon-like peptide 1 (Glp-1) and gastric inhibitory peptide (GIP) (Bell, Santerre et al. 1983), 
which will be discussed in a later section.  Glucagon is secreted from dense core granules in the 
pancreatic α-cells and drives an increase in blood glucose levels (Deconinck, Van Assche et al. 
1972).  Stimulation of glucagon secretion is complex and can arise from a number of states, 
including exercise, fasting, and trauma, as well as hypoglycemia and high blood glucose levels 
of amino acids.   
Under normal physiological conditions, however, when blood glucose levels decrease 
below ~4 mM, glucagon is secreted from islet α-cells.  In human, glucose transport into the α-
cells occurs via the facilitated glucose transporter GLUT1.  The GLUT1 transporter is 
responsible for low-level glucose uptake that is required for maintenance of basal respiration in 
all cells and has a high affinity for glucose with a Km of 1-2 mM (Gould and Holman 1993).  
GLUT1 expression is also up-regulated under glucose starvation conditions (Kumagai, Kang et 
al. 1995; Seidner, Alvarez et al. 1998).  Additionally, the effect of glucose on metabolic redox 
state, as measured by NAD(P)H autofluorescence, is similar to that of the β-cells, but has a 
higher basal level at low glucose that results in a decreased dynamic range (Le Marchand and 
Piston 2010).  Other studies have shown that the β-cells are more efficient in glucose oxidation 
and the α-cells rely more on anaerobic glycolysis (Sekine, Cirulli et al. 1994; Schuit, De Vos et 
al. 1997; Quesada, Todorova et al. 2006).  These properties suggest that α-cells are less 
coupled to glycolytic events and provide an explanation for the metabolic activity in α-cells 
during hypoglycemia.  Glucose is metabolized by the rate-limiting enzyme glucokinase, leading 
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into glycolysis, oxidative phosphorylation, and the generation of ATP (Heimberg, De Vos et al. 
1995; Heimberg, De Vos et al. 1996).  
Similar to the well-characterized β-cells, the α-cell cytosolic ATP/ADP ratio increases 
and KATP channels are closed, leading to a membrane depolarization.  The KATP channels in α-
cells reportedly have a higher ATP sensitivity, allowing for maximal inhibition of KATP channel 
conductance at low levels of cytosolic ATP (Leung, Ahmed et al. 2005).  Single nucleotide 
polymorphisms in the KATP channels identified in genome-wide association studies (GWAS) 
result in defective channel activity, reviewed in (Denton and Jacobson 2012), which by either 
direct or indirect action on the α-cell channels, lead to dysregulation of glucagon secretion 
(Tschritter, Stumvoll et al. 2002; Rorsman, Salehi et al. 2008; Quoix, Cheng-Xue et al. 2009; 
Unger and Orci 2010).  These ion channels are certainly critical in the regulation of glucagon 
secretion at low glucose levels, but the extent to which they drive glucose-dependent regulation 
in the α-cells is unknown and under debate (Cheng-Xue, Gomez-Ruiz et al. 2013; Zhang, 
Ramracheya et al. 2013).  
Other ion channels also contribute to membrane potential dynamics, including voltage-
dependent Na+ channels, voltage-gated K+ channels, and N-, L-, and T-type Ca2+ channels that 
are important for action potential regulation, reviewed in (Quesada, Tuduri et al. 2008).  The 
membrane-level organization and distal steps of glucagon exocytosis are much less well-
characterized due to significant challenges in studying native islet α-cells.  However, several 
proteins involved in β-cell vesicle exocytosis are expressed in the α-cells, suggesting the 
capacity for similar mechanisms.  For example, the F-actin modifying Rho-GTPases are key 
players in regulating insulin exocytosis and will be discussed further in Chapter 3, which 
addresses the possibility that α-cells share this regulatory function for glucagon secretion. 
The metabolic target tissues for glucagon action include the liver, adipose tissue, and 
the islet itself.  In the liver, glucagon stimulates the breakdown of glycogen stores to liberate 
glucose for delivery to the blood stream, a process called glycogenolysis.  The production of 
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cAMP and activation of PKA in this signaling pathway, via glucagon receptor activation, leads to 
the phosphorylation and activation of glycogen phosphorylase.  This enzyme removes the α 
(1→4) linkage between glucose units forming glucose-1-phosphate, which in turn is converted 
to glucose-6-phosphate.  Finally, glucose-6-phosphatase removes the phosphate and releases 
free glucose (Imazu, Strickland et al. 1984; Imazu, Strickland et al. 1984).  This process is 
enhanced in the hyperglucagonemic environment of type 2 diabetes and insulin resistance 
(Iozzo, Pratipanawatr et al. 2001).  In fact, the most prescribed drug for type 2 diabetes patients 
is the biguanide compound metformin, which decreases hepatic glucose output and counters 
excessive glucagon stimulation (Leavens and Birnbaum 2011; Miller, Chu et al. 2013). 
 In adipose tissue, glucagon functions via a similar mechanism to stimulate the release of 
free fatty acids and glycerol into the blood stream, by increasing cAMP production and PKA 
activation.  The PKA then phosphorylates hormone-sensitive lipase (HSL), which hydrolyzes 
fatty acids from diacylglycerols.  Lastly, the fatty acid is released from monoglycerides via 
monoglyceride lipase that also liberates glycerol (Berg 2002).  The chronic elevation of free fatty 
acids in circulation is a major risk factor for insulin resistance and metabolic syndrome, which 
provides a link between obesity and type 2 diabetes.  Under normal, healthy conditions the 
adipose tissue is more heavily influenced by insulin than glucagon (Liljenquist, Bomboy et al. 
1974).  In a diabetic state, however, the chronic hyperglucagonemia strongly stimulates 
lipolysis, which insulin signaling is no longer sufficient to overcome due to resistance 
(Liljenquist, Bomboy et al. 1974; Liljenquist, Bomboy et al. 1974; Boden 1997).   
  
β-cells and insulin signaling 
 Insulin is also a peptide hormone, composed of 51 amino acids, that is synthesized as 
pre-proinsulin, which becomes proinsulin following a series of cleavages in the rough ER and 
Golgi.  Once packaged into secretory granules, proinsulin is further cleaved to produce insulin 
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and c-peptide, which are secreted together from dense-core vesicles by exocytosis from 
pancreatic β-cells (Rhodes and Halban 1987).  The primary role of insulin in normal physiology 
is to lower blood glucose levels in response to hyperglycemia by acting on the muscle, liver, and 
adipose tissue to take up glucose from the blood and store it in the form of glycogen (Berg 
2002).  Additionally, insulin signaling in the liver and adipose tissue inhibits the degradation of 
glycogen and release of free fatty acids, respectively.  Since the β-cells are the only known cells 
that secrete insulin, no other tissue can provide compensatory function.  This is why insulin has 
been so important for diabetes, which is defined by a profound lack of insulin function.   
 In terms of glucose-stimulated insulin secretion from β-cells, a wealth of knowledge has 
been gathered over the last several decades.  Glucose is transported into the β-cell by 
facilitated glucose transporter 2 (GLUT2), which has a Km of ~15 mM (Gould and Holman 
1993).  Then glucose is converted by glucokinase to glucose-6-phosphate, the leading molecule 
for glycolysis.  The subsequent production of ATP from the normal metabolic cycle leads to an 
increase in the ATP/ADP ratio, closure of KATP channels, membrane depolarization, and 
eventual activation of voltage-gated Ca2+ channels that allow Ca2+ influx from the extracellular 
space.  Downstream exocytotic events in the β-cell are much better characterized than in the α-
cell and the F-actin modifying small Rho-GTPase, Rac1, has been shown to be important in 
insulin exocytosis (Li, Luo et al. 2004; Konstantinova, Nikolova et al. 2007).  This enzyme 
remodels the F-actin network proximal to the membrane, allowing vesicle fusion and release of 
insulin and the co-secreted factors (Asahara, Shibutani et al. 2013).  Insulin exocytosis is a 
pulsatile process with Ca2+ waves occurring across the β-cells in the islet, which is mediated by 
gap junctional coupling between the β-cells that allows the islet cells to behave like an electrical 
syncytium (Head, Orseth et al. 2012).  Importantly, the syncytial activity of islet β-cells varies 
wildly across species.   
 Once secreted into the bloodstream, insulin acts through the insulin receptor, which is a 
member of the receptor tyrosine kinase family of enzymes.  The insulin receptor is composed of 
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two extracellular and 2 intracellular subunits that dimerize upon activation by insulin binding.  
This initiates a transphosphorylation and conformational change that induces phosphorylation of 
insulin receptor substrates (IRS).  There are two primary downstream pathways from this point: 
activation of PI3K-AKT (AKT is also known as PKB) signaling, or the Ras-mitogen-activated 
protein kinase (MAPK) pathway, which regulates cell growth.  The PI3K-AKT pathway is 
predominantly critical in metabolic regulation, and is depicted in Figure 1-3.  Active PI3K leads 
to the production of lipid signaling molecule phosphatidylinositol-3,4,5-triphosphate (PIP3) at the 
plasma membrane.  This second messenger recruits AKT to the membrane along with the 
activating enzyme phosphoinositide dependent kinase.  Upon activation, AKT translocates from 
the membrane and participates in a number of downstream intracellular signaling pathways 
depending largely on the tissue, subcellular distribution, and availability of substrates 
(Taniguchi, Emanuelli et al. 2006).  
 
 
 
Figure 1-3. Insulin signaling overview.  
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In the liver, insulin is a multifunctional signaling molecule.  Upon AKT activation, insulin 
stimulates amino acid uptake and protein synthesis via mTORC1 signaling.  Glucose uptake via 
GLUT2 transporter is also stimulated by relieving the inhibition of glycogen synthase kinase 
(GSK3) and allowing glycogen synthesis.  Finally, hepatic fatty acid and triacylglycerol synthesis 
is increased by lipoprotein lipase activity and transcription of lipogenic genes (Mounier and 
Posner 2006).  Additionally, gluconeogenesis is inhibited by AKT’s activation of 
phosphodiesterase 3B (PDE3B), which catalyzes the degradation of cAMP and reduces the 
downstream effectors, thus opposing the stimulatory effect of glucagon through its GPCR (Choi, 
Park et al. 2006).  Insulin action is primarily opposed by protein tyrosine phosphatases that 
dephosphorylate the insulin receptor and reduce its activity (Elchebly, Payette et al. 1999).  
During diabetes, the loss of insulin signaling is a key defect and leads to dramatic increases in 
glucose release, poor glycogen synthesis, poor protein synthesis, and dysregulated 
gluconeogenesis (Michael, Kulkarni et al. 2000).  There are also a number of indirect effects of 
insulin signaling dysfunction during diabetes that ultimately impact the liver, as described briefly 
in (Cherrington 2005). 
In adipocytes, insulin signaling also progresses through the PI3K-AKT-PDE3B pathway 
to inhibit cAMP production, which reduces lipolysis.  Insulin also upregulates lipoprotein lipase 
and stimulates lipogenic enzymes like acetyl-CoA carboxylase and fatty acid synthase (Kersten 
2001).  Additionally, AKT stimulates glucose uptake and glucose transporter GLUT4 
translocation (Kohn, Summers et al. 1996).  In a diabetic state, where insulin signaling is 
insufficient, there is a significant increase in free fatty acids delivered to the blood stream and a 
repartitioning of lipid stores to inappropriate tissues, like the skeletal muscle, liver, and islet cells 
(Yu and Ginsberg 2005).  The inhibitory role of insulin signaling on cAMP generation via PDE3B 
activation in both the liver and adipose tissue was a significant contributor to the experimental 
design and hypothesis behind the work described in Chapter 2.  
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δ-cells and somatostatin signaling 
 Somatostatin is a short 14- or 28-amino acid peptide secreted from multiple cells 
throughout the body including in the hypothalamus, the gastrointestinal tract, and the pancreatic 
islet δ-cells.  Somatostatin-14 inhibits both insulin and glucagon secretion from the islet. 
Somatostatin-28, which is produced by an alternate posttranslational cleavage, has 
neuroendocrine function and may act as a neurotransmitter.  
Somatostatin secretion from the δ-cells is stimulated by glucose and amino acids, 
though comparatively little is known about the molecular mechanisms underlying δ-cell function.  
This secretion is pulsatile and synchronous with insulin while being asynchronous with 
glucagon.  Additionally, the dose response curve for somatostatin resembles that of insulin while 
being slightly left-shifted, such that it leads insulin secretion in response to elevating glucose 
levels (Hellman, Salehi et al. 2009).  While somatostatin is known to be a potent inhibitor of 
insulin and glucagon secretion in the islet, until recently, less attention has been given to 
studying the intra-islet functions.  Furthermore, since somatostatin is locally secreted from other 
tissues in the body, the relative contributions of circulating and islet-derived hormones on α- and 
β- cells is another important avenue of research (Cejvan, Coy et al. 2003; Hauge-Evans, King et 
al. 2009; Kailey, van de Bunt et al. 2012; Schwetz, Ustione et al. 2013). 
Somatostatin functions as the ligand for a family of GPCRs that associate with an 
inhibitory Gαi subunit.  There are 5 known subtypes of these receptors, called somatostatin 
receptors (SSTR) type 1-5 that are encoded by five genes.  SSTR1, SSTR2 and SSTR5 are the 
primary receptors localized in the islet cells, with SSTR2 being predominantly functional in α-
cells (Kailey, van de Bunt et al. 2012) and SSTR5 dominating in the β-cells (Strowski, Parmar et 
al. 2000).  The subtype distribution of these receptors appears conserved in both humans and 
mice, though the subtype specificity data is relatively variable (Kumar, Sasi et al. 1999; Cejvan, 
Coy et al. 2003; Hauge-Evans, King et al. 2009).  The molecular mechanism of somatostatin 
function is debated, due to the large number of possible downstream effects from GPCR 
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activation, described below and depicted in Figure 1-4.  For example, several studies have 
shown that the Gαi subunit is responsible for inhibiting adenylyl cyclase and decreasing cAMP 
levels (Schuit, Derde et al. 1989; Gromada, Hoy et al. 2001; Hauge-Evans, King et al. 2009).  
However, there are also a number of reports suggesting that the βγ complex plays a role in 
somatostatin function via activation of K+ channels that hyperpolarize the membrane to reduce 
Ca2+ activity and exocytosis (Yoshimoto, Fukuyama et al. 1999; Gromada, Hoy et al. 2001; 
Schwetz, Ustione et al. 2013).  These data were instrumental in the hypothesis and 
experimental design for the studies described in Chapter 2. 
 
Regulators of islet function 
 There are several peripheral factors and islet factors that participate in regulating islet 
functions like secretion, protein synthesis, and proliferation.  Many of these tissues have directly 
reciprocal relationships with the islet hormones, such as the adipose tissue, and were described 
above.  The gastrointestinal and nervous system contributions are just as critical, particularly in 
certain physiological states, such as extreme duress.  Additionally, the differences in 
mechanism for these factors between the islet cells provide multiple levels of physiological 
specificity for context-dependent stimulation, which are extensively reviewed here (Quesada, 
Tuduri et al. 2008).   The stimulus-dependent molecular regulation of islet cells is facilitated by a 
number of membrane G-protein coupled receptors (GPCR), including the glucagon and Glp-1 
receptors, which are members of Family B, or the secretin receptor family, of GPCRs.  These 7-
transmembrane domain receptors represent an important paradigm in molecular regulation of 
intracellular function and feature in a variety of different cellular types and organismal functions 
including development, sensory perception, and others.  Additionally, GPCRs represent the 
most common class of receptors targeted for pharmaceutical intervention in disease, and recent 
efforts in designing new drugs for diabetes are targeting the glucagon receptors and Glp-1 
19 
 
receptors (Madsbad 2009; Christensen, Bagger et al. 2011; Christensen, Knop et al. 2011).  
Upon activation by a specific ligand, a conformational change in the GPCR leads to the 
dissociation of the intracellular Gα and Gβγ subunits, which are responsible for the variety of 
downstream effects (Gilman 1987).  There are several types of α subunits that determine their 
function, and for which the receptors are named, as reviewed in (Kimple, Bosch et al. 2011).  
GPCRs coupled to a Gαs subunit stimulate the action of adenylyl cyclases to drive the 
production of cAMP and subsequent signaling events that can lead to ion channel regulation, 
transcriptional activation, and exocytosis.  The Gαi/o subunits inhibit the adenylyl cyclases and 
reduce cAMP generation. Finally, the Gαq subunit family activates PLC and produces lipid 
signaling molecules diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3), which regulate 
downstream ion channel function and release of Ca2+ from intracellular stores (Neves, Ram et 
al. 2002).  
In addition to α subunit signaling, the βγ complex is also a critical component of GPCR 
function, which normally inhibits α subunit function.  However, upon dissociation with receptor 
activation, it is also capable of working as a signaling molecule with such downstream effects as 
ion channel modulation, phosphoinositide3-kinase (PI3K) activation, PLC activation, and 
inhibition of the exocytotic machinery (Brock, Schaefer et al. 2003).  The complexity of these 
downstream signaling pathways and their effects, particularly under conditions where multiple 
ligands are binding their receptors, makes it quite challenging to tease apart the signals that 
drive cellular function for any given cell type.  Particularly since the islet cells influence each 
other only in part via GPCRs (Ahren 2009), and are connected by proximity and junctional 
complexes (Cirulli, Baetens et al. 1994; Konstantinova, Nikolova et al. 2007), deconvolving the 
signaling has been challenging research.  In Figure 1-4, a schematic of several different GPCR-
mediated signaling cascades is shown. The Gαs and Gαi subunit pathways play key roles in the 
studies presented in Chapter 2 with regard to glucagon secretion.   
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Figure 1-4. GPCR signaling examples by α-subunit specificity and primary downstream targets.  
These few examples are prevalent in islet tissue, but make up a small fraction of the systemic 
functions mediated by this family of receptors. 
 
 
Incretin system 
Incretin hormones, like gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (Glp-
1), are produced by specialized intestinal cells and regulate insulin secretion and blood glucose 
in response to a meal.  These hormones account for the differences in response to oral glucose 
load vs intravenous administration.  Glucose-dependent insulinotropic polypeptide (GIP), is a 42 
amino acid peptide that results from cleavage of the proglucagon gene and is secreted from 
gastrointestinal K-cells.  This hormone stimulates insulin secretion from pancreatic β-cells and 
may enhance glucagon secretion from the α-cells, though the role of GIP in regulating glucagon 
is controversial (Lynn, Pamir et al. 2001).  GIP is a glucose-dependent insulin secretagogue 
(Andersen, Elahi et al. 1978).  The GIP receptor in β-cells is a GPCR coupled to a Gαs subunit 
and, thus, stimulates insulin secretion by ramping up cAMP levels in the cytosol and activating 
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PKA/Epac (Christensen, Vedtofte et al. 2011).  This function is lost in type 2 diabetes and in 
animal models including the diabetic Zucker fatty rat, which have a decreased incretin response 
and elevated response to oral glucose load (Lynn, Pamir et al. 2001).  Additionally, some 
reports indicate that GIP increases glucagon secretion at low glucose levels (Pederson and 
Brown 1978; Christensen, Vedtofte et al. 2011), though clinical studies in human subjects show 
little to no change with oral glucose tolerance tests (Theodorakis, Carlson et al. 2004). 
Glp-1, however, has been the focus of much recent research as a potential target for 
treating diabetes due to its inhibitory effect on glucagon secretion and stimulatory role in insulin 
secretion.  A cleavage product of the proglucagon transcript, this 36-residue peptide is secreted 
from intestinal L cells in the presence of ingested carbohydrates, lipids, and proteins.  Like GIP, 
this secretion is glucose dependent, which makes it particularly attractive as a therapeutic target 
for diabetes.  In addition to its roles in islet cell secretion regulation, Glp-1 has been shown to 
inhibit β-cell apoptosis and stimulate proliferation and differentiation (Farilla, Hui et al. 2002).  
Furthermore, Glp-1 inhibits glucagon secretion and gastric emptying, though it remains unclear 
whether or not the glucagon inhibition is due to direct action on the α-cells (Dillon, Lu et al. 
2005; Tornehave, Kristensen et al. 2008).  These functions have led to the development of 
many Glp-1 mimetics, including exenatide and liraglutide, which are currently on the market as 
therapeutics for type 2 diabetes.   
Glp-1 and GIP are both rapidly degraded by dipeptidyl peptidase-4 (DPP-4), which is a 
critical enzyme for regulating incretin function.  This provides another therapeutic avenue by 
inhibiting the Glp-1 inhibitor to increase Glp-1 availability.  Sitagliptin is a DPP-4 inhibitor that 
has recently shown clinical significance by inhibiting glucagon secretion in some contexts 
(DeFronzo, Okerson et al. 2008; Watanabe, Kobayashi et al. 2013).  However, data from 
diabetic patients treated with these drugs have revealed negative side effects such as 
pancreatitis (Garg, Chen et al. 2010; Singh, Chang et al. 2013) and increased risk for pancreatic 
cancer (Alves, Batel-Marques et al. 2012).  The lack of insight into the molecular mechanisms of 
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Glp-1 action in the islet, as well as other tissues, requires further scrutiny, though this peptide 
remains a significant target for type 2 diabetes therapy. 
 
Nervous system 
 In addition to circulating neural factors that can regulate islet function, islet tissue is 
highly innervated.  Parasympathetic innervation is derived from preganglionic parasympathetic 
nerves under the control of the vagus.  A number of neurotransmitters from this system are 
relevant to islet function including acetylcholine, vasoactive intestinal polypeptide, NPY, pituitary 
adenylate cyclase-activating polypeptide, and others.  Parasympathetic stimulation increases 
secretion of insulin, glucagon, somatostatin, and pancreatic polypeptide during hyperglycemia, 
thus coordinating an increase in whole-islet function (Ahren, Paquette et al. 1986; Ahren and 
Taborsky 1986).    
By contrast, the sympathetic nerves in the islet are postganglionic, with cell bodies 
located in the celiac ganglion or paravertebral sympathetic ganglia.  The sympathetic nervous 
system and hypothalamic-pituitary-adrenal (HPA) axis are important components of a high 
stress response in the islets.  In the absence of a normal glucagon response or in periods of 
high stress, the sympathetic nervous system can stimulate glucagon secretion while also 
inhibiting insulin release.  Neurotransmitters secreted from the sympathetic nervous system, like 
neuropeptide Y (Morgan, Kulkarni et al. 1998; Kulkarni, Wang et al. 2000; Schwetz, Ustione et 
al. 2013) and galanin (Dunning, Ahren et al. 1986; Lindskog, Dunning et al. 1990; Ahren, 
Ar'Rajab et al. 1991), inhibit insulin secretion.  Norepinephrine also inhibits insulin and 
somatostatin secretion but simultaneously stimulates glucagon secretion from islets (Ahren, 
Veith et al. 1987; Kurose, Seino et al. 1990; Kurose, Tsuda et al. 1992; Yajima, Komatsu et al. 
2001; Cheng, Straub et al. 2003).  Epinephrine release also stimulates glucagon secretion while 
inhibiting insulin secretion via differential expression of adrenergic receptors, and is discussed in 
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more length in Chapter 2 (Tian, Sandler et al. 2011).  There are also a number of neural 
peptides that have been shown to affect islet function, but the relative contributions of these 
factors have yet to be determined (Ahren 2000).  The nervous system is, thus, a critical 
regulator of islet function, as it provides several options for modulating blood glucose levels in 
order to retain brain function under duress. 
 
Intra-islet regulators 
In support of the paracrine model of glucose-inhibited glucagon secretion, there have 
been a number of identified mechanisms by which the islet cells regulate each other.  While 
none of these has proven a sufficient explanation for glucagon suppression alone, they do show 
the importance of intracellular signaling within the islets.  To begin with the α-cells at low 
glucose, glucagon secretion stimulates insulin and somatostatin secretion from the β- and δ-
cells via increased cAMP signaling. It also exerts an autocrine effect, whereby glucagon 
potentiates its own secretion (Ma, Zhang et al. 2005).  Thus, as glucagon increases, autocrine 
stimulation decreases, and inhibitory molecules are secreted from neighboring cells.  
Additionally, acetylcholine is secreted from human α-cells to potentiate glucose-stimulated 
insulin secretion from β-cells (Rodriguez-Diaz, Dando et al. 2011).  
Insulin has a much more controversial role in the regulation of glucagon secretion from 
α-cells.  Studies in insulin receptor knockout mice have demonstrated that insulin is a critical 
mediator of glucagon secretion but the mechanism by which this occurs is far from agreed upon 
(Kulkarni, Bruning et al. 1999; Diao, Asghar et al. 2005).  Since insulin is insufficient alone to 
suppress glucagon from α-cells isolated from the islet environment, it is likely that several 
molecules are required in combination for the cessation of glucagon exocytosis.  In the δ-cells, 
insulin has been suggested to regulate somatostatin secretion.  However, while insulin receptor 
mRNA has been identified in δ-cells, the evidence that there is a direct action these cells is 
24 
 
controversial and varies between rodent and human studies (Brunicardi, Kleinman et al. 2001; 
Muller, Huang et al. 2007; Hauge-Evans, Anderson et al. 2012).  Somatostatin has been shown 
to inhibit both glucagon and insulin secretion via a couple of different pathways described above 
in the δ-cells and somatostatin secretion section.  One of the major goals of the work presented 
here aimed to shed light on the molecular mechanism by which insulin and somatostatin 
participate in the glucose-dependent inhibition of glucagon secretion, and the results are 
documented in Chapters 2 and 3.  
 
Models of islet hormone secretion 
The opposing functions of insulin and glucagon with respect to blood glucose levels are 
critical in both normal function and the pathophysiology of diabetes, hence the bi-hormonal 
hypothesis of glucose homeostasis.  Because of the therapeutic success of insulin, the majority 
of diabetes research has focused on the β-cells and how to modulate their function to treat or 
prevent dysfunctional glucose-stimulated insulin secretion.  However, the hyperglucagonemia 
associated with diabetes suggests dysfunctional inhibitory mechanisms for glucagon secretion 
from the α-cell as well.  While the importance of glucagon secretion from α-cells is now widely 
accepted, the mechanism by which glucose induces a cessation of glucagon secretion from the 
α-cells is far from clear and hotly debated (Gromada, Franklin et al. 2007).  This debate is at the 
center of the work described in Chapter 2, and continuing studies toward its resolution. 
There are a large number of similarities between α- and β-cells, which have driven the 
development of one of the prevailing models for glucose-inhibited glucagon secretion, called the 
electrophysiology model.  This model proposes that α-cells intrinsically contain the machinery 
for inhibiting exocytosis, including many of the similar membrane potential dynamics as seen in 
the β-cells (Newgard and McGarry 1995; Shiota, Rocheleau et al. 2005; Ramracheya, Ward et 
al. 2010).  Since both cell types metabolize glucose via glucokinase and contain ATP-sensitive 
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K+ (KATP) channels, high-voltage-gated calcium channels, and secretory granules, the molecular 
tools are available for an analogous mode of regulating exocytosis; though Na+ channels are 
proposed to play a different role in α-cell membrane potential (Ramracheya, Ward et al. 2010).  
As recently reviewed (Zhang, Ramracheya et al. 2013), a number of studies on channel activity 
in α-cells from isolated islets demonstrate glucose-dependent KATP channel activity that appears 
similar to the β-cells.  Additionally, some Ca2+ channel studies support this model by 
demonstrating changes in channel activity that are glucose-dependent and decrease with 
increasing glucose (Gopel, Kanno et al. 2000; Gromada, Ma et al. 2004; MacDonald, De Marinis 
et al. 2007).   
However, there is also a wealth of evidence against a direct, intrinsic inhibition of 
glucagon secretion.  Purified α-cells, for example, in the absence of paracrine factors, are 
stimulated by glucose and secrete glucagon in a dose-dependent manner (Franklin, Gromada et 
al. 2005; Olsen, Theander et al. 2005).  There are also reports in clonal α-cell lines in support of 
a direct action of glucose where paracrine factors are negligible (Gromada, Ma et al. 2004; 
Vieira, Salehi et al. 2007).  Unfortunately, the clonal α-cell lines are notoriously poor models of 
the physiology observed in intact islet α-cells, which makes interpretation of data collected in 
these cell lines difficult (Hamaguchi and Leiter 1990; Powers, Efrat et al. 1990).  Thus, the 
relative roles of ion channels in regulating glucagon secretion are still unclear, with increasingly 
complex theories being produced to explain their roles in the stimulation and inhibition of 
glucagon secretion (Zhang, Ramracheya et al. 2013).  
Another hypothesis, known as the store-operated model, has also been recently 
developed and is based on the observation that inhibiting the sarcoplasmic-endoplasmic 
reticulum Ca2+ ATPase pump (SERCA) causes Ca2+ oscillations in α-cells.  In this model, a Ca2+ 
dependent store-operated depolarizing current is inhibited as glucose increases, thus 
decreasing intracellular Ca2+ availability for granule exocytosis (Liu, Vieira et al. 2004; Vieira, 
Salehi et al. 2007).  However, inhibiting the SERCA pump by thapsigargin does not affect 
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glucose-stimulated glucagon secretion from purified α-cells, so the contribution of this 
mechanism in regulating glucagon secretion is unclear (Olsen, Theander et al. 2005). 
Finally, the paracrine model states that secreted islet factors such as Zn2+, γ-
aminobutyric acid (GABA), or insulin itself, inhibit glucagon secretion by overcoming the 
depolarizing effect of glucose metabolism (Starke, Imamura et al. 1987; Unger and Orci 2010; 
Chen, Philippe et al. 2011; Unger and Cherrington 2012).  This model was produced partially by 
data that did not support the electrophysiology model, as described above.  Additionally, several 
secreted factors have been shown to be required for glucagon suppression (Starke, Imamura et 
al. 1987; Xu, Kumar et al. 2006; Unger and Orci 2010; Chen, Philippe et al. 2011; Unger and 
Cherrington 2012).   These data strongly suggested a critical role for either a paracrine 
molecule(s) released from neighboring cells, juxtacrine connections between the islet cells, or 
both in the suppression of glucagon exocytosis.  However, we have shown that several 
candidate inhibitors, including somatostatin, insulin, and GABA are insufficient alone to inhibit 
glucagon secretion from purified populations of α-cells, suggesting that a more complex 
mechanism is involved (Le Marchand and Piston 2010).  A promising candidate from this study 
was Zn2+, which is co-secreted with insulin and c-peptide, and did inhibit glucagon secretion 
from purified α-cells.  Studies done in Zn2+ transporter knockout mice have ruled out this factor 
as a regulator of glucagon inhibition, as glucagon secretion was not altered in those animals or 
islets (Nicolson, Bellomo et al. 2009). 
All of these models commonly assume that a decrease in intracellular Ca2+ is required 
for glucagon inhibition.  However, it has been shown that glucose stimulation in α-cells does not 
reduce global intracellular Ca2+ activity, which indicates that suppression of glucagon secretion 
occurs independent of Ca2+ signaling (Le Marchand and Piston 2010; Le Marchand and Piston 
2012).  A consensus on the molecular mechanism of glucagon suppression has yet to be 
reached because the data from any given experiment are insufficient to explain all of the 
observations reported.
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CHAPTER 2 
 
ROLE OF SOMATOSTATIN AND INSULIN RECEPTORS IN GLUCOSE-INHIBITED 
GLUCAGON SECRETION 
 
(Adapted and expanded from Elliott & Piston, Submitted, Diabetes, 2014) 
 
Introduction 
 Glucagon secretion from pancreatic islet α-cells is inhibited during hyperglycemia, and this 
inhibition plays a critical role in blood glucose homeostasis.  During diabetes, α-cell 
dysregulation leads to hyperglucagonemia, which in turn over-stimulates liver glucose 
production and exacerbates chronic hyperglycemia.  In spite of the therapeutic success of 
insulin, it has recently been suggested that glucagon hypersecretion, rather than a lack of 
insulin, is the primary driver of chronic hyperglycemia (Unger and Cherrington, 2012).  
Regardless of the root cause of diabetic phenotypes, persistent glucagon secretion during 
diabetes makes the α-cell an important target for therapeutic intervention.  Current glucagon-
related therapies address hyperglycemia by mimicking natural glucagon inhibitors (such as 
GLP-1 mimetics (Drucker and Nauck, 2006)) or antagonizing the glucagon receptor 
(Christensen et al., 2011).  However, data from diabetic patients treated with exenatide have 
revealed negative side effects such as pancreatitis (Singh et al., 2013) and pancreatic cancer 
(Alves et al., 2012).   
 Various hypotheses have been put forth to explain the suppression of glucagon secretion, 
including paracrine regulation by islet factors (Koh et al., 2012), changes in ion channel activity 
(Zhang et al., 2013), and others; but they commonly assume that a decrease in intracellular 
28 
 
Ca2+ activity ([Ca2+]i) is required.  By contrast, our laboratory (Le Marchand and Piston, 2010, 
2012) and others (Tian et al., 2011) have shown that glucagon suppression is independent of 
[Ca2+]i, and none of the current hypotheses explain the loss of glucose inhibition of glucagon 
secretion from α-cells isolated from the native islet environment (Le Marchand and Piston, 
2010).   
 Under normal physiological conditions, euglycemia is maintained in the face of rising blood 
glucose by a rise in somatostatin and insulin secretion from islet δ- and β-cells, respectively, 
accompanied by an inhibition of glucagon secretion.  In Type I and advanced Type II diabetes, 
where β-cells are absent or mostly dysfunctional, somatostatin is believed to play a primary role 
in the inhibition of glucagon secretion (Cheng-Xue et al., 2013; Hauge-Evans et al., 2010; Kailey 
et al., 2012; Strowski et al., 2000; Yue et al., 2012).  However, a global somatostatin deletion 
does not lead to increased basal glucagon secretion (Hauge-Evans et al., 2009) and infusion of 
a specific somatostatin receptor type 2 (SSTR2) antagonist in the absence of insulin does not 
affect blood levels of glucagon or blood glucose (Yue et al., 2012).  Isolated islets from SSTR2 
knockout mice show a two-fold increase in glucagon secretion compared with wild type, though, 
suggesting a role for somatostatin in glucagon inhibition (Strowski et al., 2000).  While multiple 
somatostatin receptors have been identified in islets, SSTR2 is the most abundant in human α-
cells (Dorrell et al., 2011), and is the only isoform expressed in murine α-cells (Strowski et al., 
2000).  Additionally, SSTR2 has been shown to be the functionally dominant isoform in α-cells 
from both species (Kailey et al., 2012).  When somatostatin activates this receptor, the Gαi 
subunit inhibits adenylyl cyclases to reduce cAMP and glucagon secretion is decreased.  
 Knockdown of the insulin receptor (IR) in isolated islets leads to changes in glucose 
inhibition of glucagon secretion, without any effect on insulin secretion, which points to a direct 
role of the insulin receptor in α-cells (Diao et al., 2005).  Tissue-specific insulin receptor 
knockout mice have also been characterized for both α-cells (αIRKO) and β-cells (βIRKO).  The 
βIRKO mice exhibit normal fasting glucose levels, but have impaired glucose tolerance.  
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Glucagon secretion from isolated βIRKO islets was not reported (Kulkarni et al., 1999).  In 
contrast, the αIRKO mice exhibit hyperglycemia, hyperglucagonemia, and glucose intolerance, 
but again, glucagon secretion from these islets was not reported (Kawamori et al., 2009).   
 While the role of insulin signaling in the α-cell is debated, it has been suggested that insulin 
reduces KATP channel sensitivity (Franklin et al., 2005; Matsumura et al., 1999), or activates 
Akt downstream of PI3-kinase to recruit GABA-A receptors to the membrane, which allows for 
inhibition by secreted GABA (Xu et al., 2006).  These mechanisms still rely on a change in Ca2+ 
signaling, which is not observed in α-cells (Le Marchand and Piston, 2010, 2012).  However, 
insulin receptor stimulation can also activate phosphodiesterase 3B, which degrades cellular 
cAMP (Zmuda-Trzebiatowska et al., 2006).  Phosphodiesterase inhibitors have been shown to 
increase amino-acid stimulated glucagon secretion from isolated islets by increasing cAMP 
(Jarrousse and Rosselin, 1975), and the phosphodiesterase inhibitors rolipram and cilostazol, 
have shown efficacy in preventing diabetes in rodents and diabetic complications in humans 
(Katakami et al., 2010; Liang et al., 1998).   
 Collectively, experiments from our laboratory in islet α-cells and the work of many others led 
us to the hypothesis that somatostatin and insulin may be exerting their inhibitory functions by 
cooperatively decreasing cAMP and PKA signaling to reduce glucagon secretion; rather than by 
decreasing intracellular Ca2+ in the cell.  Thus, to determine the role that cAMP and its 
somatostatin- and insulin-dependent changes play in inhibiting α-cell glucagon secretion, we 
combined hormone secretion assays, [Ca2+]i imaging, and immunofluorescence of whole islets 
and purified α-cells.  The results point to a mechanism for glucagon suppression where 
somatostatin and insulin signaling converge to lower cAMP by both decreasing its production 
and driving its degradation, leading to reduced phosphorylation of PKA.  This chapter includes 
the detailed results of these studies, methodology employed, and a brief summary of the 
significance of the findings, which will be expanded upon in Chapter 5: Conclusions and Future 
Directions.  
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Materials and Methods 
Islet isolation and culture 
All animal studies were conducted in compliance with the Vanderbilt University Institutional 
Animal Care and Use Committee (IACUC).  Pancreata from 8-15 week old transgenic male 
mice (C57BL/6 genetic background) that express tandem-dimer Red Fluorescent Proteins 
(tdRFP) in α-cells were isolated as described (Le Marchand and Piston 2010; Schwetz, Ustione 
et al. 2013), and cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum 
(FBS; Invitrogen), penicillin/streptomycin (Invitrogen), and 11 mM glucose until use.  Human 
islets were kindly provided by Dr. David Jacobson and upon receipt, were hand-picked into 
RPMI 1640 (Invitrogen) with 11 mM glucose and 2% BSA (Sigma) and allowed to recover for 3-
4 hours before use.  
 
Glucagon secretion assay 
 Isolated islets were cultured overnight inn media, then incubated for 1 hour in buffer consisting 
of 644.1 mM NaCl, 24 mM KCl, 6 mM KH2PO4, 6 mM MgSO4•7H2O, 12.5 mM CaCl2, 20 mM 
Hepes, and 5 mM NaHCO3  (pH7.4) with 2.8 mM glucose.  12-15 islets per sample were 
transferred to buffer with low (1 mM) or high (11 mM) glucose with and without the following 
drugs: 300 µM 8-Bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP - Sigma), 300 µM 8-
(4-Chlorophenylthio)-2′-O-methyladenosine 3′,5′-cyclic monophosphate monosodium hydrate (8-
O-Me-CPT - Sigma), 300 µM  N6-Benzoyladenosine-3′,5′-cyclic monophosphate sodium salt (6-
Bnz-cAMP - Sigma), 100 nM insulin (Sigma), 1 µM insulin, 1 µM somatostatin (sigma), 1 µM 
epinephrine (Acros Organics), 1 µM S961 (Novo Nordisk), 50 µM forskolin (Sigma), 100 µM 
IBMX (Sigma), 100 µM Rp-cAMPS (Sigma), cyclosomatostatin (Tocris), and/or 200 nM 
CYN154806 (Tocris) for 45 minutes with occasional agitation at 37ºC.  The samples were 
centrifuged briefly (Beckman) and supernatants collected as secretion samples.  1.5% HCl/70% 
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ethanol was added to the remaining islet sample and vortexed for islet content quantification.  
Glucagon and insulin content and secretion were measured in duplicate with Glucagon ELISA 
(RayBiotech), Mouse UltraSensitive Insulin ELISA (Alpco), or Human Insulin ELISA (Alpco), and 
detected on a Spectra Max M5 spectrometer (Molecular Devices).  Studies with pertussis toxin 
(Sigma) were accomplished by an overnight pre-treatment of isolated islets and follow-up 
secretion experiments as described above.  
 
Immunofluorescence 
 Islets were treated as for secretion assays described above and then fixed in PBS containing 
2% of paraformaldehyde at 4°C.  Samples were permeabilized overnight at 4°C in PBS with 
0.3% Triton X-100, 5 mM sodium azide, 1% bovine serum albumin, and 5% goat serum (from 
Jackson ImmunoResearch Laboratories, West Grove, PA).  Human islets were incubated with 
rabbit anti-glucagon (1:250), guinea pig anti-human insulin (1:250), and mouse anti-cAMP 
(1:250) primary antibodies for 24–48 h at 4°C, washed (2X), and incubated with secondary 
antibodies conjugated with Alexa Fluor 488 (1:1000), Alexa Fluor 546 (1:1000), and Alexa Fluor 
594 (1:1000) or Cy5 (1:1000) for  24 h, and washed (2X) before mounting in gelvatol.  Mouse 
islets were stained similarly, but with rabbit anti-insulin (1:250), guinea pig anti-glucagon 
(1:250), mouse anti-cAMP (1:250), or rabbit anti-phospho-PKA primary antibodies.  All islets 
were washed overnight between primary and secondary antibodies as an additional blocking 
step with the permeabilization buffer above.  The washing buffer consists of PBS with 0.1% 
Triton X-100, 5 mM sodium azide, and 1% bovine serum albumin.  Immunofluorescence was 
detected by confocal microscopy using 488 nm (AF488), 561 nm (AF561), or 633 nm (AF594 or 
Cy5) excitation and corresponding spectral windows (LSM780, Carl Zeiss).  All analysis was 
performed only on raw data, but for display purposes, image look-up tables were compressed 
equally for gamma and brightness to aid the eye.   
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Live-cell imaging 
Live islets were imaged as described (Le Marchand and Piston 2010).  For calcium imaging, 
islets were incubated with 5 μM of Fluo4-AM for 30 minutes at 2.8 mM glucose.  After washing, 
islets were allowed to equilibrate on the microscope stage for 15 minutes in the same solution.  
Fluo4 was excited at 488 nm and detected between 490 and 560 nm.  Red α-cells were 
localized by recording tdRFP fluorescence excited by 561 nm.  Confocal sections were obtained 
with an LSM710 or LSM780 (Carl Zeiss) using a Fluar 40x/1.3NA lens and a 2 Airy unit pinhole.  
Because β-cells constitute ~ 80% of the cells in the islet (Gromada, Bokvist et al. 1997), the 
Fluo4 signal from non-tdRFP cells in the center of the islet was considered to represent the 
average β-cell response.  Mean intensities were normalized to the first 5 frames of data 8 
minutes after reagent change. 
 
Cell dispersion and FACS sorting 
Isolated islets were cultured overnight in islet medium with 11 mM glucose and washed in DPBS 
at pH 7.4 without calcium and magnesium chloride.  Accutase (Life Technologies) was used for 
digestion for 15 minutes at 37ºC (gentle shaking) and cells were pelleted and resuspended in 
secretion buffer at 11 mM glucose.  One to two hours after Accutase dispersion, fluorescent 
cells were isolated by fluorescence-activated cell-sorting (FACS).  The Vanderbilt Flow 
Cytometry Core facility utilized a BD FACSAria cell sorter (BD Biosciences, San Jose, CA) for 
purification and DAPI (0.5 μg/ml) was used for exclusion of non-viable cells.  Yields were 100-
800 viable α-cells per mouse pancreas. 
 
Data analysis and statistics 
Data were analyzed with ImageJ, MatLab, or GraphPad Prism software.  For all imaging data 
collected, the background signal was subtracted and the mean fluorescence intensity was 
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determined by region of interest.  Data are reported as mean ± S.E.M. with p < 0.05 considered 
statistically significant as determined by Student’s t-test.  
 
Results 
There are several challenges with studying islet α-cells, including their identification 
within the islet and isolation for the purposes of studying pure populations.  To address these 
challenges, we have utilized a mouse model that expresses selectively a red fluorescent protein 
(tdRFP) in the α-cells by using a Cre-recombinase system driven by the glucagon promoter.  
This model has facilitated imaging and immunofluorescence studies of theα-cells.  It also allows 
us to use fluorescence-activated cell sorting (FACS) to purify the α-cells upon dispersion of the 
islets.  However, previous studies with the FACS-sorted cells have revealed a large deviation in 
function from α-cells in the native islet environment, particularly with regard to inhibiting 
glucagon secretion.  None of the known candidate inhibitors of glucagon secretion, except Zn2+, 
were sufficient to inhibit exocytosis from the isolated cells.  Mouse models with deficiencies in 
Zn2+ transport have no phenotype with regard to glucagon secretion, thus ruling it out as the 
primary mechanism of glucagon suppression.  We have concluded from such studies that the 
junctional contacts between islet cells, which are still being elucidated, and possibly several 
secreted products from neighboring cells play a major role in the nominal function of α-cells.  
Our hypothesis, then, began with the idea that cAMP rather than Ca2+ may be the 
signaling pathway at the heart of glucose-inhibited glucagon secretion.  Additionally, there are a 
number of surface receptors expressed in α-cells that are known to function by modulating 
cAMP levels, which provided several candidates to test.  However, we first needed to identify 
whether or not cAMP was regulated by increasing glucose levels in the α-cells, as has been 
reported by other groups, and second, we needed to determine whether or not such a regulation 
was dependent on changes in Ca2+ activity.  
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Glucose regulation of cAMP in human and mouse islets  
To establish the effect of glucose on α-cell cAMP levels, we used semi-quantitative 
immunofluorescence to measure cAMP in human and murine islets that were stimulated with 
low (1 mM) or high (11 mM) glucose.  While there are several drawbacks to using 
immunofluorescence as a quantitative measuring system, reviewed in (Taylor and Levenson 
2006), it was the most practical technique available for studying α-cells in their native islet 
environment.  However, in addition to the standard challenges with immunofluorescence 
measures, fixing the islets after stimulation to capture the transient changes in cAMP levels was 
another potential concern.  The localized cAMP measured by this technique is likely bound to 
receptors, as the washing and fixation process may result in the loss of free, soluble nucleotides 
(Greene, Shanfeld et al. 1980).  However, the bound cAMP is still in equilibrium with the free 
cAMP and thus, provides a semi-quantitative means of comparing control and treatment groups.  
It has been shown that a as a semi-quantitative method, relative changes in cyclic nucleotides 
can be addressed with immunostaining and provide informative results (Dousa, Barnes et al. 
1977; Ong and Steiner 1977; Ortez 1978). 
 Using whole islets, this method also allowed us to measure the cAMP in β-cells, where 
it is much better characterized, and this provided an intrinsic control for all of our experiments in 
α-cells using this method.  Thus, assuming our hypothesis was correct; we expected to see a 
decrease in cAMP levels in the α-cells at 11 mM glucose as compared to 1 mM glucose.  
Representative images for one human islet and one murine islet are displayed in Figure 2-1, 
where islet α-cells were identified via primary antibodies to glucagon and mean intensities for 
each channel were background-corrected by pre-immune control images.  By eye, the 
differences in cAMP levels (green channel) are more evident in the murine tissue; however our 
conclusions were drawn from the quantitative results shown in Figure 2-3, below.  
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Figure 2-1: cAMP is decreased with high glucose in human and murine α-cells.  (A-B) 
Immunofluorescence from donor human or isolated murine islets statically incubated with 1 or 
11 mM glucose before fixing and staining for glucagon and cAMP; cAMP in green, glucagon in 
red and glucagon-positive cells outlined in white.  Images from representative (A) human islets 
and (B) murine islets shown with merged pre-immune control images (top). 
 
 
As mentioned, primary antibodies against insulin were also used to identify the effect of 
glucose on cAMP levels in β-cells.  Based on a wealth of previous literature, we expected to see 
an increase in cAMP with glucose.  This parallel experiment provided a very nice control for the 
immunofluorescence; as a way to be sure the cAMP antibody would exhibit differences in cAMP 
levels in the islet cells, and also to demonstrate that the protocol used for stimulation, fixing, and 
staining was effective.  Figure 2-2 shows representative immunofluorescence images from the 
same islets as in 3-1, with the β-cells labeled in blue and cAMP again in green.  
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Importantly, the antibody used to measure cAMP exhibited enough dynamic range to 
identify differences in cAMP levels in the islets with a variety of experimental treatments.  
Standardizing the imaging settings allowed us to compare directly the mean intensity from the α- 
and β-cells from many islets after normalizing to pre-immune controls.  The paradigm developed 
with these first studies using the immunofluorescence was carried on throughout the remainder 
of the work in this chapter, though for simplicity, only representative merged (cAMP and 
glucagon or insulin) images will be shown along with the quantification, from which we drew our 
conclusions.  
 
 
Figure 2-2:  In islet β-cells, cAMP increases with increasing glucose levels in humans and mice.  
Representative images from (A) human islets and (B) murine islets; cAMP in green, insulin in 
blue. 
 
 
 Figure 2-3 shows the quantification of mean intensities for cAMP from the α- and β-cells 
treated with either low or high glucose averaged across isolated islets from 4 human donors and 
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10 mice, including those represented in Figures 3-1 and 3-2.  We found that  islets treated with 
11 mM glucose showed reduced cAMP in both human (32.6% ± 3.43) and murine (24.4% ± 
3.98) islet α-cells compared with islets stimulated with 1 mM glucose.  In contrast, islet β-cells 
displayed an increase in cAMP at high glucose in human (27% ± 4.6) and murine (21.5% ± 3.7) 
islets, as expected from the literature.  These studies lent credence to our initial hypothesis, but 
we did some additional control experiments to convince ourselves that the immunofluorescence 
method would be fruitful for testing the other components of our theories.  
 
 
Figure 2-3: cAMP is differentially regulated between α- and β-cells in human and murine islets. 
Quantification of mean intensity normalized to pre-immune controls from the 
immunofluorescence images in 3-1 (A) and 3-2 (B).  Error bars represent the S.E.M. across 
islets from 4-6 human donors or 4-10 mice and p values were determined by Student’s t-test. * 
indicates p < 0.05, ** p < 0.01, *** p < 0.0001. 
 
 
Thus, we also used this technique to confirm that phosphodiesterase inhibitor 3-isobutyl-
1-methylxanthine (IBMX) and adenylyl cyclase activator (forskolin) would exhibit the known 
stimulatory effects on cAMP levels.  We expected that maximizing the activity of cAMP in the α-
cells would relieve the observed inhibition due to high glucose levels.  Since the treatment with 
IBMX and forskolin maximized the amount of cAMP available for the primary antibodies to bind, 
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we used this experiment to identify the upper bound of expected signal and dynamic range of 
the assay.  We found that murine islet α-cells treated with IBMX/forskolin showed no 
significantly differences between those stimulated at 1 mM or 11 mM glucose.  However, 
compared with control islets (11 mM glucose alone), cAMP intensity was increased 21.6% ± 5.8 
across islets isolated from 6-10 mice, as shown in Figure 2-4.  
Of note, the similarity in the cAMP levels in α-cells treated with IBMX/forskolin is 
consistent with a maximal level that can be produced, which should be limited, in part, by the 
amount of ATP available for the reaction by adenylyl cyclases.  Additionally, the lack of further 
stimulation in cAMP levels at 1 mM glucose in the presence of IBMX/forskolin suggests that this 
pathway is already maximally being utilized by the α-cells in response to low glucose, which 
implies that these cells rely heavily on this signaling pathway for normal function.  
 
 
Figure 2-4: Glucose-inhibition of cAMP can be overcome by stimulating production and 
inhibiting degradation of cAMP.  (A) Representative images of islets treated with 100 μM IBMX 
and 50 μM forskolin at 1 (left) and 11 (right) mM glucose.  (B) Quantification of mean intensity 
normalized to pre-immune controls from the immunofluorescence images.  Error bars represent 
the S.E.M. across 6-10 mice in each experiment and p values were determined by Student’s t-
test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001. 
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Effect of forced cAMP elevation on glucagon secretion 
In several endocrine cell types, including islet α- and β-cells, stimulating cAMP has been 
shown to increase secretion.  Thus, to determine if forcibly elevating cAMP is sufficient to 
overcome the glucose inhibition of glucagon secretion from α-cells, we measured glucagon 
secretion from donor human islets and isolated murine islets treated with IBMX and/or forskolin.  
In human islets, we observed a 3.22 ± 0.14 fold increase in glucagon secretion following 
IBMX/forskolin treatment compared to glucose alone at 11 mM glucose; but no significant 
difference was found at 1 mM glucose.  Similarly, in murine islets at 11 mM glucose, the 
forskolin-treated samples exhibited a 2.1 ± 0.06 fold increase in glucagon secretion over 11 mM 
glucose alone, with no difference at 1 mM glucose, as shown in Figure 2-5.  From these data, 
we conclude that modulating cAMP levels exerts a glucose-dependent effect on glucagon 
secretion in the islet α-cells.   
 
 
Figure 2-5: Forced elevation of cAMP overcomes glucose-inhibition of glucagon secretion.  (A) 
Glucagon secretion from islets treated with 100 μM IBMX and 50 μM forskolin from the islets of 
4 human donors.  (B) Glucagon secretion from isolated murine islets treated with forskolin.  
Error bars represent the S.E.M. and p values were determined by Student’s t-test. * indicates p 
< 0.05, ** p < 0.01, *** p < 0.0001. 
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We know from the literature that IBMX/forskolin stimulation of cAMP also strongly 
stimulates β-cells and insulin secretion (and possibly somatostatin secretion from δ-cells), 
particularly at high glucose levels, so we concluded that the rise in cAMP and glucagon 
secretion that we observed in the α-cell were due to direct action upon them.  However, to 
control for possible cAMP-mediated effects on β-cell regulation, we also measured insulin 
secretion from the same islets.  Insulin secretion from cAMP-stimulated islets was increased 
1.78 ± 0.61 and 15.3 ± 2.8 fold in humans and mice, respectively, at 11 mM glucose, as shown 
in Figure 2-6.  Since we still see a loss of glucagon inhibition from the α-cells after cAMP 
stimulation in spite of the increase in available insulin, we maintain that cAMP must be 
decreased in the α-cell for proper suppression of glucagon exocytosis and that this effect is not 
mediated by the β-cells. 
 
 
Figure 2-6: cAMP stimulation increases insulin secretion from islet β-cells.  (A) Insulin secretion 
from islets treated with 100 μM IBMX and 50 μM forskolin from the islets of 3 human donors.  
(B) Insulin secretion from isolated murine islets treated with forskolin.  These data are from the 
same samples as those in Fig. 2-5).  Error bars represent the S.E.M. and p values were 
determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001. 
 
 
41 
 
The maximal stimulation of cAMP by forcibly activating adenylyl cyclase and inhibiting 
degradation by phosphodiesterases can be expected to have many effects, particularly at high 
glucose levels, where a superfluity of events are occurring across the islet cells.  To determine if 
activating cAMP signaling could overcome the inhibition of glucagon in a more physiological 
manner, we treated islet cells with a cell-permeant cAMP analog, which has a slight 
phosphodiesterase resistance, at low and high glucose.  We expected this molecule to elicit the 
same effects as treatment with IBMX/forskolin, and that is what we observed.  Islet stimulation 
with the cAMP analog 8-Br-cAMP caused a 2.48 ± 0.05 fold increase in glucagon secretion over 
glucose-only controls at 11 mM glucose, with no significant effect at 1 mM glucose, as shown in 
Figure 2-7.  This confirms that there is a glucose-dependent effect on glucagon secretion via 
cAMP pathway modulation that is detectable without maximally stimulating this pathway.   
 
 
Figure 2-7: A cAMP analog overcomes glucagon inhibition at high glucose.  Glucagon secretion 
from isolated murine islets treated with 300 μM 8-Br-cAMP at 1 and 11 mM glucose.  Error bars 
represent the S.E.M. and p values were determined by Student’s t-test. * indicates p < 0.05, ** p 
< 0.01, *** p < 0.0001. 
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Glucose-dependent α-Cell cAMP signaling is independent of intracellular calcium 
The prevailing models of glucose-inhibited glucagon secretion all rely on a decrease in 
intracellular Ca2+ ([Ca2+]i)as the primary mechanism for suppressing exocytosis.  However, we 
and other have demonstrated that this is not the case and part of the motivation for looking at 
the role of cAMP in glucagon inhibition was to identify a mechanism that explained the previous 
data.  Since cAMP and Ca2+ signaling often cross-talk, and several cAMP-related signaling 
cascades lead to a modulation of [Ca2+]i, we tested the effect of stimulating cAMP signaling on 
[Ca2+]i.  The expected candidate system for suppressing glucagon secretion with increasing 
glucose must not rely on a decrease in [Ca2+]i  to be consistent with our previous findings.  
To determine whether modulating cAMP affects [Ca2+]i in α-cells, we utilized loaded 
islets isolated from mice with tdRFP-expressing α-cells (Le Marchand and Piston 2010) with the 
fluorescent Ca2+ indicator dye Fluo4.  Using a microfluidic device (Rocheleau, Walker et al. 
2004), Fluo4 intensity was monitored over time in islets treated with IBMX and forskolin.  No 
significant differences in [Ca2+]i were observed between either 1 and 11 mM glucose, nor 
between the IBMX/forskolin treated  and untreated groups.  Additionally, the percentage of α-
cells that were oscillating was unaffected by change in glucose concentration and treatment with 
IBMX/forskolin, as demonstrated by single cell time-course traces of Fluo4 intensity, consistent 
with other published observations (Quesada, Todorova et al. 2006; Le Marchand and Piston 
2010).  Figure 2-8 displays the results from measuring [Ca2+]i in 2-6 isolated islets from 4 mice. 
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Figure 2-8: cAMP stimulation is independent from changes in α-cell [Ca2+]i.  Isolated murine 
islets were exposed to 1 mM or 11 mM glucose in the absence (white bars) and presence (black 
bars) of 100 µM IBMX and 50 µM forskolin (Fsk) and subjected to Ca2+ imaging via Fluo4 
intensity.  (A) [Ca2+]i as measured by Fluo4 intensity (AUC) in murine isolated islets treated with 
glucose alone or in the presence of IBMX and Fsk.  (B) Mean percent of cells with oscillations in 
Ca2+ as a function of glucose, where α-cells were identified by td-RFP expression in islets from 
4 mice.  Representative [Ca2+]i response to glucose alone or IBMX/Fsk stimulation at 1 mM (C) 
and 11 mM (D) glucose.  Timecourse traces are offset for clarity.  Error bars represent the 
S.E.M. 
 
 
 
As the role of [Ca2+]i in the glucose-dependent suppression of glucagon secretion is 
debated in the field, we also analyzed the β-cells to determine the effect of stimulating cAMP, 
expecting an increase in activity and number of active cells based on a wealth of previous 
reports.  We observed that 11 mM glucose drove a 33.3% ± 0.12 and IBMX/forskolin a 62.1% ± 
0.2 increase in [Ca2+]i, respectively, over 1 mM glucose alone in the β-cells from the same islets 
as in Figure 2-7.  The number of oscillating cells was also increased 58.3% ± 3.8 by 11 mM 
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glucose and 63.5% ± 4.5 with IBMX/forskolin stimulation over 1 mM glucose alone.  Additionally, 
treatment with IBMX/forskolin at 11 mM glucose further significantly increased [Ca2+]i and the 
percentage of oscillating cells, which supports previous observations (Dyachok, Isakov et al. 
2006) of β-cell activity, and confirmed that our assay was effective for identifying any effects of 
cAMP stimulation on [Ca2+]i in the islets.  The β-cell data is shown below in Figure 2-9. 
From the collected data on [Ca2+]i and cAMP elevation in the islet α-cells, we conclude 
that, in contrast to β-cells, stimulating cAMP does not modulate global [Ca2+]i in the α-cells.  
 
 
Figure 2-9: Modulating cAMP signaling differentially affects insulin and glucagon signaling in 
human and murine islets.  (A) [Ca2+]i as measured by Fluo4 intensity (AUC) in murine isolated 
islets treated with 1 and 11 mM glucose alone (white bars) or in the presence of 100 µM IBMX 
and 50 µM forskolin (black bars).  (B) Mean percent of cells with oscillations in Ca2+ as a 
function of glucose, where β-cells were identified as those not expressing td-RFP in islets from 4 
mice.  (C) Representative intracellular free-calcium response to glucose alone or IBMX/forskolin 
at 1 mM and (D) 11 mM glucose.  Timecourse traces are offset for clarity. 
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Epinephrine increases cAMP across glucose levels in islet α-cells 
Another important mechanism for increasing glucagon secretion is via the catecholamine 
epinephrine (a.k.a. adrenaline), which is a hormone and neurotransmitter produced by the 
adrenal medulla.  Epinephrine binds to G-protein coupled adrenergic receptors of either the α- 
or β- family and typically acts by increasing cAMP production by adenylyl cyclases.  The 
opposing functions by receptor subtype are a critical feature for islet biology.  Islet α-cells 
express β-adrenergic receptors, which when stimulated, increase production of cAMP by 
activating adenylyl cyclases.  By contrast, the β-cells express α2-adrenergic receptors, which 
are coupled to an inhibitory Gαi subunit that reduces cAMP production and Ca
2+ channel activity 
and leads to decreased insulin secretion.  In our studies, we treated isolated murine islets with 
epinephrine and measured the cAMP by immunofluorescence as with previous studies.  As 
expected, we found a significant increase in cAMP mean intensity in the α-cells at both low and 
high glucose in islets treated with epinephrine compared with glucose-only treated islets, as 
shown in Figure 2-10.  Since glucagon secretion has been heavily characterized with 
epinephrine treatment, we did not perform those experiments.  However, several publications 
(Gromada, Bokvist et al. 1997; Kawamori, Kurpad et al. 2009; Hauge-Evans, King et al. 2010; 
Tian, Sandler et al. 2011) demonstrate the glucose-independence of epinephrine in stimulating 
glucagon secretion from islets.  
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Figure 2-10: Epinephrine stimulates cAMP independently of glucose levels in islet α-cell.  (A)  
Normalized cAMP intensities from isolated islets of 4 mice treated with either 1 mM glucose 
(white bars) or 11 mM glucose (black bars) in the presence and absence of epinephrine.  (B) 
Normalized phospho-PKA intensities from (A).  Error bars represent the S.E.M. and p values 
were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
We also analyzed the β-cells from the same islets treated with epinephrine to confirm 
that there is no increase in cAMP levels in epinephrine-treated vs glucose-only treated islets.  
Consistent with the literature, we find no increase in cAMP with epinephrine treatment of 
isolated islets, as compared with glucose alone, which is shown in Figure 2-11.  Treatment with 
epinephrine significantly blunted the normal stimulation of cAMP by glucose in the β-cells and 
produced no significant affect at low glucose.  These experiments confirmed that cAMP 
signaling can be regulated in glucose-dependent and independent ways in the α-cells, which is 
an important factor in stimulus-secretion coupled systems.  Finally, while [Ca2+]i is a known 
downstream target of epinephrine signaling, we did not see a glucose-dependent change in 
Ca2+ with forced elevation of cAMP (Fig. 3-8).  These data demonstrate the different 
mechanisms by which second messengers can be utilized by various stimuli in the islet cells to 
control hormone secretion differentially among the specific cell types. 
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Figure 2-11: Epinephrine does not stimulate cAMP in islet β-cells.  (A)  Normalized cAMP 
intensities.  Error bars represent the S.E.M. and p values were determined by Student’s t-test. * 
indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
These data solidified cAMP signaling as a candidate pathway whose activity must be 
decreased in mediating the inhibition of glucagon secretion with glucose.  Additionally, there are 
a number of G-protein coupled receptors present in the α-cells, with at least one, the 
somatostatin receptor, having an inhibitory Gαi subunit that might explain how cAMP is being 
reduced with glucose.  This was the basis for the following line of enquiry in our studies: to 
determine if somatostatin is driving the decrease in cAMP at high glucose that we observed in 
the α-cells. 
 
Somatostatin prevents cAMP production via the Gαi subunit of SSTR2 
Another important regulator of glucagon secretion is the δ-cell product somatostatin, 
which has been shown also to affect intracellular cAMP levels.  Somatostatin is a potent 
inhibitor of glucagon secretion and the most highly expressed somatostatin receptor in the α-
cells is somatostatin receptor type 2 (SSTR2).  We hypothesized that somatostatin exerts its 
inhibitory effect on glucagon secretion via SSTR2 by decreasing the production of cAMP from 
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adenylyl cyclase activity.  To test this, we measured cAMP using the immunofluorescence 
methodology to identify if somatostatin decreased cAMP levels at low glucose, and if 
antagonizing the SSTR2 would prevent such a decrease at high glucose.  In murine islets 
treated with somatostatin at 1 mM glucose, cAMP was reduced by 39.8% ± 3.1 compared with 
glucose alone.  SSTR2 antagonism by CYN154806 elicited a 39.4% ± 4.6 increase in cAMP 
over 11 mM glucose alone, as shown in Figure 2-12.   
 
 
Figure 2-12: Somatostatin inhibits cAMP production via the Gαi subunit of SSTR2.  (A-B) Mean 
intensities from immunofluorescence studies where murine islets were fixed after treatment and 
stained for cAMP and glucagon and normalized to pre-immune control images; cAMP in green, 
glucagon positive-cells outlined in white.  (A) Islets were treated with 100 nM somatostatin (Sst) 
at 1 mM glucose (N = 6) or with glucose alone (N = 13).  (B) Islets were treated with 200 nM 
SSTR2 antagonist CYN154806 (CYN) at 11 mM glucose (N = 8) or with glucose alone (N = 10).  
Error bars represent the S.E.M. and p values were determined by Student’s t-test. * indicates p 
< 0.05, ** p < 0.01, *** p < 0.0001 
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From these immunofluorescence studies, we concluded that somatostatin inhibits 
adenylyl cyclases responsible for cAMP production via the action of SSTR2.  We next measured 
glucagon secretion from islets treated with SSTR2 antagonist CYN154806 at 1 and 11 mM 
glucose to determine if the effect on cAMP was mirrored by a loss of glucagon suppression at 
high glucose.  SSTR2 antagonism in human islets exhibited no difference in secretion at 1 mM 
glucose and a 2.5 ± 0.41 fold increase over 11 mM glucose alone.  Similarly, glucagon secretion 
from murine islets exhibited a 2.61 ± 0.04 fold increase in glucagon secretion upon addition of 
CYN154806 at 11 mM glucose, and no significant difference was observed at 1 mM glucose, 
shown in Figure 2-13.  This confirms a glucose-dependent effect of somatostatin on both cAMP 
production and glucagon secretion that is mediated by the SSTR2.  
 
 
Figure 2-13: Somatostatin inhibits glucagon secretion via SSTR2 activation.  (A) Human islet 
glucagon secretion (N = 3-5 donors) with glucose alone (white bars) or with glucose and CYN 
(black bars) after static incubation.  (B) Isolated murine islet glucagon secretion with glucose 
alone in white squares and CYN-treated islets in black circles.  Error bars represent the S.E.M. 
and p values were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 
0.0001 
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Since the CYN154806 only specifically antagonized the SSTR2, we repeated the 
secretion experiment with a broad somatostatin receptor antagonist to both account for the 
possibility of compensatory function from another SSTR subtype, and also to test the hypothesis 
that SSTR2 sufficiently explains the effects we observe with glucagon secretion.  Treating islets 
with a putative SSTR antagonist, cyclosomatostatin (cSST), we observed a 2.02 ± 0.05 increase 
in glucagon secretion over glucose-alone control islets, as shown in Figure 2-14.  Additionally, 
the SSTR2-specific antagonist produced a significantly stronger effect on glucagon secretion 
than the cSST (p < 0.05).  These data support the SSTR2 being functionally dominant in the α-
cells, suggest that glucagon inhibition with glucose requires somatostatin, and shows that 
SSTR2 accounts for this effect. 
 
 
Figure 2-14: A broad somatostatin receptor antagonist also relieves glucagon inhibition at high 
glucose.  Glucagon secretion from murine islets treated with somatostatin receptor antagonist 
cyclosomatostatin (cSST) at 1 and 11 mM glucose.  Error bars represent the S.E.M. and p 
values were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
As somatostatin is expected to act via the inhibitory Gα (Gαi) subunit of the G-protein 
coupled receptor, we next measured glucagon secretion after pertussis toxin (PTX) treatment to 
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inactivate the Gαi subunit, shown in Figure 2-15 below.  At 1 mM glucose, pretreatment with 
PTX led to a 2.10 ± 0.05 fold increase in glucagon secretion over somatostatin-treated control 
islets.  At 11 mM glucose, PTX caused a 2.35 ± 0.08 fold increase in secretion over glucose 
alone.  To test whether the effect of PTX is due to a direct inhibition of Gαi signaling in α-cells 
rather than an indirect effect through β-cells, we also measured insulin secretion.  As previously 
reported (Cawthorn and Chan 1991), somatostatin did not inhibit insulin secretion from these 
islets, which was increased 5.91 ± 0.34 fold and 5.95 ± 0.58 fold at 1 and 11 mM glucose, 
respectively, with PTX pretreatment.  Presumably, the PTX would prevent any Gαi signaling in 
the δ-cells as well, which further supports the hypothesis that the effect we observe in the α-
cells is due to a direct effect. 
 
 
Figure 2-15: Somatostatin inhibits glucagon secretion via Gαi subunit of SSTR2.  (A) Murine 
islets were pretreated with 1 mg/ml pertussis toxin (PTX) for 18 hours, and then stimulated with 
100 nM Sst (black triangles) at 1 mM glucose or 11 mM glucose.  Control islets treated with 
glucose alone (white squares) or with 100 nM Sst (black circles) are also displayed.  (B) Insulin 
secretion from isolated murine islets from (A) with PTX-pretreated islets in black diamonds and 
glucose-only controls in white squares.  Error bars represent the S.E.M. and p values were 
determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
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These data demonstrate that somatostatin’s primary inhibitory mechanism in glucagon-
secreting α-cells is by Gαi submit-mediated inhibition of adenylyl cyclase.  We further conclude 
that it is a direct effect on the α-cells due to the concomitant increase in insulin secretion from β-
cells that we measured.  Since PTX pretreatment prevents somatostatin from inhibiting insulin 
as well as glucagon at high glucose, we next wanted to see if a high enough concentration of 
insulin could compensate for the lack of somatostatin and drive down glucagon secretion.  As 
insulin signaling does not proceed via GPCRs, we reasoned that the PTX should not prevent 
the mechanism of insulin’s inhibition.  Thus, islets pretreated with PTX were subsequently 
stimulated with 1 mM or 11 mM glucose with and without 100 nM insulin, as shown in Figure 2-
16.  Interestingly, the added insulin was still unable to rescue glucagon inhibition at 11 mM 
glucose in PTX-pretreated islets.  At 1 mM glucose, pretreatment with PTX led to a 2.30 ± 0.08 
fold increase in glucagon secretion over insulin-treated control islets.  At 11 mM glucose, PTX 
caused a 3.32 ± 0.06 fold increase in secretion over insulin-treated control islets.  These values 
are comparable to those observed with somatostatin treatment after PTX pretreatment.  
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Figure 2-16: Excess insulin cannot inhibit glucagon secretion in the absence of somatostatin.  
Murine islets were pretreated with 1 mg/ml pertussis toxin (PTX) for 18 hours, and then 
stimulated with 100 nM Insulin (Ins - black inverted triangles) at 1 mM glucose or 11 mM 
glucose.  Control islets treated with glucose alone (white squares) or with 100 nM Ins (black 
circles) are also displayed.  Error bars represent the S.E.M. and p values were determined by 
Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
Taken together these data demonstrate that even an excess of insulin is insufficient for 
glucose-inhibited glucagon secretion in the absence of somatostatin, which decreases cAMP 
production by the activity of the SSTR2 Gαi subunit on adenylyl cyclases.  This suggests that 
insulin is an insufficient inhibitor of glucagon secretion in the absence of somatostatin, which 
previous studies have shown in purified populations of α-cells (Le Marchand and Piston 2010).  
Another interesting observation we made while studying the effects of IBMX and forskolin on 
glucagon secretion was that, when used independently, IBMX had a more significant effect than 
forskolin.  At low glucose, IBMX increased glucagon secretion 1.36 ± 0.08 fold compared with 
forskolin-treated islets.  Additionally, at 11 mM glucose, IBMX increased glucagon secretion 1.8 
± 0.06 fold over forskolin-treated islets, as shown in Figure 2-17.  From this data, we concluded 
that phosphodiesterase activity may be a critical factor in the glucose-dependent regulation of 
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cAMP and glucagon secretion from the α-cells.  Combined with the observation that insulin was 
incapable of exerting an inhibitory effect when somatostatin activity was blocked by PTX, we 
were encouraged to take a look at the possible role of insulin in the glucose-inhibition of 
glucagon secretion. 
 
 
Figure 2-17: Phosphodiesterase activity is critical in the suppression of glucagon exocytosis.  
Glucagon secretion from murine islets treated with glucose alone at 1 or 11 mM, or stimulated 
with 50 µM Forskolin (Fsk), or 100 µM IBMX.  Error bars represent the S.E.M. and p values 
were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
 
Insulin mediates α-Cell cAMP degradation by phosphodiesterase 3B 
The insulin receptor is known to play a role in α-cell physiology (Kawamori, Kurpad et al. 
2009), and insulin receptor signaling can lead to phosphorylation of phosphodiesterases, driving 
degradation of cAMP (Zmuda-Trzebiatowska, Oknianska et al. 2006).  To test the regulatory 
role of insulin in α-cells, we utilized immunofluorescence as for the somatostatin studies above 
to identify if insulin affects cAMP levels.  Islets treated with insulin exhibited a 23.1% ± 7.2 
reduction in α-cell cAMP as compared with 1 mM glucose alone.  α-cell cAMP in islets treated 
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with insulin receptor antagonist S961 (Vikram and Jena 2010) showed a 30% ± 7.8 increase in 
cAMP over 11 mM glucose, as shown in Figure 2-18.   
 
 
Figure 2-18: Insulin decreases cAMP in the α-cells.  (A-B) Mean intensities from 
immunofluorescence studies where murine islets were fixed after treatment and stained for 
cAMP and glucagon and normalized to pre-immune control images; cAMP in green, glucagon 
positive-cells outlined in white.  (A) Islets were treated with 100 nM insulin at 1 mM glucose (N = 
5), glucose alone (N = 13); or (B) with 1 µM insulin receptor antagonist S961 (N = 6) at 11 mM 
glucose or with glucose alone (N = 10).  Error bars represent the S.E.M. and p values were 
determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
We also measured glucagon secretion from islets treated with S961, expecting the loss 
of insulin receptor signaling to drive an increase in glucagon secretion, which has been 
demonstrated previously.  In human islets, antagonism of the insulin receptor increased 
glucagon secretion 2.42 ± 0.39 fold over 11 mM glucose alone, with no significant difference in 
secretion at 1 mM glucose between control and treated islets.  In murine islets treated with 
56 
 
S961, glucagon secretion showed a 3.35 ± 0.1 fold increase at 11 mM glucose, and no 
significant difference at 1 mM glucose, as shown in Figure 2-19.  
 
 
Figure 2-19: Insulin receptors mediate glucagon inhibition with glucose in human and murine 
islets.  (A) Glucagon secretion from islets of 4 human donors incubated with 1 µM insulin 
receptor antagonist S961 at 1 or 11 mM glucose (black bars) and glucose alone (white bars).  
(B) Glucagon secretion from isolated murine islets treated with S961 at 1 or 11 mM glucose 
(black inverted triangles) or glucose alone (white squares).  Error bars represent the S.E.M. and 
p values were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
Importantly, one of the caveats of antagonizing the insulin receptor is that the β-cells are 
also affected and they rely upon positive feedback for glucose-stimulated insulin secretion.  
Thus, blocking the insulin receptor, including by use of genetic knockout animals, prevents the 
standard increase in insulin secretion seen with increasing glucose.  To be sure that the S961 
antagonist was working as reported, we measured insulin secretion from islets treated with the 
S961.  As expected, while there was no effect at 1 mM glucose in the β-cells, insulin secretion 
was blunted 3.28 ± 0.05 fold in islets treated with S961 compared with glucose-alone controls, 
shown in Figure 2-20.  Additionally, there have been reports of this peptide having selectively 
agonistic activity at very low concentrations [31] in human islets.  Thus, even though its affinity 
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for the insulin receptor is in the nanomolar range, we utilized a concentration of 1 µM for our 
studies both to ensure antagonistic properties and also with the expectation of low diffusion 
through the core of the islets.  Collectively, from these data, we conclude that the insulin 
receptor plays a critical role in the glucose-dependent suppression of glucagon secretion. 
 
 
Figure 2-21: S961 blunts glucose-stimulated insulin secretion.  Insulin secretion from islets 
treated with glucose alone (white squares), or with 1 µM insulin receptor antagonist S961 at 1 
and 11 mM glucose.  Error bars represent the S.E.M. and p values were determined by 
Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
Our next goal was to identify the mechanism by which insulin is acting in the α-cells.  As 
mentioned in the introduction to this chapter, there are a number of hypothesis regarding this 
mechanism.  However, the only one that reconciled all of our data with the phosphodiesterase 
inhibitor was the possibility that insulin is activating phosphodiesterases to degrade cAMP.  
Turning to the literature on insulin signaling in other cell types, we found that in hepatocytes and 
adipocytes, insulin decreases cAMP by activating phosphodiesterase 3B (PDE3B) and this 
leads to the inhibition of gluconeogenesis and lipolysis.  Thus, we began our experiments with 
this idea in mind. 
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To test the hypothesis that insulin decreases glucagon secretion via phosphodiesterase 
activation, we measured glucagon secretion from islets at 1 and 11 mM glucose in the presence 
of insulin and the non-specific phosphodiesterase inhibitor IBMX, displayed in Figure 2-21.  
While there are at least two IBMX resistant phosphodiesterases (PDE8 and PDE9), neither of 
them have been reported to be expressed in the α-cells (Bramswig, Everett et al. 2013).  We 
found that at 1 mM glucose, treatment with IBMX and insulin yielded no significant differences in 
secretion when compared to glucose alone.  However, when compared to insulin treatment at 1 
mM glucose in the absence of IBMX, glucagon secretion was increased 2.23 ± 0.11.  
Additionally, 11 mM glucose, IBMX with exogenous insulin increased glucagon secretion 3.17 ± 
0.12 fold compared with glucose alone, and 3.61 ± 0.05 compared with glucose with exogenous 
insulin.  These data demonstrate that insulin is ineffective at inhibiting glucagon secretion when 
phosphodiesterases are blocked.  
 
 
Figure 2-21: Excess insulin cannot inhibit glucagon secretion in the presence of 
phosphodiesterase inhibitors.  Glucagon secretion from murine islets stimulated with 100 nM 
Insulin (Ins - black inverted triangles) at 1 or 11 mM glucose in the presence and absence of 
100 µM IBMX.  Error bars represent the S.E.M. and p values were determined by Student’s t-
test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001  
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We measured glucagon secretion in the presence of either a hydrolyzable (8-Br-cAMP) 
or non-hydrolyzable (6-Bnz-cAMP) cAMP analog together with insulin at 1 mM glucose and 11 
mM glucose.  While the 8-Br-cAMP does have a slight phosphodiesterase resistance, we still 
expected to see that a high enough dose of insulin would be able to degrade enough to detect a 
difference if this was the mechanism by which insulin is functioning in the α-cells.  We found that 
in islets treated with 100 nM insulin, glucagon secretion was not significantly different from 
glucose alone for either the 8-Br-cAMP or 6-Bnz-cAMP.  However, with 1 µM insulin, glucagon 
secretion from islets treated with 8-Br-cAMP was reduced 1.5 ± 0.15 fold, as we expected.  The 
addition of even a high concentration of exogenous insulin did not have a statistically significant 
impact on glucagon secretion from islets treated with the non-hydrolyzable 6-Bnz-cAMP, as 
demonstrated in Figure 2-22.  
 
 
Figure 2-22: Insulin decreases glucagon secretion by activating phosphodiesterases to break 
down cAMP.  At 11 mM glucose, murine islets were incubated with hydrolyzable 100 nM 8-Br-
cAMP (white squares) in the presence of no exogenous insulin (N = 6), 100 nM insulin (N = 6), 
or 1 µM insulin (N = 5).  300 µM non-hydrolyzable 6-Bnz-cAMP (white diamonds) was also 
tested with no insulin (N = 6), 100 nM insulin (N = 4), or 1 µM insulin (N = 4).  Error bars 
represent the S.E.M. and p values were determined by Student’s t-test. * indicates p < 0.05, ** p 
< 0.01, *** p < 0.0001 
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Our next goal was to identify the specific phosphodiesterase responsible for the 
observed effects.  From the literature, we expected that PDE3B would be the enzyme of choice 
for insulin receptor signaling.  However, there are other phosphodiesterases in the islet cells. 
PDE3B and PDE4 have been shown to be expressed in α-cells (Pyne and Furman 2003; 
Zmuda-Trzebiatowska, Oknianska et al. 2006).  To test the hypothesis that one or both of these 
phosphodiesterases are involved in glucose suppression of glucagon, we measured glucagon 
secretion in the presence of specific inhibitors for PDE3B (cilostamide) and PDE4 (rolipram).  
Cilostamide treatment showed a 2.65 ± 0.86 fold increase in glucagon secretion at 11 mM 
glucose with no significant difference between treated and control islets (glucose alone) at 1 mM 
glucose.  By contrast, rolipram increased glucagon secretion at both 1 mM and 11 mM glucose, 
with a fold increase of 1.51 ± 0.1 and 2.98 ± 0.06, respectively.  Looking at Figure 2-23, only the 
cilostamide data show significant glucose dependence, which points toward a primary role for 
PDE3B in insulin-dependent degradation of cAMP and inhibition of glucagon secretion.  
 
 
Figure 2-23: PDE3B mediates insulin’s effect on cAMP and glucagon secretion.  Glucagon 
secretion from islets treated with glucose alone (white squares), or with phosphodiesterase 
inhibitors 250 nM cilostamide (PDE3B; N = 5; black diamonds) or 400 nM rolipram (PDE4; N = 
4; black squares) at 1 and 11 mM glucose.  Error bars represent the S.E.M. and p values were 
determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
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Insulin signaling proceeds via Akt to activate PDE3B 
 Several studies have reported the importance of the insulin receptor in regulating 
glucagon secretion from the α-cells (Kaneko, Shirotani et al. 1999; Kulkarni, Bruning et al. 1999; 
Ishihara, Maechler et al. 2003; Franklin, Gromada et al. 2005; Xu, Kumar et al. 2006; Kawamori 
and Kulkarni 2009; Kawamori, Kurpad et al. 2009).  However, there is little agreement between 
them about the mechanism by which this occurs.  Despite the disparity, these mechanisms have 
in common the core insulin signaling pathway.  This includes insulin binding its receptor, 
triggering the activation of PI3 kinase, a promiscuous kinase with several downstream 
phosphorylation targets, and subsequent activation of Akt/Protein Kinase B (PKB).  Akt/PKB is a 
key component of insulin’s regulatory mechanism in α-cells and has been shown to activate 
phosphodiesterase 3B in hepatocytes.  Furthermore, an increase in Akt/PKB activity has been 
shown in islets and cultured α-cells at high glucose (Kulkarni, Bruning et al. 1999; Xu, Kumar et 
al. 2006).  Since this data agrees with our results on the role of insulin and PDE3B in regulating 
glucagon secretion, we expected that insulin signaling would lead to the activation of Akt/PKB 
upstream of PDE3B.  
To test this idea, we used a well-regarded antibody against phosphorylated Akt/PKB and 
immunofluorescence to characterize the response to glucose, as done with previous 
experiments.  We found that phospho-Akt was increased at 1 mM glucose in the presence of 
exogenous insulin when compared with 1 mM glucose-alone in the islet α-cells.  Insulin caused 
a 199% ± 9.4 increase in phospho-Akt mean intensity, as depicted in Figure 2-24. 
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Figure 2-24. Phosphorylated Akt is increased by insulin at low glucose in the alpha cells.  Mean 
intensities from immunofluorescence studies where murine islets were fixed after treatment with 
low glucose alone (white bar) or low glucose in the presence of 1 μM insulin (black bar), and 
stained for phospho-Akt and glucagon and normalized to pre-immune control images.  
 
 
A concomitant decrease of cAMP and PKA is required for glucagon suppression 
At this point, our data suggest that somatostatin and insulin are both decreasing cAMP 
as a means of regulating glucose-inhibition of glucagon secretion.  To flesh out the cAMP-
dependent signaling pathway that is being inhibited, we next needed to identify the downstream 
activator that cAMP is targeting to promote secretion.  The two proximal targets for cAMP 
signaling are protein kinase A (PKA) and exchange protein activated by cAMP (Epac).  To 
determine if one or both of these targets may be involved in glucose-inhibited glucagon 
secretion, we measured secretion from murine islets in the presence and absence of a PKA (6-
Bnz-cAMP) or Epac (8-pCPT-2′-O-Me-cAMP) specific agonist.  Epac activation produced a 1.68 
± 0.03 fold increase in glucagon secretion over 1 mM glucose alone and a 4.0 ± 0.10 fold 
increase over 11 mM glucose alone.  PKA activation, however, increased glucagon secretion by 
2.77 ± 0.08 fold only at 11 mM glucose, with no significant difference at 1 mM glucose, over 
glucose alone, as shown in Figure 2-25.  
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Figure 2-25: PKA activation glucose-dependently stimulates glucagon secretion.  Glucagon 
secretion from murine islets after static incubation with glucose alone (white squares), 300 µM 
Epac agonist 8-pCPT-2′-O-Me-cAMP (8-O-Me-CPT; black inverted triangles), or 300 µM PKA 
agonist 6-Bnz-cAMP (black circles) at 1 and 11 mM glucose.  Error bars represent the S.E.M. 
and p values were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 
0.0001 
 
 
We also tested the effect of the PKA-specific agonist on glucagon secretion in human 
islets and found a similar result.  There was no significant difference in glucagon secretion when 
treated with 6-Bnz-cAMP at 1 mM glucose, but at 11 mM glucose, we observed a 1.79 ± 0.12 
increase in glucagon secretion, shown in Figure 2-26, consistent with our murine results 
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Figure 2-26: PKA activation glucose-dependently stimulates glucagon secretion in human islets.  
Glucagon secretion from donor human islets after static incubation with glucose alone (white 
bars) or 300 µM PKA agonist 6-Bnz-cAMP (black bars) at 1 and 11 mM glucose.  Error bars 
represent the S.E.M. and p values were determined by Student’s t-test. * indicates p < 0.05, ** p 
< 0.01, *** p < 0.0001 
 
 
We next needed to determine whether PKA activity must be decreased for glucose-
inhibited glucagon secretion, so we measured secretion from murine islets treated with the 
specific PKA inhibitor Rp-cAMPS in the presence of forskolin.  With this experiment, we 
expected the Rp-cAMPS to counter the increase in cAMP promoted by forskolin if PKA was the 
dominant signaling pathway mediating glucose-inhibited glucagon secretion at high glucose.  
We observed at 1 mM glucose that PKA inhibition did not cause a significant difference in 
glucagon secretion compared with glucose alone.  However, inhibiting PKA partially rescued 
glucagon suppression at 11 mM glucose, producing a 1.84 ± 0.61 (p < 0.0001) fold decrease 
compared to 1 mM glucose, which is not significantly different from 11 mM glucose alone.  
Unlike the effects seen with PKA inhibition, inhibiting Epac with Brefeldin-A did not affect the 
forskolin-stimulated glucagon secretion at either 1 mM or 11 mM glucose, as shown in Figure 2-
27. Importantly, this mimics the results from stimulating islets with the Epac-specific agonist 
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shown earlier.  We conclude from these studies that PKA, rather than Epac, is glucose-
dependently inhibited as a result of decreasing cAMP levels. 
 
 
Figure 2-27: Glucagon inhibition is partially rescued by PKA inhibition.  Glucagon secretion from 
murine islets treated with glucose alone (white squares) or 50 µM forskolin (Fsk) and 250 µM 
Brefeldin A (BFA – black circles) to inhibit Epac or 100 µM PKA-specific antagonist Rp-cAMPS 
(black squares).  Error bars represent the S.E.M. and p values were determined by Student’s t-
test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
We next wanted to directly measure PKA activity in the α-cells to determine if the effects 
observed with somatostatin and insulin on cAMP would translate to the same decrease in PKA 
activity, as our secretion data suggested that it should.  Thus, to measure PKA activity from islet 
α-cells after modulation of cAMP, we imaged immunofluorescence of an antibody against 
phosphorylated PKA (phospho-PKA) after exposure to 1 and 11 mM glucose in the absence 
and presence of IBMX/forskolin.  We found that phospho-PKA was reduced 24.5% ± 1.3 in 
islets treated with 11 mM glucose compared with 1 mM glucose alone.  Furthermore, phospho-
PKA in islet α-cells stimulated with IBMX/forskolin was increased 28.9% ± 1.3 at 1 mM glucose 
and 73.8% ± 3.1 at 11 mM glucose compared with glucose alone, as shown in Figure 2-28.  
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This is consistent with what we found for cAMP in the same type of study shown earlier in the 
chapter.   
 
 
Figure 2-28: Phosphorylated PKA is decreased at high glucose.  Mean intensities from islets or 
purified α-cells treated as described and then fixed and stained for phospho-PKA and glucagon 
and normalized to pre-immune control images.  (A) Images from islets treated and stained for 
phospho-PKA; p-PKA in yellow, glucagon-positive cells outlined in white.  (B) Normalized 
phospho-PKA intensity from islet α-cells treated at 1 mM glucose (white bars) or 11 mM glucose 
(black bars) with IBMX/Fsk (N = 6) or glucose alone (N = 7).  Error bars represent the S.E.M. 
and p values were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 
0.0001 
 
 
Our initial hypothesis was based on the observation that the glucagon inhibition pathway 
should function independently of Ca2+ and yet significant crosstalk between cAMP/PKA 
signaling and Ca2+ signaling has been reported in many cell types.  To address this question, 
we measured intracellular Ca2+ activity in islet α-cells stimulated with the same PKA-specific 
agonist, 6-Bnz-cAMP, that we used in our secretion studies.  Had PKA been exerting its effect 
on secretion by directly affecting [Ca2+]i, we would have expected to see an increase in [Ca
2+]i at 
high glucose in the presence of the agonist.  However, at low glucose, where secretion is 
already dominated by [Ca2+]i, the PKA stimulation may not have a detectable effect. 
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We found no statistically significant differences in  [Ca2+]i as determined by area under 
the curve from time-lapse imaging or the number of cells that displayed active Ca2+ oscillations, 
in the control glucose only-treated islets nor the 6-Bnz-cAMP stimulated islets.  We conclude 
from the data in Figure 2-29 that at low glucose, [Ca2+]i is already maximal to drive the rapid 
exocytosis of glucagon-containing vesicles and thus increasing PKA activity does not have a 
measurable effect.  Furthermore, the lack of response in  [Ca2+]i at high glucose mimics the 
IBMX/Fsk data above and supports the hypothesis that cAMP/PKA signaling and [Ca2+]i are 
decoupled at high glucose concentrations in the α-cells.  
 
 
Figure 2-29: PKA activation does not significantly affect [Ca2+]i in islet α-cells.  (A) Intracellular 
Ca2+ ([Ca2+]i) as measured by Fluo4 intensity (AUC) in murine isolated islets treated with 
glucose alone or in the presence of 6-Bnz-cAMP.  (B) Mean percent of cells with oscillations in 
Ca2+ as a function of glucose, where α-cells were identified by td-RFP expression in islets from 
4 mice.  Error bars represent the S.E.M. and p values were determined by Student’s t-test. * 
indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
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Somatostatin and insulin lower islet α-Cell cAMP and inhibit glucagon secretion 
Earlier studies with the Pertussis toxin suggested that when somatostatin signaling was 
inhibited, insulin was rendered incapable of inhibiting glucagon secretion suggested a 
requirement for both paracrine regulators.  Additionally, we have shown in previous work that 
neither somatostatin nor insulin is sufficient to suppress glucagon in isolated α-cells.  Thus, we 
wanted to pursue the possibility that these two paracrine molecules are working together to 
decrease cAMP/PKA and inhibit glucagon secretion.  We tested whether the combination of 
somatostatin and insulin synergistically lowers cAMP in α-cells.  In murine islets treated with 
both somatostatin and insulin, cAMP was reduced by 56.8% ± 3.07 compared with 1 mM 
glucose alone, and by 39.6% ± 4.6 and 43.8% ± 7.18 compared to somatostatin and insulin 
alone, respectively.  Additionally, phosphorylated PKA was reduced 41% ± 1.3, 34.4% ± 1.25, 
and 39.2% ± 1.83 compared with 1 mM glucose alone, respectively, when treated with 
somatostatin, insulin, or somatostatin with insulin, displayed in Figure 2-30.   
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Figure 2-30: Somatostatin and insulin significantly decrease cAMP and phosphorylated PKA at 
high glucose.  (A) Normalized cAMP intensity from islet α-cells treated with 1 mM glucose (N = 
13) or somatostatin (Sst) with insulin (Ins) at 1 mM glucose (N = 7).  (B) Normalized phospho-
PKA (N = 6) intensity from islet α-cells incubated with 1 mM glucose alone (N = 7; white bar) or 
in the presence of Sst, Ins, or Sst with Ins (N = 5, 4, 5; black bars).  Error bars represent the 
S.E.M. and p values were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p 
< 0.0001 
 
 
These data demonstrate a synergistic relationship between insulin and somatostatin on 
decreasing cAMP levels.  We next wanted to test the hypothesis by the inverse experiments, 
shown in Figure 2-31.  We treated islets with receptor antagonists against somatostatin 
(CYN154806) and insulin (S961), and observed an 80.4% ± 11.8 increase in mean intensity for 
cAMP compared with 11 mM glucose alone.  Additionally, this was a 40.8% ± 4.6 and 45.6% ± 
7.1 increase in cAMP compared to   CYN154806 and S961 alone, respectively. Inhibiting both 
somatostatin and insulin receptors also yielded an increase in phospho-PKA of 130% ± 3.93 
over 11 mM glucose alone (data shown in above sections).  
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Figure 2-31: Somatostatin and insulin antagonism significantly increases cAMP and 
phosphorylated PKA at high glucose.  (A) Normalized cAMP intensity from islet α-cells treated 
with 11 mM glucose (N = 13) or CYN154806 (CYN) with S961 at 11 mM glucose (N = 4).  (B) 
Normalized phospho-PKA (N = 4) intensity from islet α-cells treated with 11 mM glucose alone 
(white bar) or with CYN and S961 (black bar).  Error bars represent the S.E.M. and p values 
were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
We next wanted to determine if the effects of somatostatin and insulin on glucagon 
secretion are also additive, so murine islets were treated with 1 mM or 11 mM glucose in the 
presence and absence of somatostatin and insulin or antagonists CYN154806 and S961, as 
depicted in Figure 2-32.  Combined somatostatin and insulin reduced glucagon secretion at 1 
mM glucose 2.07 ± 0.33 fold compared with glucose alone and produced no significantly 
different response at 11 mM glucose compared with glucose alone.  Combined CYN154806 and 
S961 increased glucagon secretion 2.82 ± 0.47 fold over 11 mM glucose alone and elicited no 
difference in secretion at 1 mM glucose, which is similar to the effect of either CYN154806 or 
S961 alone.   
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Figure 2-32: Somatostatin and insulin antagonism significantly increases glucagon secretion at 
high glucose.  (A) Glucagon secretion from murine islets stimulated with combined Sst and Ins 
(black inverted triangles) or glucose alone (white squares).  (B) Glucagon secretion from murine 
islets treated with CYN and S961 (black circles) or glucose alone (white squares).  Error bars 
represent the S.E.M. and p values were determined by Student’s t-test. * indicates p < 0.05, ** p 
< 0.01, *** p < 0.0001 
 
 
Having established that somatostatin and insulin exert an additive effect on lowering 
cAMP levels in the α-cells, we next wanted to determine whether these regulators are 
interdependent, as suggested by the Pertussis toxin data shown earlier.  To address this 
question we combined the insulin receptor antagonist S961 with exogenous somatostatin and 
measured glucagon secretion. In addition, we did the reciprocal experiment with the SSTR2 
receptor antagonist CYN154806 in the presence of exogenous insulin.  These data are 
displayed in Figure 2-30 below. In the first experiment, we found that at 1 mM glucose, there 
was not a significant difference between the glucose alone and combination treatment of S961 
and somatostatin.  At 11 mM glucose, S961 and somatostatin increased glucagon secretion 
over glucose alone by 2.40 ± 0.07 fold. Similarly, at 1 mM glucose, islets exposed to 
CYN154806 and insulin showed no significant difference between treated and control islets, but 
at 11 mM glucose, secretion was increased 2.59 ± 0.08 fold over glucose alone, shown in 
72 
 
Figure 2-33.  From these data, we conclude that somatostatin and insulin are necessary, and 
neither one alone is sufficient, for the glucose-inhibition of glucagon secretion.  
 
 
Figure 2-33: Neither somatostatin nor insulin alone is sufficient to suppress glucagon secretion 
in islets.  (A) Glucagon secretion from murine islets treated with S961 and Sst (black circles) or 
glucose alone (white squares).  (B) Glucagon secretion from murine islets treated with CYN and 
Ins (black triangles) or glucose alone (white squares).  Error bars represent the S.E.M. and p 
values were determined by Student’s t-test, *** p < 0.0001. 
 
 
Somatostatin and insulin together are sufficient to inhibit cAMP and glucagon secretion 
from purified islets 
Previous work demonstrated that neither somatostatin nor insulin alone inhibited 
glucagon secretion from sorted cells (Le Marchand and Piston 2010), which is consistent with 
what we observed by inhibiting these receptors in whole islets.  However, the combination of 
both effectors was not tested in the initial screen for inhibitors in sorted α-cells.  To study the 
effect of combined somatostatin and insulin on isolated α-cells, we FACS-sorted tdRFP-
expressing α-cells from whole islets and assayed them for cAMP, phospho-PKA, and glucagon 
secretion at 1 mM glucose alone, or in the presence of somatostatin and insulin.  From the 
73 
 
immunofluorescence experiments, we found that the dispersed α-cells treated with 
somatostatin, insulin and 1 mM glucose exhibited a significant decrease in cAMP of 92% ± 8.6 
compared with glucose-alone control cells.  Additionally, phospho-PKA was reduced 78% ± 11.6 
compared with 1 mM glucose alone, as depicted in Figure 2-34.  
 
 
Figure 2-34: Somatostatin and insulin decrease cAMP and phosphorylated PKA from purified α-
cells.  (A)  Normalized cAMP intensities from tdRFP-expressing α-cells purified from 5 mice and 
treated with either 1 mM glucose (white bar) or 1 mM glucose with Sst and Ins (black bar).  (B) 
Normalized phospho-PKA intensities from (A).  Error bars represent the S.E.M. and p values 
were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001 
 
 
Isolated α-cells treated with somatostatin and insulin exhibited a 4.61 ± 0.41 fold 
decrease in glucagon secretion compared with glucose alone, shown in Figure 2-35.  This is 
consistent with our observations using the antagonists of somatostatin and insulin receptors in 
whole islets.  The data shown here demonstrate that, in the absence of normal islet cell-cell 
contacts, somatostatin and insulin are sufficient to inhibit glucagon secretion.  
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Figure 2-35: Somatostatin and insulin together are sufficient to suppress glucagon secretion in 
isolated α-cells.  Glucagon secretion from purified α-cells treated in static incubation with 1 mM 
glucose (gray squares) or 1 mM glucose with Sst and Ins (black inverted triangles).  Error bars 
represent the S.E.M. and p values were determined by Student’s t-test. * indicates p < 0.05, ** p 
< 0.01, *** p < 0.0001 
 
 
Summary 
In this chapter, background material was described that led directly to our hypothesis 
that somatostatin and insulin inhibit glucagon secretion by decreasing cAMP/PKA signaling in 
the islet α-cells.  We first examined the role of cAMP in regulating glucose inhibition of α-cell 
glucagon secretion, which showed that cAMP and glucagon secretion are reduced in a similar 
manner with increasing glucose in both human and mouse islet α-cells.  This is in contrast to β-
cells, where cAMP increases with increasing glucose, and is consistent with other reports 
showing similar difference between α- and β-cells (Gromada, Bokvist et al. 1997; Dyachok, 
Idevall-Hagren et al. 2008).  Forced elevation of cAMP in the islet via IBMX and forskolin 
overcomes the natural inhibition of glucagon secretion at high glucose levels, suggesting that 
cAMP signaling must be decreased for glucagon suppression.  Importantly, the forced cAMP 
changes do not affect [Ca2+]i activity or oscillations in the α-cells.  Together, these data support 
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a model where cAMP plays a central [Ca2+]i-independent role in regulating the inhibition of 
glucagon secretion.  
It is difficult to inhibit all of the receptors in any given cell even when using monolayers of 
tissue cultured cells.  In the islet, a multicellular, dense, and highly interconnected tissue, this 
problem is amplified.  Sorting the α-cells into a pure population is the only way to completely 
remove any endogenous paracrine factors.  The fact that sorted α-cells have dysregulated 
glucagon secretion argues in favor of both the paracrine and juxtracrine contacts playing critical 
roles in the normal suppression of glucagon. 
 Decreased cAMP at high glucose in islet α-cells requires activation of both somatostatin 
and insulin receptors.  Our data show that the combination of somatostatin and insulin 
decreases cAMP more than either somatostatin or insulin alone at low glucose.  Further, 
inhibiting simultaneously somatostatin and insulin receptors increases cAMP significantly more 
than either antagonist alone.  Combined exposure to somatostatin and insulin leads to inhibition 
of glucagon secretion from isolated islet cells, while neither alone is sufficient (Le Marchand and 
Piston 2010).  This requirement of combined signaling is consistent with the results from mice 
with genetic deletion of either somatostatin or insulin, both of which show only a partial 
disruption in the inhibition of glucagon secretion (Kulkarni, Bruning et al. 1999; Yue, Burdett et 
al. 2012).  It has also been reported that neither somatostatin nor insulin alone is able to 
decrease glucagon secretion from a purified population of islet α-cells (Le Marchand and Piston 
2010).  However, we show here that the combination of these paracrine factors is sufficient to 
decrease in cAMP and inhibit glucagon secretion in the absence of normal islet architecture.   
 Somatostatin acts through a G-protein coupled receptor (SSTR) with an inhibitory Gαi 
subunit, and SSTR2 has been shown to be the functionally dominant receptor in both human 
and mouse α-cells (Kailey, van de Bunt et al. 2012).  We determined that cAMP levels are 
reduced at low glucose in the presence of somatostatin, and that glucagon secretion from these 
islets was significantly reduced as well.  Both a broad somatostatin receptor antagonist 
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(cyclosomatostatin) and a SSTR2-specific antagonist (CYN154806) significantly increased 
cAMP and glucagon secretion at high glucose, suggesting that glucagon inhibition with glucose 
requires somatostatin.  However, there was no difference in glucagon secretion at low glucose 
from either human or murine islets after exposure to the SSTR2 antagonist.  The comparison 
between the results using a broad SSTR antagonist and one specific for SSTR2 showed that 
inhibiting only the SSTR2 is sufficient to prevent the glucose-inhibition of glucagon secretion.  
Further treatment of islets with pertussis toxin to prevent the inhibitory Gαi subunit of the SSTR2 
blocked the ability of somatostatin to inhibit glucagon or insulin secretion.  We conclude from 
these data that somatostatin signaling plays an important role in glucose inhibition of glucagon 
secretion and that it does so by decreasing the production of cAMP by adenylyl cyclases via the 
Gαi subunit of the SSTR2. 
We observed a difference in glucagon secretion at high glucose between islets treated 
with IBMX (phosphodiesterase inhibitor) and forskolin (activates adenylyl cyclases).  This 
indicted that degradation of cAMP by phosphodiesterases might also be critical in glucagon 
suppression, which prompted us to test the role of insulin signaling in the α-cells.  Insulin 
receptor expression is well-characterized in the α-cell, and PI3-kinase inhibition has been 
reported to block insulin-mediated glucagon inhibition (Chen and Ostenson 2004; Ravier and 
Rutter 2005).  The PI3-kinase target Akt is required for glucose-inhibition of glucagon secretion 
and is up-regulated at high glucose (Diao, Asghar et al. 2005; Kawamori, Kurpad et al. 2009) in 
α-cells.  We found that insulin exposure significantly decreased cAMP in islet α-cells, and that 
inhibiting the insulin receptor produced significant increases in both cAMP and glucagon 
secretion at high glucose in both human and murine islets.   
To test the hypothesis that insulin inhibits glucagon secretion by activating 
phosphodiesterases (PDE), we treated islets with a range of cAMP analogs and selective PDE 
inhibitors.  At high concentrations of insulin (1 µM) and high glucose levels, glucagon secretion 
from islets could be partially rescued by treatment with a hydrolyzable cAMP analog.  However, 
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glucose inhibition of glucagon secretion was entirely lost in the presence of a PDE-resistant 
analog.  We examined selective inhibitors for two of the common phosphodiesterases in islet 
cells, PDE3 and PDE4. A PDE4-selective inhibitor, rolipram, stimulated glucagon secretion 
across all glucose levels.  On the other hand, a PDE3B-specific inhibitor, cilostamide, also 
elicited a significant increase in glucagon secretion, but strictly in a glucose-dose-dependent 
manner.  From these data, we conclude that insulin decreases cAMP in α-cells via PI3-kinase 
phosphorylation of Akt and PDE3B.  This is consistent with studies in other metabolic cell types, 
such as hepatocytes and adipocytes, that are regulated by insulin signaling through 
phosphodiesterase 3B to decrease cAMP and limit glycogenolysis and lipolysis (Choi, Park et 
al. 2006; Ahmad, Lindh et al. 2009; Degerman, Ahmad et al. 2011). 
There are two primary downstream effector proteins in cAMP signaling: PKA and Epac, 
and both can be involved in secretory dynamics (Gromada, Bokvist et al. 1997; Dyachok, 
Sagetorp et al. 2006; Hatakeyama, Takahashi et al. 2007; Idevall-Hagren, Barg et al. 2010; 
Benninger, Head et al. 2011).  To test the potential role of each of these proteins in α-cells, we 
measured glucagon secretion after exposure to specific activators of PKA and Epac.  We found 
that stimulating Epac increases glucagon secretion at all glucose concentrations, whereas PKA 
activation elicited a secretory response only at high glucose levels.  Additionally, when islets 
were treated with forskolin to activate adenylyl cyclases, glucagon inhibition was partially 
rescued at high glucose by a PKA-specific inhibitor.  Thus, we conclude that stimulating PKA is 
sufficient to overcome glucose-inhibited glucagon secretion, and that PKA signaling must be 
lowered for glucose inhibition of glucagon secretion to occur.  
An important feature of our work is that most experiments were performed using whole 
islets, so that juxtracrine and paracrine contacts were in place between the islet cells.  We also 
measured responses from all of the α-cells (identified by glucagon immunoreactivity), which 
eliminates potential bias due to sampling only the minority of α-cells that are active at low 
glucose (Le Marchand and Piston 2012).  Figure 7 schematically outlines how somatostatin and 
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insulin receptor activation contribute to suppressing α-cell glucagon secretion in islets with 
increasing glucose via decreasing cAMP, but independently of intracellular Ca2+ ([Ca2+]i).  
Glucagon secretion always requires [Ca2+]i (De Marinis, Salehi et al. 2010), but our data support 
a model where [Ca2+]i becomes uncoupled from secretion as glucose increases.  Together, 
these data demonstrate a crucial role for both somatostatin and insulin in regulating glucagon 
inhibition, whereby a decrease in cAMP leads to glucagon suppression despite the presence of 
stimulatory [Ca2+]i levels.   
We have further shown that signaling through PKA is required for cAMP-inhibition of 
glucagon secretion, but the link between PKA and the exocytotic machinery remains unknown 
at this point.  Recent literature has demonstrated the critical role of Rac-1 GTPase (Rac1), a 
member of the Rho family of small GTPases, in regulating the actin network to allow vesicle 
fusion (Konstantinova, Nikolova et al. 2007).  Additionally, other studies have shown a cAMP-
dependent regulation of Rac1, which would fit nicely with the studies described above (Goto, 
Hoshino et al. 2011).  Thus, we tested the hypothesis that this was also a critical point of 
regulation in the α-cells.  Chapter 3 will cover in detail the relevant literature that led to this 
hypothesis and the data we collected in addressing it. 
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CHAPTER 3 
EXPLORING RHO-GTPASE FUNCTION IN ALPHA CELLS 
 
Introduction 
The majority of data we have collected concerning the α-cells demonstrate that glucagon 
secretion is suppressed downstream of any membrane depolarization and resulting Ca2+ influx 
(Le Marchand and Piston 2010; Le Marchand and Piston 2012).  In an effort to determine the 
mechanism of inhibition at the level of vesicle fusion and exocytosis, we turned to the familiar β-
cell for ideas.  Recent studies have shown that a key gate keeper for vesicle fusion and 
exocytosis is Rac1-GTPase (Rac1), a member of the Rho family of GTPases that also includes 
Cdc42 and RhoA (Konstantinova, Nikolova et al. 2007).  There are at least three Rac isoforms 
characterized in mammals with Rac1 expressed ubiquitously, Rac2 in hematopoietic cells, and 
Rac3 mostly expressed in the brain (Haataja, Groffen et al. 1997).  The critical function of Rac1 
with regard to insulin exocytosis is in transiently depolymerizing the filamentous actin, F-actin, 
network to allow vesicles access to the exocytotic machinery for subsequent docking and fusion 
with the membrane and expulsion of insulin and c-peptide (Kalwat and Thurmond 2013).  
Additionally, Rac1 is primarily implicated in regulating the second, sustained phase of insulin 
secretion, where cytoskeletal remodeling is critical for the trafficking of internal vesicle stores to 
the membrane (Li, Luo et al. 2004; Wang, Oh et al. 2007).  
In model cell types including chromaffin and PC12 cells, F-actin has been shown to form 
a cortical ring just beneath the membrane that acts as a barrier to vesicle fusion (Momboisse, 
Ory et al. 2010).  This is believed to  play a critical role in limiting basal insulin secretion as well 
(Kalwat and Thurmond 2013).  Rac1, like all small GTPases, is activated when GTP is bound 
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and is inactivated upon hydrolysis of the GTP to GDP and an inorganic phosphate.  The cycling 
of nucleotides provides a switch on/off mechanism for the regulation of these proteins, whereby 
GTP hydrolysis is accelerated by GTPase activating proteins and exchange is catalyzed by 
guanine nucleotide exchange factors, schematized in Figure 3-1.  Additionally, guanosine 
nucleotide dissociation inhibitors hold the small GTPases in their inactive state until released.  
These enzymes play critical roles in such cellular processes as cytoskeletal reorganization, 
membrane trafficking, and cell growth; and have been found to be cell type specificity in these 
roles (Hall 1998).   
 
 
Figure 3-1. Rho-GTPase family signaling.  Guanine nucleotide exchange factors (GEFs) and 
GTPase-activating proteins (GAPs) regulate the cycling between active (GTP-bound) and 
inactive (GDP-bound) small GTPases.  GEF activity, modulated by a number of ligand-binding 
events with cellular surface receptors, regulates the activity of individual GTPases, conferring 
specificity.  Activated GTPases are then able to interact with a number of effectors to mediate 
cellular responses such as growth, motility, and secretion.  
 
 
 
The cellular signaling that leads to Rac1 activation and subsequent F-actin remodeling in 
the β-cells is not yet fully elucidated.  However, it has been shown that Rac1 knockout mice 
exhibit glucose intolerance and impaired glucose-stimulated insulin secretion (Greiner, Kesavan 
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et al. 2009; Asahara, Shibutani et al. 2013).  Clonal β-cells expressing a dominant-negative 
Rac1 construct showed a considerable reduction in exocytosis (Asahara, Shibutani et al. 2013).  
but overexpression of constitutively active Rac1 revealed no difference in secretion, suggesting 
that Rac1 is necessary for facilitating secretion, but is insufficient to drive or enhance secretion 
(Shibutani, Asahara et al. 2013).  Another report demonstrated that, upon glucose metabolism, 
an as yet unknown signaling molecule activates the small GTPase Cdc42 (Kepner, Yoder et al. 
2011) that in turn activates p21-activated kinase, PAK-1 (Kalwat, Yoder et al. 2013), which is an 
upstream activator of Rac1.  Furthermore, β-cell cAMP signaling has been shown to lead to 
PAK1 activation (Nie, Sun et al. 2012; Nie, Lilley et al. 2013).  A recent study in HEK293 cells 
demonstrated that the adrenergic receptor activation and downstream cAMP signaling could 
lead to Rac1 activation via complex formation with PKA.  This complex was found to stabilize 
the PKA regulatory subunits and compartmentalize the holoenzyme (Bachmann, Riml et al. 
2013).  Furthermore, in endothelial cells, cAMP-dependent Rac1 activation has been shown to 
play important roles in barrier stabilization (Schlegel and Waschke 2009)and enhancing the 
peripheral actin cytoskeleton and adherens junctions (Birukova, Zagranichnaya et al. 2007). 
The primary goal of this work was to elucidate the molecular mechanisms responsible 
for the glucose inhibition of glucagon secretion.  This cAMP-dependent pathway is independent 
of intracellular Ca2+ influx and Rac1 has been shown to block insulin secretion from the β-cell 
when Ca2+ is elevated, which makes it an attractive candidate regulator for glucagon secretion 
from the α-cell.  Since the α-cell and β-cell are closely related, we hypothesized that Rac1 might 
be mediating this inhibition, potentially downstream of cAMP.  To address this idea, we 
combined hormone secretion assays, whole islet immunofluorescence, and [Ca2+]i imaging with 
pharmacological tools.  The results suggest that, contrary to our expectations, Rac1 is unlikely 
to be a key player in regulating the glucose-inhibition of glucagon secretion.  This chapter 
includes the detailed results of these studies, methodology employed, and a brief summary of 
the significance of the findings.  
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Materials and Methods 
Islet isolation and culture 
As described in Chapter 2, Materials and Methods section. 
 
Cell dispersion and FACS sorting 
Isolated islets were cultured overnight in islet medium.  They were then washed in DPBS at pH 
7.4 without calcium and magnesium chloride.  Accutase was used for digestion for 15 minutes 
at 37ºC (gentle shaking) and cells were pelleted and resuspended in secretion buffer at 11 mM 
glucose.  One to two hours after Accutase dispersion, fluorescent cells were isolated by 
fluorescence-activated cell-sorting (FACS).  The Vanderbilt Flow Cytometry Core facility utilized 
a BD FACSAria cell sorter (BD Biosciences, San Jose, CA) for purification and Dapi (0.5 μg/ml) 
was used for exclusion of non-viable cells.  Yields were 100-800 viable alpha cells per mouse 
pancreas. 
 
qPCR 
Sorted alpha cells expressing tdRFP were pooled from six mice and RNA was extracted using a 
Qiagen RNEasy kit.  SuperScript II Reverse Transcriptase (Life Technologies) was used to 
reverse transcribe the extracted RNA to cDNA and samples were detected using the SYBR 
green PCR master mix and the following protocol: 95°C for 3 min preceding 40 cycles of 95°C 
for 10 seconds and 70°C for 30 seconds, followed by 10 seconds at 95°C and 5 seconds at 
65°C. Primers were designed for Rac1 using VectorNTI (Invitrogen).  
 
Secretion assays 
After isolation and overnight culture, islets were equilibrated for one hour in KRBH solution 
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containing 2.8 mM glucose at 37ºC.  Islets were then placed into eppendorf tubes (15-20 islets 
per tube) and stimulated with differing glucose concentrations with and without 1 mM 
NSC23766 (Gao, Dickerson et al. 2004), a Rac1 inhibitor, at 37ºC for 45 minutes in a water bath 
with occasional agitation.  Secretion samples were taken after centrifugation and total islet 
glucagon content was obtained by freezing islets overnight in 1% Triton X-100.  Samples were 
analyzed for glucagon by radioimmuno assay in the Hormone Core.  Each condition was 
measured in duplicate and glucagon secretion was expressed as the percentage of total 
hormone content over the course of the experiment.  Insulin from these same samples was 
measured using a Mouse UltraSensitive ELISA (Alpco).  
 
Immunofluorescence 
Islets were fixed in PBS containing 2% of paraformaldehyde for 30 min and permeabilized 
overnight at 4°C in PBS with 0.3% Triton X-100, 5 mM sodium azide, 1% bovine serum albumin 
and 5% goat serum (from Jackson ImmunoResearch Laboratories, West Grove, PA).  Islets 
were incubated in permeabilization solution supplemented with primary guinea pig anti-glucagon 
antibodies (1:500) and rabbit anti-phospho-Rac1 antibodies (1:100) for 24–48 h at 4°C, washed 
with PBS three times, incubated with secondary anti-guinea pig antibodies conjugated with 
Alexa Fluor 488 (1:1000) and anti-rabbit antibodies conjugated with Alexa Fluor 568 (1:250 from 
a stock of 2 mg/ml) for another 24–48 h, and washed three times before mounting in gelvatol for 
imaging.  Alexa 488 and 568 were excited at 488 and 561 nm, and their emission was collected 
through a short (520–560 nm) and a long pass filter (>560 nm), respectively. 
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Results 
Rac1 expression in α- and β-cells 
Toward the goal of elucidating the role of Rac1-GTPase in α-cells, we first needed to 
verify the presence of Rac1.  At the start of these experiments, there was little data available on 
gene expression in the α-cells. In more recent years, however, RNAseq has been utilized in 
dispersed islets to characterize the gamut of mRNA in relatively pure populations of glucagon-
containing cells (Dorrell, Schug et al. 2011; Eizirik, Sammeth et al. 2012).  We took advantage 
of our mouse model with tdRFP-expressing α-cells to FACS-sort them and performed 
quantitative RT-PCR with primers directed against the Rac1 gene.  Additionally, with a mouse 
insulin promoter-driven GFP-expressing β-cells purified from another mouse model (Hara, 
Wang et al. 2003), we performed the same experiment in purified β-cells both as an 
experimental control (since this had been shown previously) and to determine the similarities 
and differences in Rac1 expression levels between cell types.  We found that α- and β-cells 
have comparable levels of Rac1 mRNA, as shown in Figure 3-2.  
In addition to the qPCR experiments for mRNA expression, we obtained an antibody 
raised against the GTP-bound, or active, Rac1-GTP and performed semi-quantitative 
immunofluorescence to determine levels of active Rac1, its localization, and to confirm protein 
expression in murine islets.  Thus, islets were isolated, fixed, and stained for Rac1-GTP, 
glucagon, and/or insulin and subjected to confocal microscopy.  We found similar levels of 
Rac1-GTP present in the α- and β-cells, which was primarily membrane-localized.    
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Figure 3-2. Rac1-GTPase expression in primary islet cells.  QPCR was used to identify the 
mRNA levels in FACS-purified α-cells (white bar) and β-cells (black bar).  Immunofluorescence 
with an anti-Rac1GTP antibody was used to detect Rac1 levels in whole islets (Rac1GTP in 
green, glucagon in red).  
 
 
 
Glucose effect on Rac1-GTPase activity in α- and β-cells 
Second, to identify the effect of glucose on the activation state of Rac1, we used semi-
quantitative immunofluorescence to identify glucagon and active Rac1-GTP in isolated islets 
after stimulation with 1 mM or 11 mM glucose.  In these experiments, for simplification of the 
staining procedure, we considered the Rac1-GTP positive cells that did not co-stain for 
glucagon to be β-cells, as they make up the majority of islet cells.  In the β-cells, we expected to 
see increased Rac1 activation at high glucose compared with low glucose, and indeed this was 
what was measured (Figure 3-3), consistent with known Rac1 function in insulin secretion.    
Assuming similar function in the α-cell, we expected to see decreased activation at elevated 
glucose levels, where glucagon exocytosis is suppressed, but instead, the α-cells also showed 
increased activity at high glucose.  This suggests that Rac1 has a different function in the α-cell 
that is not related to remodeling the F-actin for secretion.  Thus, it does not appear that Rac1 is 
responsible for mediating glucose-dependent glucagon suppression.  Due to the difficulty in 
delivering engineered protein constructs to primary islet tissue and lack of functional α-cell lines, 
we were unable to take advantage of the dominant negative and constitutively active forms of 
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Rac1.  Thus, to measure the effect of Rac1 modulation on hormone secretion, we turned to a 
pharmacological inhibitor that we also tested for its impact on Rac1 activity, via 
immunofluorescence. 
 
 
Figure 3-3. Rac1 activity increases with glucose in both α- and β-cells.  (A) Rac1GTP mean 
intensity from islets treated with 1 mM or 11 mM glucose in the α-cells and (B) the β-cells (N = 
4-6 islets from 8 mice in (A) and 4 mice in (B).  p values were determined by Student’s t-test. * 
indicates p < 0.05, ** p < 0.01, *** p < 0.0001. 
 
 
Effect of Rac1 inhibition on Rac1-GTPase activity in islet cells 
The specific Rac1 inhibitor NSC23766 (Gao, Dickerson et al. 2004) prevents the 
exchange of the guanidine nucleotide required for activation, without affecting the other Rho 
family members Cdc42 or RhoA, and prevents its downstream effects.  This drug has been 
characterized in the β-cells and was found to prevent the Rac1-dependent modulation of the 
actin cytoskeleton required for exocytosis (Veluthakal, Madathilparambil et al. 2009).  We 
utilized a concentration of 1 mM NSC23766, which is well above the EC50 of ~50 μM, in an 
attempt to overcome any diffusion issues that might arise from treating whole islets.  We 
expected to see a decrease in Rac1-GTP in the islet β-cells and α-cells after treatment with the 
Rac1 inhibitor as a control for the antibody used to detect Rac1-GTP and the ability of the drug 
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to reduce global levels of active Rac1 in the islets.  We found that Rac1-GTP levels were 
reduced across glucose levels in both islet cell types after treatment with the specific inhibitor, 
as shown in Figure 3-4. 
 
 
Figure 3-4. A Rac1-GTPase inhibitor blocks Rac1-GTP immunofluorescence.  (A) Normalized 
mean intensity of Rac1-GTP in islet α-cells treated with 1 mM and 11 mM glucose in the 
absence and presence of NSC23766.  (B) Rac1-GTP mean intensity from β-cells in the same 
islets as in (A).  N = 4-6 islets from 6 mice, p values were determined by Student’s t-test. * 
indicates p < 0.05, ** p < 0.01, *** p < 0.0001. 
 
 
Effect of Rac1 inhibition on glucagon and insulin secretion 
 
Finally, the Rac1 inhibitor was utilized to test the dependence of insulin and glucagon 
secretion on the activity of Rac1.  Since this drug has been used before to study β-cell 
exocytosis, we expected a decrease in insulin secretion upon treatment with the Rac1 inhibitor.  
By contrast, in the α-cell, based on the experiments done above looking at the glucose 
dependence of Rac1, we expected to see no effect on glucagon secretion since it does not 
appear that Rac1 was responsible for glucagon suppression.  Interestingly, we found that 
glucagon secretion was potentiated at low glucose and stimulated at high glucose, as shown in 
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Figure 3-5, when Rac1 activation is prevented.  This data is consistent with the Rac1 activation 
data described above and further demonstrates that Rac1 is unlikely to perform the same 
modulation of exocytosis in both α- and β-cells. 
 
 
Figure 3-5. Hormone secretion from islets treated with a Rac1-GTPase inhibitor.  (A) Glucagon 
secretion from islet α-cells treated with 1 mM and 11 mM glucose in the absence and presence 
of NSC23766.  (B) Insulin secretion from β-cells in the same islets as in (A). N = 4-6 mice, p 
values were determined by Student’s t-test. * indicates p < 0.05, ** p < 0.01, *** p < 0.0001. 
 
 
Summary 
Toward the goal of elucidating the role of Rac1 in regulating glucagon secretion from 
pancreatic α-cells, we first confirmed its expression in the islets using quantitative RT-PCR on 
cDNA from sorted β- and α-cells.  Immunofluorescence was used to identify the cellular 
localization of active Rac1 (Rac1-GTP) in isolated islets, as shown in Figure 3-2.  Similar 
expression profiles were observed in both cell types and localization was largely at the 
membrane, as expected for the active form of the enzyme.  To identify the effect of glucose on 
the activation state of Rac1, semi-quantitative immunofluorescence was used to identify 
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glucagon and Rac1-GTP in isolated islets after treatment with low (1 mM) or high (11 mM) 
glucose levels.  In the β-cell, Rac1 activation was increased at high glucose, compared with low 
glucose, consistent with known Rac1 function with regard to insulin secretion.  In the α-cell, we 
also observed an increase in Rac1 activation at high glucose, in contrast to what we expected.  
This suggests that Rac1 has a different function in the α-cell and that Rac1 activation is not a 
gatekeeper for exocytosis of glucagon containing vesicles.  
We also utilized an inhibitor that specifically prevents Rac1 activation.  Upon staining the 
islets after treatment with low or high glucose in the absence and presence of the inhibitor, we 
found the mean intensity was reduced in both α- and β-cells, which provided confirmation of 
both the inhibitor and the antibody used to identify active Rac1.  We treated islets in a similar 
fashion and measured insulin and glucagon secretion at low and high glucose with and without 
the Rac1 inhibitor.  Consistent with previous reports, we found that inhibiting Rac1 drastically 
reduced insulin secretion from the islets compared with glucose-only controls.  However, 
glucagon secretion was potentiated at low glucose and stimulated at high glucose levels.  
We conclude from this study that Rac1 activity in the α-cells is not glucose dependent 
and that Rac1 is not a critical player in regulating glucagon secretion.  As the function of Rac1, 
like many small GTPases, is cell-type specific and varies significantly from cell to cell, this is not 
a particularly surprising finding.  However, it does leave open another line of questioning in 
determining the precise molecular regulators of glucagon suppression from the α-cells.  The 
other two small GTPases in the Rho family, Cdc42 and Rho-GTPase, are the next most likely 
candidates for cortical F-actin regulation and future directions may include testing their function 
in the α-cells using a similar paradigm as described here.  Additionally, the recent development 
of novel tools including tissue specific knockout mouse models (Gu, Filippi et al. 2003), 
photoactivatable GTPases (Wu, Frey et al. 2009), and specific pharmacological agents (Gao, 
Dickerson et al. 2004) should drive increased understanding about the molecular regulation and 
roles of F-actin in insulin secretion.
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CHAPTER 4 
QUANTITATIVE FLUORESCENCE IMAGING OF CELLULAR FUNCTIONS 
 
(Adapted from Elliott & Gao, et al. JCS, 2012; Elliott, et al. in preparation, 2014; Grabowska, et 
Mol Endo, 2014) 
 
Introduction 
 The complexity of islet physiology, particularly with regard to molecular events, requires 
the pursuit of novel and creative methodologies for studying these processes in living cells.  In 
addition to metabolic regulation by glucose, there are many external factors that modulate 
cellular function by manipulating intracellular signaling.  While an increasing number of 
fluorescent reporters are available for the study of such signaling pathways, the overlapping 
emission spectra of commonly used fluorophores, especially for the fluorescent proteins, limit 
the number of reporter molecules that can be used in any given experiment.  Thus, a limiting 
factor in studying molecular events in islet tissue is our inability to detect simultaneously multiple 
biosensors.  One solution to this problem is spectral imaging, which potentially allows 
background-free live-cell imaging with two or more fluorescent markers.   
The goal of the work described here was to exploit hyperspectral imaging to measure 
simultaneously the temporal and spatial dynamics of multiple fluorescent biosensors that report 
on signaling pathways in live cells.  We validated this approach in the context of β-cell biology, 
which is described in Part 1.  As part of this work, we developed a novel snapshot spectral 
imaging system for widefield microscopy and also utilized state-of-the-art confocal spectral 
imaging.  We utilized the confocal spectral imaging technique to study transcription factor 
protein-protein interactions, described in Part 2. 
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Spectral and hyperspectral imaging 
Spectral imaging techniques combine imaging with spectroscopy and are increasingly 
used in biological experiments for detecting fluorescence from two or more reporter molecules.  
While well-matched dichroic/filter combinations are available for segregating different 
fluorescent signals, the emission spectra of most fluorescent proteins (FPs) are 50-150 nm wide 
with long red-edge tails.  Thus, one FP’s signal may bleed-through into another’s emission 
channel making distinction difficult (Piston and Kremers 2007).  Utilizing spectral imaging 
removes the problem of crosstalk and increases the signal to noise because the full spectra can 
be collected since a narrow bandpass is not required.  This provides a particular advantage as 
the ongoing development of fluorescent proteins, organic fluorophores, and other optical 
highlighters greatly expands the toolkit for interrogating cellular dynamics (Pinaud, Michalet et 
al. 2006; Lavis and Raines 2008; Rizzo, Davidson et al. 2009).  
An important technique used in building fluorescent biosensors is Förster resonance 
energy transfer (FRET), which is the phenomenon of non-radiative transfer of photon energy 
absorbed by a donor fluorophore to a nearby (<10 nm) acceptor fluorophore.  Upon transfer of 
energy to the acceptor, the emitted photon will reflect the emission spectrum of the acceptor.  
When the donor and acceptor are further away than ~10 nm, transfer will not occur so the 
emission spectrum will reflect only the donor.  This technique is often used to create genetically 
encoded biosensors composed of donor and acceptor fluorescent proteins conjugated to either 
end of an environmentally sensitive peptide (Rizzo, Springer et al. 2006).  
Since FRET is a distance-limited phenomenon, it is also useful for studying protein-
protein interactions, whereby each protein of interest is tagged with a fluorescent protein (FP-
FRET).  This is also used to indicate the proximity of proteins of interest to identify if a direct 
interaction is possible.  However, there are significant challenges with conducting quantitative 
FRET experiments with the primary limiting factor being crosstalk, or bleed-through, between 
the two FPs (Piston and Kremers 2007).  Spectral imaging techniques can be used to resolve 
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the overlapping spectra and obviate the need for complicated correction procedures or 
photobleaching experiments to account for the crosstalk.  Thus, the FP-FRET experiments 
conducted in the course of this dissertation were all performed using a novel hyperspectral-
imaging device, the Image Mapping Spectrometer (Part I), or spectral imaging with confocal 
microscopy and two-photon excitation (Part II). 
 
Part 1 
Introduction 
Hyperspectral imaging has a number of applications including medical imaging, 
environmental chemical detection, geographical information, and others (Graham, de Pater et 
al. 1995; Ferris, Lawhead et al. 2001; Kandpal, Lee et al. 2013).  In the snapshot class of 
hyperspectral imagers, there are several approaches to achieve a 3D spatial-spectral datacube 
(x, y, λ).  These include image slicers, lenslet arrays or fiber field splitting, and image mapping 
spectrometers, all of which have a unique method of redistributing the spatial information in an 
object to collect simultaneously spectral and spatial information onto one or more detectors 
(Matsuoka, Kosai et al. 2002; Gao, Kester et al. 2009; Gao, Kester et al. 2010).  The ability of 
such devices to collect the whole spectrum per pixel allows for the use of multiple probes in a 
single experiment.  While the increasing number of available biosensors makes this 
methodology attractive for studying multiple molecular processes simultaneously, the spectral 
windows of available fluorescent proteins limit its ultimate usefulness.  Additionally, high quality 
data is necessary for measuring the small changes often associated with FP-FRET sensors 
(Piston and Kremers 2007).  
Most multispectral imaging systems that are available for studying multiple biosensors 
use scanning, either in the spatial domain, e.g. hyperspectral confocal microscope [9] or in the 
spectral domain, e.g., liquid-crystal tunable filter or AOTF [10].  As mentioned above, the 
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confocal method requires increased illumination to achieve a high enough SNR across the 
spectrum, which may result in photodamage.  Additionally, these methods rely on sequential 
image acquisition so are limited in temporal resolution, which is another critical factor in 
measuring cellular activity with fluorescent biosensors.  A solution that can overcome these 
problems is a recently developed snapshot device, the Image Mapping Spectrometer (IMS), 
which acquires full spectral information simultaneously from every pixel in the field of view and 
is coupled to a widefield microscope such that all of the photons in the focal volume are 
collected (Elliott, Gao et al. 2012).  The tradeoff with the widefield configuration is the lack of 
optical sectioning afforded by a pinhole in the confocal configuration.  This makes thick 
specimens challenging to collect and interpret data from, due to the out-of-focus light and 
sample scattering.  In the experiments conducted here, monolayers of tissue culture cells were 
used to facilitate data collection and analysis.  
Briefly, the IMS maps adjacent pixels from the object to create space between them in 
the image, and then uses a grating to spread wavelength content from each pixel into this 
space.  Direct image re-mapping provides the final 3D (x, y, λ) data cube (Gao, Kester et al. 
2009; Kester, Bedard et al. 2011; Bedard, Hagen et al. 2012).  The IMS has a unique geometry 
that allows rapid collection of high-resolution spectral data in a single snapshot.  This 
methodology is based on the image mapping principle, which maps a sample’s 3D datacube (x, 
y, λ) onto a 2D detector array for parallel measurement.  The operating principle is displayed in 
Figure 4-2 and the primary constituents are described in detail below.  
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Figure 4-2: Operating principle and system configuration of the IMS. In the IMS, the object’s 
different image zones are mapped and dispersed onto different locations of a 2D camera 
detector (the object’s rows y1, y2, y3 and y4 are mapped onto the second quadrant, first 
quadrant, third quadrant, and fourth quadrant of the camera respectively in this simple 
example).  The grey pixel in the original object represents a spatial sampling point that has all 
colors.  An x, y, λ datacube is reconstructed by remapping camera pixels encoded with the 
same color back to the corresponding spectral layer.  The full-resolution datacube is acquired by 
the IMS via a single snapshot. 
 
 
The IMS system consists of four major optical components, including:  
a. Image relay.  The image relay has two functions: to transfer the intermediate image 
from the microscope image port to the image mapper; and to force the light rays to be 
telecentric at the image side.  The telecentricity at the image side is the requirement for correct 
guidance of light rays reflected from the image mapper.  The image relay optics include a Zeiss 
(Oberkochen, Germany) 2.5×/0.075 Plan-Neofluar objective and Zeiss 130 mm tube lenses 
(F.L. = 165 mm, Edmund optics, Barrington, NJ, P/N: NT58-452).  The distance between the 
objective back pupil aperture and the tube lens is set to be 165 mm, equal to the focal length of 
the objective, so that the chief rays are parallel to the optical axis at the image side.  
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b. Image mapper.  The image mapper is a custom fabricated component, which consists 
of 350 strip mirror facets (70 μm wide, 25 mm long) on a 25 mm × 25 mm high purity Kobe 
aluminum substrate.  Each mirror facet has a 2D tilt angle (αx, αy) (αx = 0.075, 0.045, 0.015, -
0.015, -0.045, -0.075 rad.; αy = 0.045, 0.015, -0.015, -0.045 rad.) to reflect light into different 
sub-pupils.  The image mapper was fabricated by the ruling approach on a 4-axis ultra-precision 
lathe (Moore Nanotechnology Systems, Swanzey, NH, 250UPL).   
c. Collecting lenses. We use an Olympus (Center Valley, PA) 1× objective (P/N: 
MVPLAPO, F.L. = 90 mm, N.A. = 0.189) to collect light reflected from the image mapper.  A 6 × 
4 sub-pupil array is formed at the back focal plane of the collecting lenses.  
d. Prism array and re-imaging lens array.  The role of the prisms and re-imaging lenses 
is to disperse the sub-pupils and re-image them onto the CCD detector.  The prisms are 
constructed as a 6×1 array of double-Amici prisms fabricated by Tower Optical, Inc (Boynton 
Beach, FL).  Each double-Amici prism consists of two identical Amici prisms separated by a 
pupil mask (Dia. = 3 mm).  The designed spectral range is from 450 nm to 650 nm.  The re-
imaging lens array is composed of 6 × 4 achromatic doublets (Edmund optics, Barrington, NJ, 
P/N: 45-408, Dia. = 5 mm, F.L. = 20 mm).  The field of view of each re-imaging lens on the CCD 
detector is of size 5.55 mm ×5.55 mm.  When the PSF on the image mapper matches the mirror 
facet width, the PSF on the CCD detector is about 16.8 μm in diameter, and is sampled by ~ 2 
camera pixels (pixel size: 7.4 μm × 7.4 μm). 
 
IMS calibration and corrections 
 There are several calibration procedures that have been developed for the IMS to 
account for mechanical and chromatic aberrations in the components.  The protocols developed 
for calibrating and standardizing the IMS after fabrication are reported here (Bedard, Hagen et 
al. 2012).  Since the IMS devices that were available to us over the course of this project were 
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fabricated before rigorous optimization of the procedures, there were a number of imperfections 
to correct for either pre- or post-data collection.  We utilized a three-step calibration procedure, 
the first of which was accounted for before arrival in our laboratory and is described in detail 
here (Bedard, Hagen et al. 2012).  A flat-field correction was performed before beginning 
experiments to account for intensity variations across the raw image.  Using a halogen lamp and 
an empty microscope stage with a neutral density filter in place, a datacube (flat-field image) 
was recorded and subsequent datacubes acquired by the IMS are divided by the flat-field image 
to normalize the response of each voxel in the datacube.  A new flat-field control image was 
collected for each set of IMS experiments to account for any changes in alignment, and an 
example is shown in Figure 4-3.  A number of mechanical issues can be identified from such an 
image and reflect small imperfections in the image mapper.  
 
 
Figure 4-3: Sample flat-field calibration image from the IMS.  
 
 
The next calibration step consisted of collecting the halogen lamp spectrum with a point 
spectrometer and multiplying this correction factor by each of the spectral images within the 
datacube to provide spectral sensitivity standardization.  This procedure was done once for 
each of the metal and plastic versions of the IMS that we used for experiments.  Additionally, 
the IMS alignment and focus was achieved after setup using a USAF resolution target.  All of 
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the calibration procedures were performed with the 40x oil immersion objective that we utilized 
for experiments to account for the specific optics and aberrations on the objective lens.  
 
Spectral data cube processing and analysis 
The 3D datacubes are read out from the detector as tiff files and custom programs have 
been created in MatLab to handle the remapping and three or four-color unmixing processes.  A 
lookup table that relates the image voxels to exact locations on the detector for the X and Y 
image planes is generated in the first calibration step and was provided with the IMS.  These 
lookup tables are required for the remapping algorithm.  Briefly, the MatLab program reads in a 
raw tiff file, multiplies it by the correction factor for spectral sensitivity, divides by the flat-field 
correction image, and remaps this corrected raw data into a useable datacube.  The algorithm 
responsible for the remapping is a bicubic interpolation of the raw detector data and is described 
in detail here (Bedard, Hagen et al. 2012).  This program outputs a folder of 70 xy tiff files, one 
for each wavelength bin, for each time point tiff.  
The lambda series are then read into the unmixing program, which executes a linear 
unmixing algorithm.  Linear unmixing is a commonly used method for extracting multiple spectra 
from an image.  It is based upon the principle that each pixel in an image represents a complex 
spectrum of intensities from more than one fluorescent species.  This mixture of signals can be 
deconvolved into the proportion of each individual fluorophore based on their reference spectra 
(Zimmermann 2005), which we collected from cells transfected with the individual fluorescent 
proteins used in the experiments.  Additionally, an untransfected control was imaged to provide 
a reference for the autofluorescence spectrum.  This unmixing program outputs a single tiff for 
each reference spectrum that has all of the remapped spatial information and can be analyzed 
using standard image processing software.  Here, ImageJ was utilized for the image processing, 
often with macros written to increase the efficiency of processing multiple files.  After 
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background correction, intensities were measured as the average over each cell, defined by a 
ROI selection.  The cellular intensities were then averaged across the FOV and for FRET pairs 
the ratio of acceptor to donor was calculated.  Finally, data were normalized to the average of 
the first several frames in each experiment to facilitate interpretation of changes over the 
timecourse due to perturbations. 
 
Hyperspectral image mapping spectrometry for live-cell imaging 
To demonstrate the IMS advantages for imaging dynamic cellular processes, we 
assayed multiple fluorescent biosensors of pancreatic β-cell signaling molecules.  While our 
current interest lies in the glucagon-secreting α-cell, as evidenced by previous chapters, the IMS 
configuration with a widefield microscope does not have optical sectioning capability and thus, 
whole islet imaging required for studying the α-cells was outside of the scope of this work.  The 
β-cells, by contrast, can be studied in monolayers of cultured cells that reasonably mimic some 
of the islet β-cell behaviors, so this was the model we worked with for characterizing the IMS 
system for live-cell imaging.  As mentioned in previous chapters, the roles of [Ca2+]i and cAMP 
signaling in regulating glucose-stimulated insulin secretion from pancreatic β-cells have long 
been known (Landa, Harbeck et al. 2005; Holz, Heart et al. 2008).  These signaling pathways 
are the targets of numerous physiological regulators and several pharmaceuticals that combat 
the symptoms of diabetes.  However, it has been challenging to study temporal relationships 
between these signaling molecules due to the spectral overlap of most [Ca2+]i and cAMP 
biosensors (Landa, Harbeck et al. 2005).  
Throughout the following studies, we utilized an optimized fluorescent protein (FP)-
based FRET biosensor for cAMP called T-Epac-VV, which contains an monomeric Turquoise 
donor and tandem circularly permuted Venus-mVenus (Venus-Venus) acceptor (Klarenbeek, 
Goedhart et al. 2011).  To image [Ca2+]i, we used a GCaMP family (Wang, Shui et al. 2008; 
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Tian, Hires et al. 2009) biosensor with a circularly permuted GFP fluorophore, called GCaMP5G 
(Akerboom, Chen et al. 2012).  While the emission spectra of the three FPs (Turquoise, Venus-
Venus, and cpGFP) overlap significantly, the IMS can simultaneously measure changes in their 
intensity and distinguish between their spectra over time.  The resulting 4D dataset (x, y, λ, t) 
permits detailed examination of the temporal dynamics and relationships between different 
signaling molecules.  However, biosensors like T-Epac-VV based on FP-FRET depend on 
measurements of small changes in FRET and thus require high signal-to-noise data (Piston and 
Kremers 2007; Lin 2010).  Using the IMS, we can resolve the effects of modulating these 
signaling molecules simultaneously to determine the effects of various perturbations. 
We also monitored Caspase-3 activity with a cleavable biosensor composed of either an 
ECFP/EYFP FRET pair (Scat3.1) (Nagai and Miyawaki 2004) or a newly prepared sensor 
(GRScat) with the recently published green/red FRET pair mClover and mRuby2 (Lam, St-
Pierre et al. 2012).  Combinations of these biosensors allowed us to monitor pairs of molecular 
processes simultaneously and we were able to use linear unmixing with either three or four 
fluorophores.  Combining the cAMP FRET biosensor and the new GRScat Caspase-3-cleavable 
sensor, we utilized a dual FRET approach with the IMS to study the relationship between cAMP 
and Caspase-3-mediated apoptosis in pancreatic β-cells, for which the molecular mechanism is 
not well understood but is known to play an important role in the pathology of type 2 diabetes.  
In the following studies, we have used the IMS approach to interrogate the normal relationship 
between [Ca2+]i and cAMP in β-cells that have been stimulated with glucose, and we have 
characterized this relationship under oxidative stress conditions along with the onset of 
caspase-3 activation that leads to apoptosis.   
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Materials and Methods 
Cellular sample preparation 
HeLa, MIN6, or βTC3 tissue culture cells were transiently transfected with plasmid DNA 
encoding one or more of the fluorescent protein-tagged proteins in the Table below.  
Transfection was accomplished using Lipofectamine2000 (Invitrogen, Carlsbad, CA) 
transfection reagent according to the manufacturer's instructions.  Cells were seeded onto No. 1 
coverglass bottomed dishes (MatTek, Ashland, MA) and cultured as previously described for 
microscopy studies.  24 hours after transfection, samples were fixed with 4% paraformaldehyde, 
washed in DPBS, and mounted on microscope slides with gelvatol. For live-cell experiments, 
imaging was accomplished in extracellular-like buffer 24-48 hours after transfection. 
 The results for this chapter are organized into sections by imaging modality, with the first 
being a technical comparison of the hyperspectral IMS and the spectral detection mode of the 
laser-scanning microscope (LSM) 710 (Zeiss).  The data collected with the IMS in β-cells is then 
presented and summarized, and this chapter ends with a collaborative project using spectral 
FP-FRET with the confocal method to study transcription factor interactions.  
 
Results 
Quantitative comparison of the IMS and LSM710 
We have compared quantitatively the detection efficiencies of the IMS system and the 
Zeiss LSM710 confocal microscope that we commonly use for spectral imaging.  While the two 
systems have comparable detection efficiencies, the IMS offers advantages in acquisition speed 
that increase as larger image sizes are used due to the snapshot format.  To compare 
quantitatively the detection efficiency (defined as the ratio of photons detected over photons 
excited, or D=Nd/Ne) of two systems, we measured their relative excitation intensities and 
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fluorescent photon detection.  We imaged the same sample volume on both systems and 
measured the collected fluorescent photons under matched excitation conditions, which were 
determined by matching the photobleaching rate in the two systems.  The procedure was as 
follows: we matched the total image acquisition time, the image size and the pixel size, then we 
measured the photobleaching rates for such settings, and their value was used to scale the 
different excitation intensities.  The imaging settings for the experiment on the IMS were: 
integration time 500 ms, pixel size 0.7 µm, image size 348 * 348 pixel, excitation filter 436/20, 
dichroic T455LP, emission filter HQ460LP, 40x/1.3 oil objective.  The imaging settings for the 
experiments on the LSM710 (Zeiss, Oberkochen, Germany) were: excitation laser 458 nm, 
power 5% of 100 mW, scan time 531 ms, dwell time 3.76 µs, pixel size 0.68 µm, pinhole 
diameter 609 µm corresponding to an optical section of 15.5 µm, image size 348 * 348 pixel, 
Zeiss Fluar 40x/1.3 oil objective. 
We designed two independent sets of experiments to calculate the relative detection 
efficiency of the two systems, DIMS/D710.  First, we compared the excitation power acting on the 
sample using microdroplets with a 10 µM aqueous solution of fluorescein (F-1300 from 
Molecular Probes, Carlsbad, CA) dispersed in a hydrophobic medium to create a layer of 
fluorescent droplets with a thickness less than 3 µm (Kremers and Piston, 2010).  The use of 
microdroplets removes the need to consider lateral diffusion in the sample, and the relatively 
thin sample thickness is also critical for the comparison.  The LSM710 is a confocal system, 
which only collects photons from a section of the sample, while the IMS is coupled to a widefield 
microscope (Nikon TE 300 inverted microscope, Melville, NY) and therefore receives photons 
from the whole sample volume.  In the confocal configuration, using a thin sample allows the 
pinhole size to be set so that all the photons coming from the sample volume are collected.  
The measured photobleaching rates were used to estimate the ratio between the 
excitation intensities delivered into the sample by the two systems, which is an estimate of the 
number of incoming photons.  For the power levels that are used in fluorescence microscopy, 
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the relationship between excitation intensity and photobleaching rate is generally accepted to be 
a linear one: k = aI.  Under this assumption with matched excitation power P, imaged area A, 
and imaging time on the two systems, the intensities and photobleaching rates are related by: 
I710/IIMS = k710/kIMS = npixel.  
For the second set of experiments we used a thin film of fluorescein solution to measure 
the number of photons collected by the two systems.  Again, the sample being thinner than the 
optical section selected on the LSM710 allowed for a direct comparison between the widefield 
and confocal systems.  The number of emitted fluorescence photons is now only proportional to 
the number of excited photons.  Moreover in these conditions there is no background to be 
subtracted from the signal and the only source of noise is the shot noise that follows Poisson’s 
distribution.  The number of detected photons (i.e. photo-electrons) Nd equals  ̅    , where  ̅  
is the mean of the grey level distribution and   is the standard deviation of the same distribution.  
For the LSM710 the number of detected photons in a single spectral bin centered at 519 nm, 
with a spectral width of 9.7 nm, was Nd710 = 78.  For the IMS the number of detected photons in 
an 8 nm spectral bin centered at 519 nm was NdIMS = 1465. Thus, assuming linear 
photobleaching, the ratio of DIMS/D710 = (NdIMS/ Nd710)·(I710/IIMS)·(AIMS/A710) = (NdIMS/ 
Nd710)·(k710/kIMS)·(AIMS/A710) = 8.4 
This large difference in collection efficiency is surprising considering the improvements 
introduced to confocal microscopy over the last 25 years.  However, these comparisons are 
based on equal amounts of photobleaching, which is an appropriate comparison for practical 
imaging but may not accurately reflect actual collection efficiency.  It has been shown that the 
photobleaching rate in laser scanning confocal microscopy is supra-linear (Patterson and 
Piston, 2000).  Assuming this supra-linear dependence k*= aI1.2, we would need to introduce a 
correction factor in the relation linking intensities and rates: I710/IIMS ≈ (k
*
710/kIMS)/(npixel)
0.2.  For an 
image of 348*348 pixels, this correction is ~10, which would bring the overall detection 
efficiencies of the two systems to nearly the same level.   
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Further optimization of the IMS system, including the use of a high quantum efficiency 
camera, will lead to higher collection efficiency in the IMS than is possible with a laser scanning 
system.  It should be noted that if image collection rates are not an issue, any hyperspectral 
imaging approach could be utilized, including confocal spectral imaging such as we have used 
with the LSM710.  In fact, the main advantages of widefield microscopy over laser scanning 
confocal imaging are the higher signal collection and resultant increased data acquisition rates.  
Further, the superior temporal resolution given by the IMS system becomes greater as larger 
frame sizes are captured.   
 
Spectral unmixing of triply-labeled HeLa cells 
Our first goal with in using the IMS for cell biology was to test its spectral resolution with 
regard to known overlapping fluorophores.  The commonly used fluorescent proteins CFP, GFP, 
and YFP have considerable overlap in their emission spectra, requiring post-collection unmixing 
to separate the signals (Kremers 2011).  To demonstrate the efficacy of the IMS system for this 
purpose, we expressed proteins with known localizations fused to ECFP, EGFP, or SYFP 
(Rizzo, Springer et al. 2006) (em 480 nm, 509 nm, and 528 nm respectively) in HeLa cells and 
fixed them for IMS imaging.  Since linear unmixing algorithms rely on reference spectra to 
calculate components, we first acquired these from singly labeled control cells.  The resulting 
base emission spectra were determined independently for all three fluorophores using the IMS 
and the shapes and emission profiles were found to be accurate compared with conventional 
methods for measuring spectra.  However, spatially distinct fluorophores are still a limited test 
as the overlapping spectra will only occur is a small percentage of pixels in the image.  A more 
robust test, and closer to the ideal experiments, would be to use spatially and spectrally 
overlapping fluorophores, as many cellular processes occur in the cytosol and are not 
compartmentalized.  
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Thus, triply labeled cells expressing ECFP in the mitochondria, EGFP on the on the 
plasma membrane, and SYFP in the nucleus were imaged by the IMS with an integration time 
of 0.5 seconds.  The spectral component images were determined by implementing a linear 
spectral unmixing algorithm (Zimmermann 2005) on the measured datacubes.  To provide a 
reference image for comparison, we used a color camera to capture an image of the same field 
of view.  In this color image, all three components appear as shades of green and cannot be 
discriminated.  In contrast, spectral unmixing reveals the three components clearly and identifies 
their sub-cellular localization.  Since each channel represents the spectral emission profile for 
each fluorophore, crosstalk from the other two fluorophores is minimized.  These data are 
presented in Figure 4-4. 
 
 
Figure 4-4: Linear unmixing of spatially separated overlapping fluorophores with the IMS.  (A) 
The baseline reference image was captured by a color camera (Infinity 2-1C) directly at a 
microscope’s side image port.  (B) A merged image of D, E, and F.  (C) The unmixed 
component spectra.  (D-F) The spectral component images were acquired by implementing a 
linear unmixing algorithm on the IMS measured datacube (captured with 0.5 s integration time).  
D-F were pseudo-color rendered to indicate FPs’ sub-cellular localizations.  
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Real-time hyperspectral imaging of [Ca2+]i and cAMP oscillations  
Having successfully demonstrated in fixed tissue that the IMS was capable of providing 
high quality spectral and spatial data for transfected cells, we next turned to a live-cell system to 
test its capabilities in measuring dynamic processes.  Since we coupled the IMS to a widefield 
microscope, we did not have the optical sectioning that is conferred by a pinhole in a confocal 
configuration.  Thus, studying the thick, dense multicellular islets was not possible, so instead 
we used MIN6 tissue culture β-cells, which form a monolayer convenient for widefield imaging 
and are functionally similar to islet pancreatic β-cells.  The MIN6 cells exhibit similar intracellular 
calcium ([Ca2+]i) pulses with a period of 30–80 s and a duration of 1–4 s that underlie pulsatile 
insulin secretion from these cells (Holz, Heart et al. 2008).  These pulses of [Ca2+]i arise due to 
[Ca2+]i flux across the plasma membrane through voltage-gated [Ca
2+]i channels (VGCCs) that 
open after membrane depolarization caused by the closure of ATP-sensitive K+ channels.  
Subsequent opening of [Ca2+]i-dependent K
+ channels then repolarizes the membrane and 
closes the VGCCs.  The observed pulses are a measure of the repeated opening and closing of 
these ion channels.   
To demonstrate the ability of the IMS to monitor the temporal dynamics of [Ca2+]i activity 
in vivo, MIN6 cells were transfected with GCaMP5G (ex. 495 nm, em. 519 nm).  GCaMP5G is 
made of a circularly permuted GFP moiety and a portion of the [Ca2+]i binding protein calmodulin 
(Baird, Zacharias et al. 1999; Nagai, Sawano et al. 2001).  In the unbound state, the fluorescent 
signal from the GFP is quenched.  Then, upon binding [Ca2+]i, the protein changes 
conformation, activates the chromophore, and produces fluorescence with peak emission of 519 
nm.  Changes in GCaMP5G fluorescence show an increase in intensity upon stimulation with 20 
mM glucose and 20 mM TEA and pulses in [Ca2+]i at the expected frequency of 1–2 per min in 
20 mM glucose, as displayed in Figure 4-5.  Thus, the IMS system provides the sub-second 
resolution needed to quantify these pulses and study calcium signaling in a time-resolved 
manner with different perturbations.  
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Figure 4-5: [Ca2+]i oscillations with GCaMP5G in MIN6 β-cells. Singly-transfected [Ca
2+]i 
intensity collected 5 minutes after stimulation with 20 mM glucose and 20 mM TEA with a 0.5 s 
integration time every 2 minutes. 
 
 
We next sought to measure an FP-FRET biosensor in live cells to demonstrate that the 
spectral resolution provided by the IMS is sufficient to unmix donor and acceptor spectra in a 
dynamic setting.  Thus, MIN6 cells were transfected with the FRET-based cAMP sensor T-Epac-
VV, a fusion protein containing Turquoise (Goedhart, van Weeren et al. 2010) and tandem 
Venus-Venus connected by a portion of the cAMP binding protein Epac1 (de Rooij, Zwartkruis 
et al. 1998).  Importantly, since this biosensor is based on intramolecular FRET, the 
stoichiometry of the donor and acceptor fluorophores is one to one, which allows for data 
analysis of the direct ratio of donor to acceptor fluorescence.  In cells, donor Turquoise and 
acceptor Venus-Venus are linked and a strong FRET signal is observed in the absence of 
cAMP.  Upon production of cAMP by adenylyl cyclases, the sensor binds cAMP and undergoes 
a conformational change resulting in a loss of FRET.  As FRET is eliminated with the change in 
fluorophore conformation, there is an increase in donor Turquoise fluorescence and decrease in 
acceptor Venus-Venus intensity, which is typically expressed as the ratio of Venus-
Venus/Turquoise (called the FRET ratio throughout this document).   
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In our first experiment, transiently transfected MIN6 cells were exposed to 20 mM 
glucose and 20 mM TEA 24 hours after transfection to stimulate cAMP signaling and were 
monitored for changes in FRET with continuous collection at 2 fps.  As expected, glucose and 
TEA stimulated an increase in cAMP activity, and led to sustainable cAMP oscillations, which 
are shown in Figure 4-6.  As with the [Ca2+]i oscillations, these occur at the expected frequency 
of 1-2 per minute.  Importantly, the oscillations are also observed in the unmixed Turquoise and 
Venus-Venus spectral components of T-Epac-VV, verifying that the cAMP oscillations we observe 
in the ratio are not the result of an unmixing artifact or background noise.  
 
 
Figure 4-6: cAMP oscillations in β-cells.  (A) The T-Epac-VV FRET ratio over time 5 minutes after 
stimulation with 20 mM glucose and 20 mM TEA collected with a 0.5 s integration time every 2 
minutes.  (B) Time-resolved components of (A) with Turquoise in blue and Venus-Venus in 
yellow. 
 
 
Simultaneous imaging of [Ca2+]i and cAMP oscillations in MIN6 cells  
A major advantage of hyperspectral imaging is its ability to correlate multiple signals.  To 
demonstrate this ability with multiple live-cell dynamic processes we transfected MIN6 cells with 
both GCaMP5G and T-Epac-VV biosensors.  This allows the measurement of both [Ca2+]i and 
cAMP activation after glucose stimulation in the MIN6 cells.  Figure 4-7 shows that the two 
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biosensors can be simultaneously measured and spectrally unmixed to indicate the expected 
dynamics as compared to singly transfected controls that were displayed in Figures 5-5 and 5-6.   
 
 
Figure 4-7: Simultaneous imaging [Ca2+]i and cAMP oscillations at 2 fps.  (A) [Ca
2+]i (gray) and 
cAMP (black) oscillations after 5 minutes of stimulation with 20 mM glucose and 20 mM TEA 
stimulation collected at 2 fps.  (B) [Ca2+] and cAMP oscillations from a cell in a different FOV 
stimulated and collected as in (A).  (C, D) Time resolved components of T-Epac-VV (Turquoise in 
gray, Venus-Venus in black) from cells A and B respectively.  Venus traces are corrected to 
account for the observed photobleaching (see Methods). 
 
 
Looking at the unmixed data, two representative cells imaged at 2 fps show that [Ca2+]i 
and cAMP oscillations occur with a similar frequency after stimulation by glucose and TEA.  Due 
to data acquisition restrictions in the IMS computer’s memory, we were restricted to collecting 
109 
 
data at 2 fps, which severely limited the number of oscillation periods in each collection record, 
and thus prohibited a detailed analysis of the temporal relationship between [Ca2+]i and cAMP 
oscillations.  At this imaging rate, we also collected data from co-transfected cells after 
stimulating with either KCl to maximize the Ca2+ signal, or IBMX and forskolin to maximize 
cAMP, as displayed in Figure 4-8.  These experiments demonstrated the dynamic range of both 
sensors and the ability of the unmixing algorithm to distinguish between signals, since we are 
able to selectively change the dynamics of one biosensor or the other based on known 
stimulatory substances.  
 
 
Figure 4-8: Functional biosensor isolation by selective stimulation.  (A) Timecourse of T-Epac-
VV in black and GCaMP5G in gray after treatment with 20 mM KCl.  (B) As in (A) after treatment 
with 100 µM IBMX and 50 µM forskolin. 
 
 
To overcome the data collection limitation imposed by the hardware, we performed 
experiments with the same 0.5 second integration time, but a frame rate of once every 2 
seconds.  This protocol allowed us to image for a longer period (400 seconds) and obtain more 
oscillations per single stimulus.  The GCaMP5G and T-Epac-VV traces over this time period for 
glucose and TEA treatment show anti-correlative oscillations, as displayed in Figure 4-9.  
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Additionally, the component traces from the cAMP sensor demonstrate that these oscillations 
are not an artifact of unmixing or averaging.   
 
 
Figure 4-9: Simultaneous [Ca2+]i and cAMP oscillations in stimulated β-cells.  (A) [Ca
2+]i (gray) 
and cAMP (black) activity average in 5 cells after stimulation with 20 mM glucose and 20 mM 
TEA collected with a 0.5 s integration time.  (B) Average components of T-Epac-VV (Turquoise in 
gray, Venus-Venus in black) cAMP sensor from (A). 
 
 
We also plotted the time variant GCaMP5G against the T-Epac-VV and confirm a negative 
correlation with a Pearson coefficient of -0.5720 (n = 5 cells).  One other cell exhibited similar 
negative correlation of its smaller-amplitude peaks, but also showed a single large-amplitude 
peak with a strong positive correlation.  For the average traces shown in Figure 4-9, data from 
this cell were not included since we could not confirm whether the single peak was an artifact or 
a unique biological event.  Additionally, a cross-correlation analysis provided the same negative 
correlation coefficient of -0.5720 for the GCaMP5G and T-Epac-VV signals, as shown in Figure 4-
10.  This analysis also demonstrated that the GCaMP5G signal rise precedes the T-Epac-VV 
decrease.  Together, these data show that [Ca2+]i and cAMP signals are anti-correlated in 
pancreatic β-cells, and [Ca2+]i oscillations lead those of cAMP by 2.5 seconds in response to 
glucose and TEA.  Because this difference in rise time is comparable to previously used 
imaging rates, the relative rise times of these two signals have not been assessed.  The 
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observed anti-correlation confirms the predictions of computational models (Holz, Heart et al. 
2008), and the superior time resolution of the IMS system represents a significant potential for 
further detailed analysis of the interplay between the [Ca2+]i and cAMP under various 
treatments.   
 
 
Figure 4-10: Correlating [Ca2+]i and cAMP oscillations.  (A) Correlation plot of average [Ca
2+]i 
and cAMP traces from Figure 4-5, r = -0.5720. (B) Cross-correlation plot of data in (A).  
 
 
Real-time hyperspectral imaging apoptosis in β-cells  
A major goal in cell biology is to correlate multiple live-cell dynamic processes in real-
time, which we demonstrated is possible using the IMS to study the relationship between [Ca2+]i 
and cAMP signaling.  These two signaling pathways are ubiquitous in nearly all cells and have 
particular relevance to islet physiology because the islet cells are bombarded with extracellular 
factors that utilize these second messengers to drive various functions.  One of the functions 
that both pathways have been implicated in is that of mitochondria-mediated apoptosis.  This is 
a critical point, as dysregulated β-cell apoptosis contributes to the development of type 1 and 
type 2 diabetes, and limits the ability of islet transplantation as a therapeutic for patients with 
type 1 diabetes (Mathis, Vence et al. 2001; Butler, Janson et al. 2003; Butler, Janson et al. 
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2003).  
Recent reports have demonstrated a strong temporal correlation between [Ca2+]i 
elevation and morphological changes, as well as Caspase-3 activity (Lee, Lu et al. 2010).  Since 
Ca2+ is known to be critical for β-cell function and is dysregulated in both type 1 and type 2 
diabetes, a better molecular understanding of this relationship would be beneficial.  
Furthermore, Ca2+ channels are commonly affected by drugs that treat diabetes, such as the 
sulfonylureas, which act directly on K+ channels to increase membrane depolarization, Ca2+ 
channel activation, and Ca2+ influx (Shiota, Rocheleau et al. 2005).  Notably, this particular class 
of drugs has also been shown to affect the cAMP pathway via Epac2 (Zhang, Katoh et al. 
2009).  However, too much [Ca2+]i activity can lead to inappropriate  mitochondrial membrane 
depolarization, cytochrome c release, Caspase-3 and -9 activation, and ultimately apoptosis 
(Boehning, Patterson et al. 2003).  
The generation of reactive oxygen species (ROS) is another route by which β-cell 
apoptosis is stimulated in the diabetic state, which has been correlated with both glucotoxicity 
and lipotoxicity (Luciani, Gwiazda et al. 2009; Syeda, Mohammed et al. 2013).  The molecular 
mechanisms underlying ROS generation and subsequent apoptosis are unclear.  However, both 
[Ca2+]i (Boehning, Patterson et al. 2003) and cAMP (Li, Li et al. 2012) have been shown to play 
roles this process, though their relative contributions have yet to be clarified.  Having 
established that we can measure [Ca2+]i and cAMP simultaneously in response to several 
stimuli, we sought to determine  the relationship between [Ca2+]i, cAMP signaling and apoptosis 
via caspase-3 activation.  To accomplish this, we utilized the IMS to detect the dynamics of 
GCaMP5G for [Ca2+]i or the cell-permeant dye Fluo4; 
T-Epac-VV cAMP FRET sensor; and two 
Caspase-3 cleavable FRET biosensors with different FPs, Scat3.1 with ECFP/EYFP, and 
GRScat with mClover/mRuby2, in pairwise combinations in pancreatic β-cells lines.  
In healthy cells, the donor and acceptor of the Caspase-3 cleavable sensors remain 
linked and FRET is observed until Caspase-3 is activated, whereupon the active protease 
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cleaves the donor from acceptor resulting in a loss of FRET.  Thus, as cleavage occurs and 
FRET is eliminated, donor fluorescence increases, and the acceptor intensity decreases.  An 
important advantage of the IMS system and the green/red FRET pair is that using a single 
excitation source, the acceptor mRuby2 in the GRScat is not stimulated directly.  Thus, the 
mRuby2 fluorescence is only observed when the cells are healthy and as the Caspase-3 
increases, the FRET ratio decreases until mRuby2 is no longer detectable.  
To induce apoptosis, we treated the transiently transfected cells with a high (30 mM) 
concentration of H2O2, a common model for oxidative stress.  βTC3 cells were exposed to H2O2 
24 hours after transfection to induce apoptosis and were subsequently monitored for changes in 
FRET (frame integration time: 0.5 s, frame interval time: 2 min).  By 50 min post-H2O2-
treatment, a significant reduction in FRET was observed and continued until the cell died, as 
demonstrated by morphological changes characteristic of dying cells (~90 min post-H2O2-
treatment).  An advantage of the IMS in this experiment is the high-throughput nature, which 
allows for extended time-lapse imaging (~2.5 hours in this case) with the low excitation 
intensities needed to minimize photobleaching and photodamage.  The IMS system also allows 
us to observe morphological changes in the cells as apoptosis occurs.  In this case, the cells 
shrink and bleb over time reflecting the gradual loss of membrane architecture (Hacker 2000).  
Snapshots of the cells in one field before and 90 min after oxidative challenge with H2O2 show 
apoptotic cell shrinking and a 85.7% decrease in the Caspase-3 sensor FRET ratio, shown in 
Figure 4-11. 
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Figure 4-11: Apoptotic dynamics and morphology in βTC3 cells.  (A) Snapshots at the onset of 
imaging and 90 minutes after H2O2 treatment where cell shrinkage becomes noticeable.  (B) 
Timecourse of FRET loss as Caspase-3 is activated by oxidative stress. 
 
 
Next, to study the relationship between [Ca2+]i and caspase-3 activation, we labeled the 
βTC3 cells expressing SCAT3.1 with the Ca2+ indicator dye Fluo4.  Using multiple biosensors 
allows us to measure changes in [Ca2+]i and caspase-3 activation as a result of oxidative 
challenge to βTC3 cells induced by H2O2.  Upon oxidative stress, our data indicate negligible 
Ca2+ pulses, despite the high glucose levels used in these experiments.  Interestingly, 150 min 
after the addition of H2O2, we observed a ~ 3.6 % increase of Fluo4 fluorescence in the first 50 
min followed by a ~ 5.4 % decrease over the remainder of the experiment, consistent with 
previous reports that show a calcium-mediated apoptosis signal in vivo (Zhang, Zhang et al. 
2000).  Simultaneously, we observed the characteristic decrease in the FRET ratio that 
indicates activation of Caspase-3 and cleavage of the biosensor, as shown in Figure 4-12.  The 
average change in FRET observed was 62% for three co-transfected cells in the field of view in 
150 minutes.  Plotting the time variant for caspase-3 activation and [Ca2+]I, we observe a 
Pearson correlation coefficient of 0.095, indicating very little correlation between oxidative stress 
induced activation of caspase-3 and the changes in [Ca2+]i.  
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Figure 4-12: Caspase-3 and [Ca2+]i dynamics upon oxidative challenge.  (A) Timecourse of 
FRET loss (orange) and [Ca2+]i (green) as Caspase-3 is activated by oxidative stress.  (B) Time-
resolved components of the T-Epac-VV cAMP sensor from (A).  
 
 
Hyperspectral Dual-FRET for screening cAMP dynamics and apoptosis in β-cells 
Since we had demonstrated the ability to unmix the cyan, green, and yellow FPs, the 
experiments performed above using a green [Ca2+]i indicator and cyan/yellow FRET pair were 
not technically challenging for the IMS.  However, the question of correlating cAMP with 
caspase-3 activation could not be done with just three colors, as there isn’t a unimolecular FP-
based sensor for either molecule.  Additionally, the majority of FRET-based biosensors are 
composed of a cyan fluorescent protein variant donor and a yellow fluorescent protein variant 
acceptor and the T-Epac-VV FRET-based cAMP biosensor and the caspase-3 cleavable FRET 
sensors we utilized previously both fall into this category. 
While there are a few green/red FRET pairs, dual-FRET is rarely attempted due to the 
overlapping emission spectra of all four fluorophores and challenges in configuring a single 
excitation with a snapshot modality, required for simultaneous imaging.  Since the IMS is ideally 
suited for this experiment in terms of excitation and data collection, we designed a green/red 
caspase-3 cleavable biosensor (easier to prepare) to be used with the traditional cyan/yellow 
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cAMP sensor to measure simultaneously caspase-3 activation and cAMP activity in the MIN6 β-
cells.  This biosensor is composed of the two best and brightest FPs in this part of the spectrum, 
mClover and mRuby2, which were recently characterized as a very strong FRET pair (Lam, St-
Pierre et al. 2012).  To test the unmixing capability of the IMS with both biosensors, we 
transiently transfected cells with single fluorophores to collect reference spectra or both FRET 
sensors.  The unmixed components from one cell in a single field of view are shown in Figure 4-
13.  These are raw data so that the relative differences in intensities for the individual FPs can 
be appreciated.  Ultimately, the readouts from these experiments are the ratios of 
acceptor/donor as with the FRET sensors utilized described in the above studies.  
 
 
 
Figure 4-13: Unmixed component spectra of a single cell expressing T-Epac-VV and GRScat.  
Raw intensities for the unmixed components of the FRET sensors from the circled cell are 
shown (left) with the RGB images of the same FOV (right).  
 
 
We next needed to ensure that we could isolate the individual biosensor functions to 
confirm that the spectra are being correctly unmixed and interpreted.  Thus, we treated co-
transfected MIN6 cells with either IBMX/forskolin, which we have shown stimulates the T-Epac-
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VV cAMP sensor (Figure 4-8), but should not activate caspase-3.  Indeed, IBMX/forskolin 
treatment elicited a 1.14 ± 0.03 increase in the T-Epac-VV FRET ratio in 30 minutes with no 
significant change in the GRScat FRET ratio even out to 60 minutes.  Additionally, the fungal 
toxin staurosporine (STS), which has been shown to directly and quickly activate caspase-3 
(Rizzo and Piston 2005), was used to isolate the GRScat sensor.  We observed a 1.88 ± 0.4 
fold decrease in the GRScat FRET ratio, indicating a significant activation of caspase-3 in 30 
minutes following STS treatment with no significant change in cAMP as indicated by the FRET 
ratio of the T-Epac-VV sensor over a 60 minute timecourse.  These data are displayed in Figure 
4-14. 
 
 
Figure 4-14: Dual-FRET biosensor isolation by selective stimulation.  Timecourse of caspase-3 
activation (orange) and cAMP (blue) after stimulation with (A) IBMX/forskolin or (B) STS.  p 
values were determined by one way ANOVA. *** indicates p < 0.0001 compared to caspase-3 
time 0.  # indicates p < 0.05 compared to cAMP time 0. 
 
 
To address the relationship between the dynamics of the two sensors, the same 
experimental paradigm of H2O2-induced apoptosis was used.  It should be noted here that two 
different IMSs were used for these experiments and while the calibration procedures are the 
same, the hardware is different, which likely accounts for some of the statistical variance in our 
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findings.  We are still processing and analyzing the data from these experiments so the 
statistics, as reported here, are preliminary.  
Oxidative stress was induced after culturing the cells for 36-72 hours post-transfection 
with high glucose (11 mM).  Then, on the day of experiments, the cells were incubated for 
several hours with a supra-physiological (20 mM) glucose concentration to simulate 
glucotoxicity, or a sub-stimulatory 5 mM glucose level prior to the addition of H2O2.  Since we 
characterized the slow time to onset of caspase-3 activation in previous experiments, we pre-
treated cells with H2O2 for 15 minutes before commencing imaging to improve the efficiency of 
the experimental setup.  In long-term imaging experiments, we find that the cells pre-treated 
with 20 mM glucose displayed a significant increase in cAMP and caspase-3 activity by 45 
minutes after treatment with H2O2 (30 minutes after start of imaging), as indicated by the loss of 
FRET from both biosensors.  The cells that were pretreated with low glucose exhibited no 
significant difference in caspase-3 or cAMP for the same duration of oxidative stress, as 
displayed in Figure 4-15.  These data demonstrate a strong correlation, as determined by a 
Pearson correlation (0.999).  By contrast, the Pearson coefficient for caspase-3 and cAMP 
FRET is 0.142 at 5 mM glucose, suggesting that the relationship between cellular apoptosis and 
cAMP elevation is glucose-dependent under conditions of oxidative damage. 
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Figure 4-15: Role of glucose in caspase-3 activation and cAMP generation under acute 
oxidative stress.  (A) Co-transfected cells were treated with 5 mM glucose prior to the addition of 
H2O2.  (B) As in (A) but with 20 mM glucose pre-treatment.  These data represent averages 
from cells in 3 different dishes, with each dish having N=4-10 cells.  (C) Correlation plot of data 
in (A).  (D) Correlation plot of data in (B). p values were determined by one way ANOVA. * 
indicates *** p < 0.0001 compared to caspase-3 time 0. # indicates p < 0.05 compared to cAMP 
time 0. 
 
 
Additionally, the baseline FRET ratio for caspase-3 after 15 minute pre-treatment with 
H2O2 and 20 mM glucose was significantly lower than the ratio at the same time point in cells 
pretreated with 5 mM glucose and H2O2.  Together, these data suggest that a high glucose 
environment is highly toxic to β-cells under oxidative stress and the elevation of cAMP with 
glucose does not appear to have an intrinsic protective effect.  However, since these data were 
collected in β-cell lines, the possibility of cAMP modulators secreted from neighboring islet cells 
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under the same stress conditions is not addressed.  Ideally, these experiments would be 
repeated in whole islets to observe whether or not the islet context is important for the cellular 
response to oxidative damage.  
Finally, we wanted to repeat the oxidative stress induction paradigm in cells co-
transfected with the T-Epac-VV biosensor and the GCaMP5G [Ca2+]i sensor to characterize the 
changes in the relationship between these two signaling molecules under the oxidative 
conditions that led to apoptosis in the earlier experiments.  Having established that within 30 
minutes of imaging with a 15 minute incubation period with H2O2, caspase-3 activity is 
significant, we chose to more closely look at the cAMP and Ca2+ dynamics leading up to this 
change.  To address this, cells were imaged over ~15 minutes at two different frame rates – 1 
frame every 2 minutes, or 1 frame every 5 seconds in an effort to characterize any faster events 
that may occur.  Looking at the slower imaging data, we observe similar anti-correlation in 
oscillations that was noted in our early experiments with high glucose and TEA, as shown in 
Figure 4-16.  
Interestingly, whereas glucose produced anti-correlated oscillations in [Ca2+]i and cAMP 
with Ca2+ spikes having a larger amplitude (Figure 4-5), pretreatment with H2O2 significantly 
increased the amplitude of cAMP spikes and reduced the correlation coefficient to -0.106, a 
significant decrease.  The low amplitude [Ca2+]i  oscillations are consistent with our previous 
data suggesting a blunted response to glucose in Ca2+ pulses during oxidative challenge.  
These data suggest that oxidative stress may decouple Ca2+ signaling from glucose and induce 
changes the crosstalk between these critical signaling pathways ahead of caspase-3 activation.  
Additionally, it highlights the importance of fast frame rates in multimodal imaging, as the 
relationship between [Ca2+]i and cAMP is less  obvious with intermittent imaging and may have 
important implications for studying the molecular processes leading up to mitochondria-
mediated apoptosis in β-cells during glucotoxic conditions like chronic hyperglycemia.  
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Figure 4-16:  Effect of H2O2 on [Ca
2+]i and cAMP activity in β-cells at high glucose.  (A) [Ca
2+]i 
(black) and cAMP (gray) activity average in 3 dishes after pre-incubation with H2O2 and 
stimulation with 20 mM glucose, collected one frame every 2 minutes with a 0.5 s integration 
time.  (B) As in (A) but collected once every 5 seconds with a 0.5 s integration time. 
 
 
Summary 
We utilized time-resolved image mapping spectrometry for real-time hyperspectral 
imaging of pancreatic β-cell dynamics, and successfully monitored [Ca2+]i and cAMP activity 
during glucose stimulation (Elliott, Gao et al. 2012).  The interplay between these two dynamic 
signaling pathways has been difficult to determine due to the spatially and spectrally 
overlapping sensors available to study them in living cells.  This is a common hurdle as the 
overlapping emission spectra of many biosensors prevent the real-time study of signaling 
dynamics from multiple pathways.  A previous study assaying the relationship of [Ca2+]i and 
cAMP in live cells using spinning disc confocal microscopy suffered from the inability to collect 
data with a single hardware configuration (Landa, Harbeck et al. 2005).  While the fluorophores 
used in that study (Fura2 for [Ca2+]i and Epac1-camps) are spectrally separated with excitation 
and emission, they are both ratiometric, with Fura2 requiring dual-excitation and Epac1-camps 
reported as a ratio of emissions.  Thus, at least three images were acquired at each time point 
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(two for Fura2 and one for Epac1) with needed configuration switching between each one, 
leading to a total acquisition time of a couple of seconds.  Our results demonstrate the ability of 
the IMS approach to address the collection of two biosensors in a snapshot format that is truly 
simultaneous.  This is particularly critical for biological questions that probe temporal 
relationships and have spectrally overlapping biosensors.   
Many questions remain about stimulus-secretion coupling in pancreatic β-cells, 
especially regarding the role of intracellular second messengers in maintaining proper cell 
health and function.  Significant progress in elucidating these roles in β-cell function will be 
possible with the simultaneous monitoring provided by the IMS system.  Since the 4-D (x, y, λ, t) 
datacube is captured in a single snapshot, there is no compromise between system throughput 
and image acquisition rate.  Thus, high dynamic range images are captured in real-time imaging 
experiments, and provide reliable measurements of spectrally overlapped biosensors.  While in 
this study we utilized FRET and cpGFP-based sensors, there are many spatially and spectrally 
overlapping sensors available for studying dynamic processes.  The IMS approach allows 
simultaneous measurement in real cells of these dynamics, and thus can assist in identifying 
relationships between multiple cellular processes as well as individual molecular events.   
Among the remaining questions in β-cell function is the role of [Ca2+]I and cAMP 
signaling during oxidative stress.  Since the β-cells do not express high levels of scavenging 
enzymes for reactive oxygen species, oxidative damage is particularly deleterious and has been 
hypothesized to be a sizeable contributor to β-cell dysfunction and death during glucotoxicity 
and diabetes (Robertson, Harmon et al. 2003; Donath, Ehses et al. 2005).  Additionally, 
mitochondria mediated apoptosis, which proceeds from DNA damage initiating Bax and Bak 
activation to the caspase cascade, which consists of a series of enzyme cleavages culminating 
in formation of an apoptosome and death.  In addition to these molecular markers of apoptosis, 
there are morphological changes including cytosolic shrinking, chromatin condensation, and 
membrane blebbing that characterize this process (van de Schepop, de Jong et al. 1996).  
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In many cell types, oxidative stress has been show to contribute to apoptotic cell death, 
but the molecular mechanism is less well understood.  It has been shown that treatment of β-
cells with hydrogen peroxide to induce oxidative damage increases apoptosis.  However, pre-
incubation with forskolin, a cAMP activator, protected against cell death.  These experiments 
were conducted using traditional biochemistry, which provides only a single snapshot (via 
Western blot) of a dynamic process [3].  We utilized our microscope-coupled IMS system to 
study oxidative-stress induced caspase-3 activation in the presence of H2O2.  Using a green/red 
caspase-3 cleavable FRET sensor simultaneously with either a unimolecular [Ca2+]I biosensor 
(three colors) or a cyan/yellow FRET biosensor in a dual-FRET configuration, we successfully 
monitored the [Ca2+]i and caspase-3 activities during cellular apoptosis.  The results presented 
here demonstrate the ability of the IMS approach to address complex biological questions with 
high sensitivity, spectral resolution, and temporal resolution.  
The acquisition rate of our current IMS system is up to 7.2 fps, which is limited by the 
CCD camera data transfer rate.  If acquisition speed was not a limiting issue, these experiments 
could be done on any spectral imaging device, including the Zeiss LSM710, which provides a 
spectral resolution to 3.2 nm.  However, upon performing the experiments on the LSM710 (data 
not shown), we found that for spectral resolution comparable to the IMS, the acquisition speeds 
of >10 sec was insufficient for drawing conclusions about the temporal relationships between 
the cAMP and [Ca2+]i signaling pathways.  Subtle changes in either cAMP or [Ca
2+]i with 
pharmacological modulation require high temporal resolution to identify changes in oscillation 
frequency, rise time, and the effect these changes have on the relationship between pathways 
in both healthy and stressed cellular conditions.   
 
124 
 
Part 2 
Introduction 
 
Prostate cancer is the second leading cause of death in men in the U.S. and roughly 
200,000 men were diagnosed in 2010.  The role of hormones, including testosterone and 
estrogen, in the development of cancer within these healthy tissues is well recognized.  
Androgen receptor (AR) signaling has important roles in the development and maintenance of 
the male reproductive system and underlies the pathology of androgen-dependent prostate 
cancer.  There are two primary courses of treatment for prostate cancer: castration and anti-
androgen therapies.  Both of these measures nearly always lead to castrate-resistant prostate 
cancer (CRPCa), which is a lethal condition.  Current research in the development of novel 
treatments is focused on identifying small molecules that limits AR translocation to the nucleus, 
which prevents the dysregulated transcription of genes that underlies CRPCa.  
However, the AR requires other transcription factors that work in combination to drive 
tissue-specific gene expression in the prostate (Gierer 1974; Matusik, Jin et al. 2008).  The 
Forkhead box A 1 (FOXA1) gene has been previously identified as an AR interacting protein 
(Gao, Zhang et al. 2003; Gao, Ishii et al. 2005), and was shown to be essential for the 
expression of AR regulated, prostate specific genes (see review (DeGraff, Yu et al. 2008)).  
FOXA1 increases transcription factor accessibility to the DNA by displacing linker histones from 
nucleosomes so that the chromatin can unfold (Cirillo, Lin et al. 2002).  
Since the identity of additional FOXA1 binding partners required for prostate-specific 
expression remains unknown, we set out to identify new FOXA1 binding partners important for 
this process.  Briefly, NFIx was one of sixteen proteins identified by tandem affinity purification 
and mass spectrometry to interact with FOXA1.  The NFI family of TF contains four genes 
(NFIA, NFIB, NFIC, NFIX), encoding proteins which bind to the consensus DNA sequence 
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TTGGCN5GCCAA (Murtagh, Martin et al. 2003).  Further, NFI family members can form either 
homodimers or heterodimers with each other. FOXA1 was previously identified to interact with a 
member of the NFI transcription factor family (Norquay, Yang et al. 2006).  While the identity of 
the NFI family member(s) capable of interacting with FOXA1 was not determined, this 
observation still has important implications for tissue-specific gene expression.  Knockout 
studies of individual NFI genes in mice revealed a variety of phenotypes, including corpus 
callosum agenesis (NFIA) (Wong, Schulze et al. 2007), lung hypoplasia (NFIB) (Grunder, Ebel 
et al. 2002), tooth defects (NFIC) (Steele-Perkins, Butz et al. 2003), and neurological and 
skeletal defects (NFIX) (Driller, Pagenstecher et al. 2007; Campbell, Piper et al. 2008).  Thus, 
each NFI family member has non-redundant roles during development.  
In the following work, we set out to identify if NFIx interacts with FOXA1, and determine 
the role of this transcription factor in complex formation with AR using Förster resonance energy 
transfer (FRET).  FRET is a phenomenon useful for studying protein-protein interactions, which 
is facilitated by tagging the proteins of interest with fluorescent proteins (FP-FRET) as reporters 
(Piston and Kremers 2007).  Since FRET occurs only when the FPs are within 10 nm, it is 
commonly used to indicate the proximity of proteins of interest.  Here, we developed FRET 
constructs for FOXA1, NFIx, and the AR to determine if these proteins are in close enough 
proximity to suggest complex formation.  These data would support a number of other studies 
and provide a useful screening system for other AR coregulators and interacting proteins both in 
healthy and diseased tissues.  
 
Materials and Methods 
FRET construct development 
The AR construct was created by amplifying the gene encoding AR with the following primers 
(Forward – AAAGCTAGCGCCACCATGGAAGTGCAGTTAGGGC; Reverse – 
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AAAACCGGTCCACGCGTCTGGGTGTGGAAA) and sequential digestion/ligation of the product 
and mCerulean3-C1 vector using NheI and AgeI restriction enzymes.  NFIX was created 
similarly with primers (Forward – AAAAGATCTATGTATAGCCCGTACTGCCTCACC; Reverse – 
AAAGGTACCTTCAGAAAGTTGCCGTCCC) for the NFIX gene and an mVenus-C1 vector was 
used with NheI and AgeI restriction enzymes.  The FOXA1 construct was created with 
amplifying primers (Forward – AAAGCTAGCGCCACCATGTTAGGAACTGTGAAG; Reverse – 
AAAACCGGTCCGGAAGTGTTTAGGACGGG) for FOXA1 and an mVenus-C1 vector using BglII 
and KpnI restriction enzymes.  Sequences of resultant constructs were verified using the 
Vanderbilt Genome Sciences Sanger DNA Sequencing laboratory.  To summarize the 
constructs, they include a 3’-mCerulean3-AR, 3’-mCerulean3-NFIx, 3’-mVenus-FOXA1, 3’-
mVenus-NFIx.  
 
Cellular sample preparation for FRET studies 
HeLa cells were transiently transfected with plasmid DNA encoding mCerulean3-tagged AR, 
mVenus-tagged NFIX and/or mVenus-tagged FOXA1; FRET8 (a dimer of ECFP and EYFP), or 
mCerulean3 and mVenus were used as controls.  Transfection was accomplished using 
Lipofectamine2000 (Invitrogen, Carlsbad, CA) transfection reagent according to the 
manufacturer's instructions.  Cells were seeded onto No. 1 coverglass bottomed dishes 
(MatTek, Ashland, MA) and cultured in DMEM medium (Invitrogen/Gibco, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Invitrogen/Gibco, Carlsbad, CA), 100 units/ml 
penicillin (Mediatech, Manassas, VA), and 100 μg/ml streptomycin (Mediatech, Manassas, VA), 
at 37ºC under 5% humidified CO2.  24 hours after transfection, samples were fixed with 4% 
paraformaldehyde, washed in DPBS (Invitrogen/Gibco, Carlsbad, CA), and mounted with 
gelvatol.  For samples containing the androgen receptor plasmid, 24 hours after transfection 
cells were incubated overnight with media containing charcoal-stripped serum and then treated 
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with dihydrotestosterone (DHT - Sigma. St. Louis, MO) for 4 hours prior to fixing as above. 
 
Fluorescence microscopy 
FRET imaging was performed using a Zeiss LSM780 confocal microscope with excitation 
provided by a Coherent chameleon two-photon laser at 800 nm with emission collected in 
spectral mode from 465-692 nm with 8.7 nm spectral resolution.  Additionally, images were 
collected with an argon laser at 514 nm to confirm cells expressing the mVenus-tagged 
constructs.  Data were analyzed using ImageJ and Graphpad Prism software.  FRET ratios 
were expressed as mVenus/mCerulean3 after linear unmixing and normalized to the vehicle 
treated AR + FOXA1 control ratios.  70-100 cells per dish were quantified for mean intensity and 
the experiments were repeated in three cellular preparations. P values are the result of ANOVA 
compared to NFIX + AR. 
 
Results 
Construction of FRET pairs with FOXA1, NFIx, and AR 
To test the hypothesis that FOXA1, NFIx and AR interact to form a complex, we used FP-FRET 
to interrogate the possibility of protein-protein interactions between them.  Constructs of FP 
tagged AR, FOXA1 and NFIx were engineered using mVenus (mVen) and mCerulean3 (mCer3) 
as the acceptor and donor FPs, respectively.  This FP-FRET pair has been well characterized 
and is robust for quantifying protein-protein interactions (Rizzo, Springer et al. 2006).  To 
confirm that tagging the AR did not impair its function, we serum-starved transiently transfected 
cells to remove the nuclear AR and then treated them with the androgen dihydrotestosterone 
(DHT), which induces nuclear translocation of the AR.  In parallel, we used the same procedure 
without the DHT, as a vehicle control to demonstrate a primarily cytosolic pool of tagged AR-
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mCer3.  As shown in Figure 4-17, DHT treatment did cause nuclear localization of the AR-
mCer3 whereas the vehicle control did not, confirming the translocation function of the tagged 
AR.  
 
 
Figure 4-17: Localization of AR-mCer3 with and without androgen stimulation.  Confocal 
microscopy images of transfected AR-mCer3 after serum starvation and treatment with DHT 
(left) or without DHT (right).  
 
 
The FOXA1 and NFIx transcription factors were tagged with mVen as the acceptor 
constructs, which gave inducible control over the FRET due to DHT translocation of the donor.  
FOXA1 and NFIx are primarily expressed in the nucleus and also show appropriate localization, 
with little to no cytosolic background expression, as shown in Figure 4-18.  
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Figure 4-18: Localization of FOXA1-mVen and NFIx-mVen.  Confocal microscopy images of 
transfected plasmids for FOXA1-mVen (left) or NFIx-mVen (right).  
 
 
NFIX interacts with FOXA1 and AR only in the presence of FOXA1  
In addition to the FRET constructs we prepared, each experiment was done in parallel 
with co-transfected mCer3 and mVen, as well as a tandem dimer of this pair, as negative and 
positive controls, respectively.  These controls also set our baselines for maximal (1.05 ± 0.07) 
and minimal (0.06 ± 0.01) normalized FRET ratios for the microscope settings that were used.  
The next test for functionality of the FRET pairs was to look at the AR-mCer3 with DHT 
treatment and FOXA1-mVen, since that interaction is well characterized by several methods. 
Consistent with our previous reports of AR and FOXA1 interaction (Gao, Zhang et al. 2003; 
Gao, Ishii et al. 2005), the FRET ratio for AR-mCer3 and FOXA1-mVen was 0.93 ± 0.052 
compared to vehicle controls in HeLa cells.   
Our next experiment was to identify if the AR-mCer3 and NFIx-mVen FRET pairs would 
be close enough to interact directly.  We have previously shown that these transcription factors 
bind the probasin promoter adjacent to each other and immunoprecipitation studies suggest an 
interaction.  The AR-mCer3 and NFIx-mVen FRET ratio of 0.23 ± 0.021 was significantly lower, 
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suggesting that these two proteins are further away from each other than the AR and FOXA1.  
These data are presented in Figure 4-19 below along with the negative and positive controls.  
 
 
Figure 4-19: AR with FOXA1, but not AR with NFIx, exhibits a high FRET ratio.  (A-B) 
Quantification of FRET ratios for three independent transfections treated with DHT (A) or left 
untreated (B).  Error bars represent the S.E.M. and p values were determined by ANOVA, ** 
indicates p < 0.001 compared with NFIX + AR. 
 
 
 
 
The results of the previous two experiments demonstrate that the AR and NFIx may 
require another factor to form a complex.  Since the AR and NFI proteins are known to form 
dimers, it is significant that with two potential donors and acceptors on the same promoter 
region, the FRET ratio was so low.  This also supports the possibility of another protein either 
preventing their interaction or facilitating it.  We hypothesized that this factor would be the 
FOXA1 that we already knew to interact with the AR.  To test this idea, we first sought 
determine whether NFIX and FOXA1 are close enough to interact directly, having already 
shown that they both localize predominantly to the nucleus.  Thus, we created another donor 
construct, by tagging FOXA1 with mCer3. Upon co-transfection, these proteins exhibited 
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nuclear localization and a FRET ratio of 0.59 ± 0.026, which was significantly higher than the 
negative control but not as strong a pairing as the AR and FOXA1.  Importantly, when we 
performed this experiment with NFIx-mCer3 as the donor and FOXA1-mVen as the acceptor, 
the FRET ratio was comparable to the negative control, as shown in Figure 4-20.  This 
demonstrates that the folding and orientation of the proteins with FP tags is critical for FRET to 
occur.  
 
 
Figure 4-20. NFIx and FOXA1 FRET is dependent on tagged terminus.  Normalized FRET ratios 
for positive (FRET8) and negative (mCer3 + mVen) controls and FoxA1 + NFIX.  Error bars 
represent the S.E.M. and p values were determined by Student’s T-test, ** indicates p < 0.01 
compared with FRET8. 
 
 
Finally, to test the idea that over-expressing FOXA1 could bridge the interaction between 
NFIX and AR, we co-transfected cells with AR-mCer3 and NFIX-mVen as before, along with 
untagged FOXA1.  After treatment with DHT, the FRET ratio of AR-mCer3 and NFIX-mVen was 
increased to 0.53 ± 0.058, a level intermediate between the FOXA1/AR and NFIX/AR pairs, as 
depicted in Figure 4-21.  
 
 
132 
 
 
Figure 4-21: FOXA1 increases the FRET ratio of AR and NFIx.  (A-B) Quantification of FRET 
ratios for three independent transfections treated with DHT (A) or left untreated (B).  Error bars 
represent the S.E.M. and p values were determined by ANOVA, ** indicates p < 0.01 compared 
with NFIX + AR. 
 
 
Summary 
Several AR coregulators have been identified that both control and fine tune AR activity, 
and previous work reported that FOXA1 interacts with AR to control multiple prostate specific 
genes (Gao, Zhang et al. 2003) and that FOXA1 expression is restricted to prostatic epithelium 
(Mirosevich, Gao et al. 2006).  Also, rescuing prostate tissue from FOXA1 knockout mice exhibit 
an arrested organ development phenotype, demonstrating a global role for FOXA1 to regulate 
organ development (Gao, Ishii et al. 2005).  Much like FOXA proteins, NFI proteins are well 
known for their ability to regulate the activity of endocrine responsive cis elements, such as the 
murine mammary tumor virus (MMTV) and the PEPCK promoter (Li, Margueron et al. 2010; 
Archer, Lefebvre et al. 1992; Aoyagi and Archer 2008).  Furthermore, NFI activity is required to 
regulate expression of mammary gland specific differentiation markers, including whey acidic 
protein (WAP) and α-lactalbumin, among others (Murtagh, Martin et al. 2003) as well as 
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estrogen and androgen regulated genes (Carroll, Liu et al. 2005; Wang, Li et al. 2007; Lupien, 
Eeckhoute et al. 2008).  The frequent occurrence of NFI sites adjacent of AR and FOXA1 sites 
in multiple genes (Jia, Berman et al. 2008; Sharma, Massie et al. 2013) suggest that the NFI 
family is a central TF for androgen-regulated genes.  
FP-FRET was used to test the prediction that AR/FOXA1/NFIX are in close contact, 
which supports a potential direct interaction and formation of a stable complex.  The high FRET 
ratios shown by AR and FOXA1 were dependent on pre-treatment of the cells with DHT to drive 
AR into the nucleus.  While AR and NFIX did not exhibit a significant FRET ratio compared to 
negative controls, the additional transfection of an untagged FOXA1 significantly increased this 
ratio.  Additionally, the strong FRET ratio of FOXA1 and NFIX supports the hypothesis that 
FOXA1 mediates the formation of a complex with AR and NFIX.  
It is also consistent with extensive data showing that these two proteins do interact and 
are frequently associated with each other on AR target genes in the prostate (Gao, Zhang et al. 
2003; Jia, Berman et al. 2008; Lupien, Eeckhoute et al. 2008; Sharma, Massie et al. 2013) and 
in breast (Carroll, Meyer et al. 2006; Eeckhoute, Carroll et al. 2006; Ross-Innes, Stark et al. 
2012).  We anticipate that this paradigm of NFI being involved in the AR/FOXA1 complex will 
extend to ER/FOXA1 complexes.  Finally, the recent in vivo ChIP-Seq report on castrate 
resistant prostate cancer patient samples shows both a progression of the AR to new target 
genes but also it demonstrates that that many common sites still involve the AR/FOXA1/NFI 
motifs.  Taken together, these data show that different NFI isoforms will play an important role in 
AR action in different cell types, and during tumor development and progression.  In summary, 
specific NFIx interacts with FOXA1, binds to androgen responsive elements and facilitates AR-
mediated gene transcription, implicating this complex as a potent controller of androgen 
responsive, prostate-specific gene expression. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Concluding remarks 
The goals of the work described above were to identify the paracrine mechanisms 
involved in suppressing glucagon secretion and develop a spectral imaging technique for 
monitoring multiple dynamic molecular processes in live cells.  These projects are unified by the 
importance of second messenger signaling and crosstalk in islet hormone regulation.  The fact 
that intracellular signaling mechanisms differ between α- and β-cells has profound implications 
for the etiology of metabolic disease and highlights the importance of developing sophisticated 
tools to tease apart the highly complex environment that constitutes the pancreatic islets.   
There are significant challenges to multi-label imaging, as islet biology is complex and 
there are many molecular events whose roles in islet function remain unclear.  Thus, monitoring 
simultaneously multiple events will help shed light on the interactions between these molecules 
and may provide insight as to their normal and disease-state functions.  Additionally, the 
development of robust biosensors for critical molecules such as cAMP, [Ca2+]I will also provide a 
significant advantage in characterizing these events.  Cell type-specific genetic labeling is 
another important tool in identifying a given cell type within the islet and comparing it with the 
other neighboring cells.  We have taken advantage of this technology in the use of a mouse with 
tdRFP-labeled α-cells in the work described here (Soriano 1999; Luche, Weber et al. 2007).  
Eventually, the confluence of these tools and unanswered questions may lead to the generation 
of robust working models for islet regulation that provide predictive power in evaluating novel 
therapeutics.  
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Toward the first goal of identifying the paracrine mechanisms responsible for glucose-
inhibited glucagon secretion, data was presented demonstrating that somatostatin and insulin 
converge on the α-cell to decrease the production of cAMP and increase its degradation, by 
means of their respective receptors, and this behavior is, at least in part, responsible for 
glucose-inhibited glucagon secretion.  Previous experiments in our laboratory had demonstrated 
a decoupling of [Ca2+]I and glucagon secretion at inhibitory glucose concentrations (Le 
Marchand and Piston 2012), which invalidated the prevailing models that rely upon decreasing 
global Ca2+ activity for glucagon inhibition (Xu, Kumar et al. 2006; MacDonald, De Marinis et al. 
2007; Tuduri, Filiputti et al. 2008; Zhang, Ramracheya et al. 2013).  In pursuit of the molecular 
mechanism that does regulate glucagon suppression; we considered intracellular signaling 
molecules other than Ca2+ that might be a key player in this regulation.  Of the other prevalent 
signaling messengers, cAMP is known to be differentially regulated between α- and β-cells and 
this made it a likely candidate for mediating glucose inhibition of glucagon secretion (Mauriege, 
Klein Kranenbarg et al. 1996; Gromada, Bokvist et al. 1997; Tian, Sandler et al. 2011).  
We first tested this hypothesis by maximizing cAMP production and inhibiting its 
degradation and measuring the effect on glucagon secretion at low and high glucose levels.  We 
found that stimulating cAMP is sufficient to overcome glucagon inhibition at high glucose.  We 
showed that cAMP levels are lower at high glucose in both human and mouse isolated islets. 
Importantly, this modulation of cAMP and glucagon secretion was not accompanied by a 
detectable change in [Ca2+]I activity, suggesting a Ca
2+-independent mechanism.  Furthermore, 
cAMP and insulin secretion were both increased by high glucose levels in β-cells of the same 
islets, which supports previous reports and validates our experimental approach.  As an 
additional control, epinephrine, which is known to selectively stimulate glucagon secretion, 
increased cAMP in the islet α-cells with no detectable effect on β-cell cAMP levels.  
To identify the signal(s) responsible for mediating this decrease in cAMP, we first tested 
the most obvious candidate – somatostatin, which is long known to be a potent inhibitor of 
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glucagon secretion (Strowski, Parmar et al. 2000; Cejvan, Coy et al. 2003).  We found that 
antagonizing the somatostatin receptor type 2, SSTR2, caused a loss of glucagon inhibition and 
increased cAMP levels at high glucose, suggesting that this receptor mediates the observed 
suppression with glucose alone.  Furthermore, somatostatin decreased cAMP levels and 
glucagon secretion at low glucose in the islets.  The fact that SSTR2 is a GPCR raised the 
possibility that the Gαi and/or the Gβγ dimer were responsible for the observed decrease.  To 
test the hypothesis that the Gαi subunit, known to inhibit adenylyl cyclases, was a critical 
mediator, we treated islets with the pertussis toxin (PTX) to prevent Gαi signaling (Cawthorn 
and Chan 1991) and found that somatostatin was incapable of decreasing glucagon secretion 
after PTX pretreatment.  These data demonstrate that somatostatin inhibits cAMP production 
via SSTR2 Gαi, which leads to a reduction in glucagon secretion. 
An early observation in experiments manipulating cAMP levels with IBMX and forskolin 
was that the phosphodiesterase (PDE) inhibitor IBMX led to an increase in glucagon secretion 
that surpassed adenylyl cyclase activator forskolin alone.  This led to the idea that the PDEs 
may play a key role in decreasing cAMP leading to inhibition of glucagon secretion.  To identify 
the possible signaling pathways regulating the PDE activity, we turned to the literature and 
found that in other metabolic tissues such as liver and adipose cells (Beebe, Redmon et al. 
1985; Choi, Park et al. 2006; Ahmad, Lindh et al. 2009), insulin signaling decreases cAMP by 
activating Akt and PDE3B downstream of insulin receptor (IR) activation.  
Previous reports in the α-cells confirmed the expression of these insulin-signaling 
constituents (Kawamori and Kulkarni 2009; Heimann, Jones et al. 2010; Dorrell, Schug et al. 
2011; Eizirik, Sammeth et al. 2012) so we pursued this line of enquiry experimentally.  We found 
that phospho-Akt was increased by insulin, consistent with previous findings.  Additionally, IR 
antagonism led to a significant glucose-dependent increase in cAMP and glucagon secretion in 
human and mouse islets at high glucose.  Exogenous insulin applied to islets at low glucose 
decreased cAMP and glucagon secretion and treatment of islets with the PDE inhibitor IBMX 
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prevented insulin from driving this decrease in secretion.  Furthermore, micromolar levels of 
exogenous insulin were able to counter islet glucagon stimulation by a hydrolyzable cAMP 
analog, but did not affect the increased secretion in islets stimulated with a PDE-resistant cAMP 
analog.  Selective inhibition of PDE3B relieved glucagon suppression in a glucose-dependent 
manner, whereas inhibiting PDE4 stimulated glucagon secretion across glucose levels.  Taken 
together, these data support the hypothesis that insulin, via IR activation of Akt and PDE3B, 
decreases cAMP and glucagon secretion in islet α-cells.  
Downstream of cAMP signaling, we showed that PKA and not Epac, must be inhibited 
for glucagon suppression.  Selectively activating PKA showed a glucose-dependent increase in 
glucagon secretion at high glucose in both human and mouse islets, while Epac stimulation 
resulted in a significant increase in secretion at both low and high glucose concentrations.  
Furthermore, the specific inhibition of PKA rescued glucagon suppression at high glucose 
levels, even in the presence of forskolin, which stimulates adenylyl cyclases to produce cAMP.  
By contrast, antagonizing Epac did not significantly impact glucagon secretion at high glucose.  
Finally, we measured phospho-PKA in the α-cells at low and high glucose and found that it is 
lower at high glucose levels, just as the cAMP is, suggesting a glucose-dependent decrease in 
phosphorylation, presumably due to the decrease in cAMP, which is the primary activator.  
Importantly, previous work in the laboratory demonstrated that neither insulin nor 
somatostatin alone was sufficient to inhibit glucagon secretion from a purified population of α-
cells (Le Marchand and Piston 2012).  Based on the above data in whole islets, we 
hypothesized that the combination of insulin and somatostatin would suppress cAMP and 
glucagon secretion at low glucose, which is exactly what we observed in purified α-cells.  
Additionally, exogenous insulin or somatostatin in whole islets was insufficient to inhibit 
glucagon secretion in the presence of either receptor antagonist.  Furthermore, the combination 
of both SSTR2 and IR antagonists significantly increased cAMP and glucagon secretion 
compared to treatment with just one antagonist.  These data, together, confirm that neither 
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insulin nor somatostatin alone is sufficient to decrease cAMP and glucagon secretion and 
demonstrate that the convergence of these pathways is required.  A schematic diagram of the 
primary findings in this study is presented in Figure 5-1.  
 
 
Figure 5-1: Glucagon inhibition via insulin and somatostatin’s effects on cAMP/PKA in α-cells at 
high glucose.  Illustration of the stimulatory effect of cAMP via PKA on glucagon secretion from 
the pancreatic α-cell (left); and the inhibitory roles of insulin and somatostatin in lowering 
cAMP/PKA signaling at high glucose (right). 
 
 
Having established the paracrine regulation of glucagon inhibition from the membrane 
through PKA, we next wanted to identify molecular target(s) being suppressed at the exocytotic 
level.  A wealth of literature exists on the role of Rho-GTPases in remodeling, by 
depolymerization, the dense network of cortical F-actin in β-cells to allow vesicle fusion with the 
membrane (Li, Luo et al. 2004; Konstantinova, Nikolova et al. 2007; Veluthakal, 
Madathilparambil et al. 2009; Asahara, Shibutani et al. 2013; Kalwat, Yoder et al. 2013).  The 
primary enzyme involved in permitting vesicle fusion was identified as Rac1-GTPase in the β-
cells.  Considering the many similarities between the α- and β-cells, as well as our own data 
showing that Rac1 is expressed in the α-cells, we expected active Rac1 (GTP-bound) to be 
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decreased with high glucose.  However, we observed the opposite; Rac1-GTP, like [Ca2+]I, 
increased with increased glucose levels, suggesting that the role it plays in α-cell physiology is 
distinct from that in β-cells.  Additionally, we treated islets with a Rac1 inhibitor (Gao, Dickerson 
et al. 2004), which locks Rac1 in the GDP-bound inactive state, and observed an increase in 
glucagon secretion across glucose levels.  The roles of the Rho-GTPases, which include Rac1, 
Rho, and Cdc42, are numerous and vary by cell type (Heasman and Ridley 2008; Schlegel and 
Waschke 2009; Momboisse, Ory et al. 2010; Baier, Ndoh et al. 2014).  However, in most 
endocrine cells, one or more of these small regulatory proteins is involved in the distal steps of 
exocytosis.  Thus, it is likely that the gate-keeper function in α-cell vesicle fusion is performed by 
another member of this family, but this question remains unanswered. 
While the studies presented in this work primarily rely on static incubations for assaying 
glucagon secretion, they do help explain some of the dynamics observed in doing perifusion 
experiments in whole islets.  The dynamics of glucagon regulation by glucose concentration 
have several important features.  Firstly, as blood glucose increases to about ~3 mM glucose, 
there is a reasonably sharp drop in glucagon secretion, which is maximally inhibited at 6-7 mM.  
While the concentrations here vary in the literature, they are consistent with our model of 
somatostatin secretion decreasing glucagon secretion followed by insulin secretion driving full 
inhibition.  However, a key point is that maximally inhibited α-cell exocytosis still retains ~40% of 
peak secretory activity (Le Marchand and Piston 2010).  Our data suggest that the equilibrium of 
cAMP production and degradation is a significant regulatory point in regulated glucagon 
exocytosis.  At high glucose levels, a plethora of signaling molecules is bombarding the islet, 
many of which are directing the activation of GPCRs and downstream cAMP activity in both the 
α-cells directly, and in neighboring cells that secrete paracrine factors to modulate α-cell 
function.  
It is tantalizing to speculate then, that in the presence of conflicting stimulatory and 
inhibitory signals, cAMP is maintained such a level that glucagon secretion cannot be 
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decreased below the observed maximum.  Furthermore, while we have shown that insulin and 
somatostatin decrease cAMP levels, there are a variety of cAMP generating adenylyl cyclases 
(AC) expressed in the islets with Gαi-inhibited AC1, Ca2+/calmodulin-inhibited AC6, and Gβγ-
stimulated AC2 being enriched in the α-cells (Bramswig, Everett et al. 2013).  This highlights the 
complexity in cAMP regulation in the α-cells and suggests the possibility that even in the 
presence of both insulin and somatostatin, there are alternative mechanisms for countering 
stimulating cAMP generation.  The fact that different adenylyl cyclases are enriched in β-cells vs 
α-cells also supports the hypothesis the regulation of cAMP generation and signaling is 
fundamentally different between the cell types.  The same studies demonstrate differences in 
the enrichment of phosphodiesterases expressed in α- versus β-cells (Bramswig, Everett et al. 
2013).  Finally, perifusion experiments show that while there is a sharp drop in secretion with 
increasing glucose levels, as the glucose levels decrease again, the resulting rise in glucagon 
secretion is quite slow (Le Marchand and Piston 2012).  This observation also fits nicely with our 
data; as the significant decrease in cAMP levels and active PKA would be expected to take 
longer to regenerate upon a relief of inhibiting signals. 
Collectively, we presented data supporting a previously uncharacterized mechanism 
underlying the glucose inhibition of glucagon secretion from α-cells.  We found that somatostatin 
and insulin in decrease cAMP/PKA signaling to inhibit glucagon secretion independently of 
global changes in [Ca2+]i, which provides new insight into a controversial problem in islet biology 
(Gromada, Franklin et al. 2007).  Importantly, this mechanism is conserved in human and 
mouse islets.  The model we developed from these data is supported in the literature by reports 
from three decades ago showing a glucose-dependent cAMP regulation (Jarrousse and 
Rosselin 1975) and recent studies measuring dynamic differences in cAMP regulation between 
α- and β-cells (Tian, Sandler et al. 2011).  Furthermore, clinical studies in diabetic patients have 
demonstrated that the combination of insulin and somatostatin has a much higher efficacy for 
lowering blood glucose in response to high glycemic load than either hormone alone (Gerich, 
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Lorenzi et al. 1974).  
This model of cAMP modulation of glucagon secretion is in sharp contrast to the current 
theories about the mechanism of glucagon inhibition, which assume that a decrease in [Ca2+]i is 
the driving factor (Salehi, Vieira et al. 2006; Vieira, Salehi et al. 2007; Zhang, Ramracheya et al. 
2013).  A major limitation in models based on ion channel modulation of  [Ca2+]i is the sampling 
bias imposed on the islets by using a single-cell patch clamping methodology to measure 
conductance and voltage changes.  In these experiments, α-cells are identified in these studies 
by a characteristic Na+ channel current (MacDonald, De Marinis et al. 2007), but studies with 
Na+ channel blockers have demonstrated that α-cells do not require this current to secrete 
glucagon (Le Marchand and Piston 2012).  The Na+ channels have been shown to be important 
in glucagon secretion in other studies, so their role is debated.  However, there is an increasing 
appreciation in the field for the heterogeneous nature of islet α-cells (Gromada, Bokvist et al. 
1997; Gopel, Kanno et al. 2000; MacDonald, De Marinis et al. 2007), which may explain the 
different reports.  Whereas β-cells generally have identical behavior across an islet, the 
relatively dispersed α-cells appear to have functional populations, which create another hurdle 
for single-cell studies.  Finally, in spite of increasingly complicated experiments and 
explanations for the Ca2+-dependent models of glucagon inhibition, looking across whole islets, 
the average [Ca2+]i response increases with glucose and purified populations of α-cells behave 
very much like β-cells in the absence of juxtacrine and paracrine regulators present in the 
whole-islet context.  Thus, a one-size-fits-all explanation of α-cell behaviors is unlikely to prove 
sufficient.   
As evidenced by the complex signaling networks described above, the ability to 
simultaneously monitor multiple molecular events is necessary for a complete understanding of 
islet cell function and regulation.  While the number of fluorescent biosensors for individual 
molecules is growing, there are a relatively limited number of fluorescent proteins (FPs) with 
distinct spectral signatures to utilize as reporters.  Furthermore, data collection and analysis of 
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multiple biosensors requires high spectral, spatial, and temporal resolution.  Traditional laser 
scanning confocal spectral imaging techniques, which provide high spectral and spatial 
resolution, sacrifice frame rates in scanning the image.  Toward the goal of developing a 
methodology that permits rapid multi-label imaging, we utilized a hyperspectral imaging system 
(Gao, Kester et al. 2010; Bedard, Hagen et al. 2012) called an image mapping spectrometer 
(IMS) coupled to a widefield microscope to study the dynamics of [Ca2+]I, cAMP, and caspase-3 
activation in cultured β-cells. 
The IMS has a unique geometry and optical components that allow for the simultaneous 
collection of spectral and spatial information per pixel in an image in a single snapshot.  This 
system overcomes many of the limitations in traditional spectral imaging by avoiding a scanning 
modality, collecting all of the photons in the focal volume, and utilizing a single excitation 
source.  Using the IMS, we measured changes in [Ca2+]i and cAMP in β-cells in response to 
stimulation with high glucose and TEA, which decreases the action potential firing frequency 
allowing measurement of [Ca2+]i oscillations during each spike.  We found oscillations in these 
two signaling molecules to be anti-correlated, which was predicted by mathematical models but 
not previously measured simultaneously.  Additionally, by using frame rates up to 4 fps and 
cross-correlation analysis, we were able to show that [Ca2+]I leads cAMP in response to glucose 
and TEA by 2.5 seconds.  These data were collected with a FRET-based biosensor for cAMP 
consisting of a mTurquoise donor and tandem cpVenus-Venus acceptor (Klarenbeek, Goedhart 
et al. 2011), and a circularly-permuted GFP-based biosensor for [Ca2+]I called GCaMP5G 
(Akerboom, Chen et al. 2012).  
Having established that the IMS was useful for studying multiple signaling events with 
three overlapping FPs, we next sought to test the system with a dual-FRET experimental 
design, which requires spectral unmixing of four FPs.  For these experiments, we used the 
same cAMP FRET biosensor as above, along with a caspase-3 cleavable biosensor consisting 
of either a mClover donor and mRuby2 acceptor, or an ECFP donor and EYFP acceptor.  This 
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biosensor allowed us to study the correlations between cAMP signaling during oxidative stress 
that lead to caspase-3 activation and apoptosis.  Our findings show a strong correlation 
between the onset of caspase-3 activation, and cAMP activity, but no correlation with [Ca2+]i.  
We next utilized the same oxidative challenge paradigm to identify any changes in the anti-
correlated oscillations in [Ca2+]I and cAMP that we observed with glucose and TEA.  Oxidative 
stress was found to cause a loss of correlation between the oscillations, greatly increased the 
amplitude of cAMP oscillations, and reduced the amplitude of [Ca2+]i oscillations compared to 
glucose and TEA stimulation.  While many experiments remain to elucidate the significance of 
these findings, these data demonstrate the capabilities of the IMS for multi-label fluorescence 
imaging for cellular dynamics.   
 
Continuing studies 
 
Paracrine regulation of glucagon secretion  
 Role of cAMP signaling and modulation in regulating glucagon secretion 
 We have shown that insulin and somatostatin increase the degradation and decrease 
the production of cAMP, respectively, which drives the inhibition of glucagon secretion with 
increasing glucose levels.  However, many questions still remain about the normal and 
pathophysiological regulation of glucagon secretion from islet α-cells.  For example, since Rac1-
GTPase did not have the expected gate-keeper role in remodeling F-actin ahead of glucagon 
vesicle fusion, the signaling events downstream of PKA and proximal to membrane fusion and 
exocytosis remain to be elucidated.  The first experiment here would be to interrogate the effect 
of glucose on the remaining Rho-GTPase family members, Cdc42 and Rho, which could be 
done with immunofluorescence as described in Chapter 2.  Pharmacological intervention with 
specific inhibitors of these enzymes should show a measurable decrease in glucagon secretion 
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if one or both are involved in exocytosis.  Additionally, identifying the proteins involved in the 
exocytotic machinery and their regulation with respect to glucose, cAMP, and PKA in the α-cells 
remains to be done for a more complete understanding of glucagon suppression.   
 As mentioned above, the glucagon secretion studies performed in this body of work 
were static incubation-based assays.  However, since the dynamics are likely to be a critical 
part of the physiological regulation of glucagon, perifusion assays should be done, particularly 
on purified α-cells, to determine whether the order of somatostatin and insulin onset is an 
important parameter in their inhibition of glucagon.  It would also be interesting to test the 
addition of insulin to isolated α-cells, followed by somatostatin, again to determine if there is 
significance in the kinetics or order that these paracrine factors are introduced to the cells.  
 
Role of [Ca2+]i in α-cell function at high glucose 
 It has been established by our group and others that glucagon inhibition does not 
depend on a decrease in [Ca2+]i, and in fact, it has been shown to increase in the α-cells with 
increasing glucose.  This decoupling along with the observed increase suggests that [Ca2+]i has 
a role in the function α-cells even at high glucose.  An important remaining question is the 
nature of that function.  A GCaMP3 Ca2+ biosensor, which is an earlier generation of the 
GCaMP5G that we utilized in Chapter 4 has been integrated into a floxed transgenic mouse line 
(Zariwala, Borghuis et al. 2012).  When crossed with the Glucagon-Cre mouse, the resulting line 
will facilitate an in-depth analysis of [Ca2+]I in the α-cells, including a much-needed 
characterization of the different populations of α-cell behaviors.  The improved dynamic range of 
the GCaMP5G sensor is also likely to be integrated into a transgenic mouse model that could 
be used for this type of study.  
 Another interesting question is the role of metabolism regulating glucagon secretion.  
The generation of cAMP is an ATP-dependent process, so changes in the cytosolic ATP levels 
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may be another potent regulator of cAMP signaling.  There is a ratiometric fluorescent biosensor 
for measuring the ATP/ADP ratio, called Perceval (Berg, Hung et al. 2009) that would be useful 
for such a line of enquiry.  It contains a circularly permuted mVenus FP, and so could be used 
with islets from the tdRFP-expressing α-cells to study cell-type specific metabolic regulation.  In 
addition to having a potential role in cAMP regulation, the cytosolic ATP/ADP ratio is a key 
player in modulating the ATP-sensitive K+ channel (KATP), which has been hypothesized to be a 
critical factor in regulating glucagon secretion (Gopel, Kanno et al. 2000; Cheng-Xue, Gomez-
Ruiz et al. 2013; Zhang, Ramracheya et al. 2013).  A significant limitation in working with 
primary islet tissue throughout the course of this study was the delivery of such genetically-
encoded biosensors to the cultured islets.  However, packaging the biosensors into viral vectors 
for transfection will greatly improve their usability in isolated islets and is an ongoing project.  
 
Glucose regulation of δ-cells and somatostatin secretion 
 The roles of somatostatin and insulin in inhibiting glucagon exocytosis have been 
described in this work and there has been a lot of research characterizing the β-cells and 
glucose-stimulated insulin secretion.  However, many questions remain about the δ-cells and 
the role of glucose and α- and β-cells in regulating somatostatin secretion.  The identification of 
δ-cells in the islet has been a significant barrier to answering these questions, but the availability 
of a somatostatin-promoter driven Cre mouse line and the tdRFP mouse line that we currently 
use has facilitated the genetic labeling of the δ-cells for interrogation by imaging.  Additionally, it 
will be important to characterize the roles of the insulin, glucagon, and somatostatin receptors in 
regulating δ-cell function during normal and pathological states.  
Having identified the primary somatostatin receptor subtype responsible for regulating 
glucagon exocytosis as SSTR2, along with others (Strowski, Parmar et al. 2000; Kailey, van de 
Bunt et al. 2012; Yue, Burdett et al. 2012), we have obtained a knockout mouse for this gene.  
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The first set of experiments to do with these knockout mice will include determining cAMP levels 
as well as glucagon and insulin secretion at low and high glucose.  While we expect the 
resulting data to match our results using the pharmacological inhibitor, the long term deletion of 
this gene may stimulate compensatory mechanisms including the up-regulation of other 
receptor subtypes.  Isolated islets from these mice do show a two-fold increase in glucagon 
secretion compared with wild type mice, supporting a critical role for these receptors in 
modulating glucagon exocytosis (Strowski, Parmar et al. 2000).  These mice may also be useful 
for studying other paracrine intra-islet regulators that may affect glucagon secretion indirectly by 
modulating the δ-cells and somatostatin secretion.  
 
Regulation of cAMP signaling during diabetes 
 One of the significant remaining questions about the regulated decrease in cAMP to 
lower glucagon secretion is whether or not this mechanism is significantly impaired during 
metabolic disease.  We have begun to address this question by obtaining isolated islets from a 
human donor with type 1 diabetes, type 2 diabetes, or severe obesity (BMI > 45).  We subjected 
these islets to a static incubation with low (1 mM) or high glucose (11 mM) and measured the 
cAMP levels and glucagon secretion.  Though we have only had the tissue to perform this 
experiment once, the preliminary data are presented in Figures 5-2 and 5-3 along with a normal 
human control (N = 6).  The obese human islets exhibited glucagon secretion and cAMP levels 
slightly lower than the normal control islets at low glucose.  However, at high glucose, glucagon 
secretion was increased over 6 fold compared to controls and cAMP levels were flat and similar 
to the high glucose levels of the normal control, rather than reduced only at high glucose.  
The type 1 diabetic islets were found to have increased glucagon secretion at both low 
and high glucose, a complete loss of inhibition.  As with the obese samples, cAMP levels at low 
glucose were slightly lower.  However, at high glucose, cAMP levels were quite high, reflecting a 
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total loss of inhibition observed at high glucose in normal controls.  Interestingly, with respect to 
the secretion profile from this sample, the type 1 diabetic islets were similar to what we have 
observed in purified α-cells.  Unfortunately, there were not enough islets from the type 2 diabetic 
human donor to perform both the glucagon secretion assay and measure cAMP levels, so we 
chose to measure cAMP, as glucagon secretion is being assessed in parallel by a collaborating 
lab.  We found that the cAMP levels in islets from the type 2 diabetic donor were considerably 
lower at low glucose compared to the normal control as well as the obese and type 1 islets, but 
were comparable at high glucose.  These experiments must be repeated before drawing any 
conclusions, but at first glance they seem to support our hypothesis that impaired cAMP 
signaling is a critical part of the glucagon dysregulation observed in metabolic diseases.  
 
 
Figure 5-2: Glucagon secretion from normal, diabetic, and obese human islets.  Glucagon 
secretion from islets statically incubated with low (1 mM) or high (11 mM) glucose from the islets 
of 5 human donors (A), 1 obese (B), and 1 type 1 diabetic human donor (C).  
148 
 
 
Figure 5-3: Relative cAMP levels from normal, diabetic, and obese human islets.  Quantification 
of mean intensity normalized to pre-immune controls from the immunofluorescence images.  (A) 
Normalized mean intensity from 4-6 islets from 5 human donors stimulated with low or high 
glucose before fixing and staining for glucagon and cAMP.  (B-D) Islets treated as in (A) from a 
single obese (B), type 1 diabetic (C), or type 2 diabetic (D) human donor. 
 
 
 
Optical sectioning and optimizing analysis of hyperspectral live-cell imaging 
The IMS system provides a significant improvement in the temporal collection of data 
from simultaneous measurement of [Ca2+]i and cAMP, and is a powerful tool for 
multidimensional analysis of signaling pathways.  The device used in the experiments described 
here would be improved by the use of a scientific CMOS (sCMOS) detector arrays, which can 
provide image acquisition rates up to 100 fps while maintaining low readout noise (< 3 e-1).  
Such a rapid imaging system would not only improve the ability to study transient relationships 
between signaling molecules, but would also be useful for very rapid biological processes like 
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action potentials in cardiac or neural tissue.   
An important consideration for utilizing the IMS with islet samples is the need for 
effective optical sectioning due to the thickness of this tissue (up to ~100 μm).  The widefield 
configuration utilized in our studies was effective for cultured cell monolayers.  However, in the 
dense, multicellular islets, this system would suffer from spatial –spectral crosstalk due to light 
scattering from out-of-focus layers, which reduces the resolution and decreases compromises 
the ability to unmix the component spectra.  There are a number of technologies available for 
addressing this problem, including the laser scanning confocal configuration, structured 
illumination microscopy (Gustafsson 2000), and light sheet microscopy (Keller, Schmidt et al. 
2010; Truong, Supatto et al. 2011).  
A depth-resolved IMS with structured illumination (SI) capability has been described, 
which implements epi-illumination with a Ronchi ruling grid in the optical path at a conjugate 
plane to the sample plane (Gao, Bedard et al. 2011).  This system has the advantage of being 
easy to implement with a standard inverted microscope and collects 4D (x, y, z, λ) datacubes 
with significantly increased contrast provided by the SI configuration.  The implementation of 
such an SI system with a sCMOS detector would provide robust improvements to the current 
capabilities of the IMS.  However, since out-of-focus light still contributes to the shot noise under 
SI, very bright samples with a dominating signal from the out-of-focus may be better served by a 
light sheet approach, also called selective plane illumination microscopy (SPIM).  
SPIM is a technique that uses a detector arm to collect fluorescence at a right angle to 
the illumination axis, which is excited by a thin laser beam from a single plane of the specimen 
(Keller, Schmidt et al. 2010).  There are several advantages to this technique, including rapid 
data collection, high signal-to-noise, and low laser power, which limits the fluorophore 
photobleaching and sample phototoxicity.  Additionally, the hardware arrangement lends itself to 
the addition of the compact IMS on the detector arm.  Recently, the addition of a second 
detector arm and an inverted configuration was shown to provide isotropic resolution (x, y and z) 
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by imaging the sample with two perpendicular light sheets.  This technique, called dual-view 
inverted SPIM (diSPIM) alternates the illumination and detection between two perpendicular 
objectives and is capable of collecting up to 200 images/second with a resolution of 330 nm 
(Wu, Wawrzusin et al. 2013).  Considering the thickness of pancreatic islets and desire to study 
rapid molecular events in the whole volume, the diSPIM configuration would be convenient.  
Spectral detection has not yet been integrated with the SPIM techniques and the 
snapshot modality of the IMS would be advantageous for maintaining the rapid imaging speeds 
necessary for many live-cell applications.  Furthermore, two-photon excitation coupled with 
SPIM has been shown to provide twice the depth of a single photon and ten times the speed of 
a two-photon coupled point scanning system (Truong, Supatto et al. 2011).  While it is expected 
that a single-photon excitation will be sufficient for most islet applications, detecting low signal 
events may benefit from the higher signal rate provided by the two-photon excitation light sheet. 
Finally, with regard to the analysis of data collected using the IMS, we have considered 
alternative methods to our current linear unmixing protocol, which requires collecting reference 
spectra that adds experimental time.  An emerging methodology called spectral phasor analysis 
can unmix multiple spectra in an image without the need for reference spectra (Fereidouni, 
Bader et al. 2012).  We have begun using the ImageJ plugin for this technique to deconvolve 
data collected with the IMS.  Briefly, the Fourier transform is taken for each pixel in an image, 
after which the real and imaginary components of the first harmonic are plotted as X and Y 
coordinates in a spectral phasor plot, shown in Figure 5-4 for data collected with the IMS from a 
three-color experiment.  The phasor of the spectrum for the linear combination of the three 
components falls within a triangle with vertices of the discrete Fourier transform.  The fractional 
contribution from each component is calculated geometrically from the area of the triangle 
defined by each phasor’s position in the plot divided by the area of a reference triangle 
(Fereidouni, Bader et al. 2012).  
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Figure 5-4: Results of spectral phasor analysis from a single three-color IMS snapshot.  (A) 
Spectral phasor plot of an image of co-transfected cAMP biosensor T-Epac-VV (mTurquoise and 
cpVenus-Venus) and [Ca2+]i sensor GCaMP5G (cpGFP).  (B-D) Phasor unmixed RGB images 
of the cpVenus-Venus (B), cpGFP (C), and mTurquoise (D) signals.  
 
 
By analyzing the same spectral snapshot collected from the IMS with the traditional 
linear unmixing and the spectral phasor approach, we find comparable intensities for each FP, 
as shown in Figure 5-5.  Interestingly, the spectral profile identified by the phasor analysis more 
closely resembles the expected spectra than that from the raw lambda stack.  This 
demonstrates one of the significant advantages to natively identifying the spectral components 
in an image for quantitative analysis.  The reference spectra, which are typically collected from 
single transfections of individual FPs, can introduce artefacts that may reduce the accuracy of 
linear unmixing.  For example, the environmental constraints of the FPs within the biosensors 
may be different enough than for the individual FPs to affect the unmixing results.  The 
reference spectra utilized by the spectral phasor analysis are provided by the phasor algorithm 
itself, which solves the possible problem of environmental artifacts and obviates the need to 
152 
 
collect separate reference spectra experimentally.  Recent improvements in the spectral phasor 
analysis have been implemented by the addition of the second harmonic, which expands the 
number of spectra that can be distinguished from each pixel in an image (Cutrale, Salih et al. 
2013).  In future, this method of data analysis may well replace the standard linear unmixing and 
we hope to apply it to the dual-FRET data described in Chapter 4 and to data collected in 
ongoing hyperspectral imaging studies.  
 
 
Figure 5-5: Comparison of linear unmixing and spectral phasor analysis.  (A) Normalized 
spectra from a single IMS snapshot (same as Figure 5-4) measured from the remapped lambda 
stack (gray) and the spectral phasor ImageJ plugin (black).  (B) Normalized intensity of 
GCaMP5G from (A) in gray bars and normalized FRET ratio of T-Epac-VV in black bars. 
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